<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003044.pub4" GROUP_ID="LIVER" ID="603599082514530094" MERGED_FROM="" MODIFIED="2016-04-19 13:48:29 +0200" MODIFIED_BY="[Empty name]" REVIEW_NO="03" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2016-04-19 13:48:29 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-03-22 15:53:00 +0100" MODIFIED_BY="[Empty name]">Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis</TITLE>
<CONTACT>
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>MD, DMSc</SUFFIX>
<POSITION>Consultant</POSITION>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+45 38621964</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 38621964</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-04-19 13:39:32 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>MD, DMSc</SUFFIX>
<POSITION>Consultant</POSITION>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+45 38621964</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 38621964</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6559" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Hendrik</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vilstrup</LAST_NAME>
<SUFFIX>Dr Med Sci</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>hendrik.vilstrup@aarhus.rm.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Hepatology and Gastroenterology</DEPARTMENT>
<ORGANISATION>Aarhus Kommunehospital</ORGANISATION>
<ADDRESS_1>Nørrebrogade 44</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aarhus C</CITY>
<ZIP>DK-8000</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 8949 3891</PHONE_1>
<PHONE_2/>
<FAX_1>+45 8949 2860</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1410141003052282658395938743116" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marsha</FIRST_NAME>
<MIDDLE_INITIALS>Y</MIDDLE_INITIALS>
<LAST_NAME>Morgan</LAST_NAME>
<SUFFIX/>
<POSITION>Principal Research Fellow and Honorary Consultant Physician</POSITION>
<EMAIL_1>marsha.morgan@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>UCL Institute for Liver &amp; Digestive Health</DEPARTMENT>
<ORGANISATION>Division of Medicine, Royal Free Campus, University College London</ORGANISATION>
<ADDRESS_1>Rowland Hill Street</ADDRESS_1>
<ADDRESS_2>Hampstead</ADDRESS_2>
<CITY>London</CITY>
<ZIP>NW3 2PF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-10-19 11:51:04 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="10" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="10" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="9" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-19 13:48:29 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-19 13:48:29 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Reference <LINK REF="REF-Gluud-2016" TYPE="REFERENCE">Gluud 2016</LINK> added to <LINK TAG="OTHER_VERSIONS_REFERENCES" TYPE="SECTION">Other published versions of this review</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-03-30 11:25:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="28" MONTH="2" YEAR="2016"/>
<DESCRIPTION>
<P>Changes to the 'Risk of bias' assessment: We updated the 'Risk of bias' assessment included in the latest version of the review. The change included the addition of the domains 'for-profit funding' and 'overall bias assessment'. We made the updates following the recommendations in the Cochrane Hepato-Biliary Group module.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-30 11:25:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="30" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>The first version of this review, published in 2000, included 10 randomised clinical trials (RCTs) evaluating non-absorbable disaccharides versus placebo/no intervention and eight RCTs evaluating lactulose versus lactitol. An update in 2004 did not identify additional RCTs. This updated review includes 38 RCTs (29 evaluating non-absorbable disaccharides versus placebo/no intervention and nine evaluating lactulose versus lactitol). The methods of the review have been updated in accordance with the recommendations made in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> and the Cochrane Hepato-Biliary Group module. The changes include updated trial searches (the searches now include several trial registries), assessment of bias control and statistical analyses (regression analyses of small study effects, meta-regression analyses and Trial Sequential Analyses). The review includes 'Summary of findings' tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-03-23 12:58:10 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>The updated review found evidence that lactulose and lactitol are associated with beneficial effects on mortality, hepatic encephalopathy, and serious adverse events.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-22 16:17:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>We excluded RCTs evaluating antibiotics for people with hepatic encephalopathy to avoid overlap with another planned review (<LINK REF="REF-Kimer-2015" TYPE="REFERENCE">Kimer 2015</LINK>). Hence, we changed the review title 'Nonabsorbable disaccharides for hepatic encephalopathy' (<LINK REF="REF-Als_x002d_Nielsen-2000" TYPE="REFERENCE">Als-Nielsen 2000</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004b" TYPE="REFERENCE">Als-Nielsen 2004b</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2005" TYPE="REFERENCE">Als-Nielsen 2005</LINK>) to 'Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-10-14 11:40:20 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2014-10-12 23:54:40 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-10-12 23:54:16 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-10-12 23:54:16 +0200" MODIFIED_BY="[Empty name]">
<NAME>No funding received</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-10-12 23:54:40 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-10-12 23:54:40 +0200" MODIFIED_BY="[Empty name]">
<NAME>No funding received</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-07 10:51:57 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-03-30 11:27:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-10-26 11:40:35 +0100" MODIFIED_BY="[Empty name]">Are non-absorbable disaccharides associated with beneficial or harmful effects in people with cirrhosis and hepatic encephalopathy?</TITLE>
<SUMMARY_BODY MODIFIED="2016-03-30 11:27:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Background</B>
</P>
<P>Cirrhosis is a chronic disorder of the liver. People with cirrhosis may develop hepatic encephalopathy, a condition that results in poor brain functioning. Hepatic encephalopathy may be clinically obvious (<I>overt</I>) with changes including poor concentration, tremor, and alterations in consciousness. Others have no obvious clinical changes (minimal) but, when tested, some aspects of brain function such as attention and the ability to perform complex tasks are impaired.</P>
<P>The reason why people develop hepatic encephalopathy is complex. The accumulation of ammonia plays a key role. The non-absorbable disaccharides, lactulose and lactitol, are indigestible sugars that reduce the levels of ammonia in the blood.</P>
<P>
<B>Review question</B>
</P>
<P>We investigated the use of non-absorbable disaccharides for the prevention and treatment of hepatic encephalopathy in people with cirrhosis by reviewing randomised clinical trials (RCTs).</P>
<P>
<B>Search date</B>
</P>
<P>The search date was October 2015.</P>
<P>
<B>Study funding sources</B>
</P>
<P>Seven RCTs received financial support and 11 RCTs received lactitol or inactive placebo free of charge from a pharmaceutical company.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included 29 RCTs comparing non-absorbable disaccharides with inactive placebo or no intervention and nine RCTs comparing lactulose with lactitol. Seven of the included RCTs evaluated the prevention of hepatic encephalopathy and 31 evaluated the treatment of hepatic encephalopathy. Sixteen of the treatment RCTs included people with <I>overt</I> hepatic encephalopathy while 15 included people with <I>minimal</I> hepatic encephalopathy. The duration of treatment varied depending on the type of hepatic encephalopathy from five days to one year.</P>
<P>
<B>Key results</B>
</P>
<P>People who received non-absorbable disaccharides were less likely to die than people given a placebo or no treatment. They were also less likely to develop serious complications of their liver disease such as liver failure, bleeding, and infections. The non-absorbable disaccharides were also effective in preventing the development of hepatic encephalopathy and increased the number of participants who recovered from hepatic encephalopathy. There was some evidence from a small number of trials that lactulose has a beneficial effect on the quality of life, but we were unable to include the data in an overall analysis. The non-absorbable disaccharides were associated with adverse events including diarrhoea, nausea, bloating, and flatulence. None of the RCTs comparing lactulose versus lactitol reported quality of life. The analyses showed no differences between the two interventions for the remaining outcomes.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>In the comparison of non-absorbable disaccharides versus placebo/no intervention, we found moderate quality evidence of benefit for the outcomes of death, hepatic encephalopathy, and serious complications. The evidence for the remaining outcomes was of very low quality.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-03-30 11:26:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2016-03-30 11:25:55 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Non-absorbable disaccharides (lactulose and lactitol) are recommended as first-line treatment for hepatic encephalopathy. The previous (second) version of this review included 10 randomised clinical trials (RCTs) evaluating non-absorbable disaccharides versus placebo/no intervention and eight RCTs evaluating lactulose versus lactitol for people with cirrhosis and hepatic encephalopathy. The review found no evidence to either support or refute the use of the non-absorbable disaccharides and no differences between lactulose versus lactitol.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-02-18 14:50:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of i) non-absorbable disaccharides versus placebo/no intervention and ii) lactulose versus lactitol in people with cirrhosis and hepatic encephalopathy. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-03-30 11:26:06 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We carried out electronic searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 10), MEDLINE, EMBASE, and Science Citation Index Expanded to 19 October 2015; manual searches of meetings and conference proceedings; checks of bibliographies; and correspondence with investigators and pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-09-08 18:27:34 +0200" MODIFIED_BY="[Empty name]">
<P>We included RCTs, irrespective of publication status, language, or blinding. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-03-30 11:26:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors, working independently, retrieved data from published reports and correspondence with investigators. The primary outcomes were mortality, hepatic encephalopathy, and serious adverse events. We presented the results of meta-analyses as risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). We assessed the quality of the evidence using 'Grading of Recommendations Assessment Development and Evaluation' (GRADE) and bias control using the Cochrane Hepato-Biliary Group domains. Our analyses included regression analyses of publication bias and other small study effects, Trial Sequential Analyses to detect type 1 and type 2 errors, and subgroup and sensitivity analyses.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-03-30 11:26:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included 38 RCTs with a total of 1828 participants. Eight RCTs had a low risk of bias in the assessment of mortality. All trials had a high risk of bias in the assessment of the remaining outcomes. Random-effects meta-analysis showed a beneficial effect of non-absorbable disaccharides versus placebo/no intervention on mortality when including all RCTs with extractable data (RR 0.59, 95% CI 0.40 to 0.87; 1487 participants; 24 RCTs; I<SUP>2</SUP> = 0%; <I>moderate quality evidence</I>) and in the eight RCTs with a low risk of bias (RR 0.63, 95% CI 0.41 to 0.97; 705 participants). The Trial Sequential Analysis with the relative risk reduction (RRR) reduced to 30% confirmed the findings when including all RCTs, but not when including only RCTs with a low risk of bias or when we reduced the RRR to 22%. Compared with placebo/no intervention, the non-absorbable disaccharides were associated with beneficial effects on hepatic encephalopathy (RR 0.58, 95% CI 0.50 to 0.69; 1415 participants; 22 RCTs; I<SUP>2</SUP> = 32%; <I>moderate quality evidence</I>). Additional analyses showed that non-absorbable disaccharides can help to reduce serious adverse events associated with the underlying liver disease including liver failure, hepatorenal syndrome, and variceal bleeding (RR 0.47, 95% CI 0.36 to 0.60; 1487 participants; 24 RCTs; I<SUP>2</SUP> = 0%; <I>moderate quality evidence</I>). We confirmed the results in Trial Sequential Analysis. Tests for subgroup differences showed no statistical differences between RCTs evaluating prevention, overt, or minimal hepatic encephalopathy. The evaluation of secondary outcomes showed a potential beneficial effect of the non-absorbable disaccharides on quality of life, but we were not able to include the data in an overall meta-analysis (<I>very low quality evidence</I>). Non-absorbable disaccharides were associated with non-serious (mainly gastrointestinal) adverse events (<I>very low quality evidence</I>). None of the RCTs comparing lactulose versus lactitol evaluated quality of life. The review found no differences between lactulose and lactitol for the remaining outcomes (<I>very low quality evidence</I>).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-03-15 17:52:01 +0100" MODIFIED_BY="[Empty name]">
<P>This review includes a large number of RCTs evaluating the prevention or treatment of hepatic encephalopathy. The analyses found evidence that non-absorbable disaccharides may be associated with a beneficial effect on clinically relevant outcomes compared with placebo/no intervention.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-07 10:51:57 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The term hepatic encephalopathy refers to a spectrum of neuropsychiatric changes occurring in people with liver disease. The joint guideline from the European and American Associations for the Study of the Liver defines hepatic encephalopathy as a brain dysfunction associated with liver insufficiency or portal systemic shunting (<LINK REF="REF-EASL-and-AASLD-guideline-2014a" TYPE="REFERENCE">EASL and AASLD guideline 2014a</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014b" TYPE="REFERENCE">EASL and AASLD guideline 2014b</LINK>). Clinically apparent or <I>overt </I>hepatic encephalopathy manifests as a neuropsychiatric syndrome encompassing a wide spectrum of mental and motor disorders (<LINK REF="REF-Weissenborn-1998" TYPE="REFERENCE">Weissenborn 1998</LINK>; <LINK REF="REF-Ferenci-2002" TYPE="REFERENCE">Ferenci 2002</LINK>). Events such as gastrointestinal bleeding, infection, and alcohol misuse can trigger this so-called <I>acute</I> or <I>episodic </I>hepatic encephalopathy. Fifty per cent of instances occur with no obvious cause. Episodes may recur. Between episodes, people may return to their baseline neuropsychiatric status or show clinical evidence of impairment (<LINK REF="REF-Bajaj-2010b" TYPE="REFERENCE">Bajaj 2010b</LINK>). Less frequently, people present with <I>persistent </I>neuropsychiatric abnormalities, which are always present to some degree, but may vary in seriousness. Often people with persistent abnormalities have extensive spontaneous portal-systemic shunting or else a surgically created or transjugular intrahepatic portosystemic shunt (TIPS).</P>
<P>Changes in <I>mental state</I> range from subtle alterations in personality, intellectual capacity, and cognitive function to more profound alterations in consciousness leading to deep coma with decerebrate posturing. The changes in <I>motor function</I> may include rigidity, disorders of speech production, resting- and movement-induced tremor, asterixis, delayed diadochocinetic movements, hyperreflexia, hyporeflexia, choreoathetoid movements, Babinsky's sign, and transient focal symptoms (<LINK REF="REF-Victor-1965" TYPE="REFERENCE">Victor 1965</LINK>; <LINK REF="REF-Weissenborn-1998" TYPE="REFERENCE">Weissenborn 1998</LINK>; <LINK REF="REF-Cadranel-2001" TYPE="REFERENCE">Cadranel 2001</LINK>). <I>Asterixis </I>(flapping tremor) is the best known motor abnormality. Individuals with overt hepatic encephalopathy also show a wide spectrum of other abnormalities, including impaired psychometric performance (<LINK REF="REF-Schomerus-1998" TYPE="REFERENCE">Schomerus 1998</LINK>), disturbed neurophysiological function (<LINK REF="REF-Parsons_x002d_Smith-1957" TYPE="REFERENCE">Parsons-Smith 1957</LINK>; <LINK REF="REF-Chu-1997" TYPE="REFERENCE">Chu 1997</LINK>), altered cerebral neurochemical/neurotransmitter homeostasis (<LINK REF="REF-Taylor_x002d_Robinson-1994" TYPE="REFERENCE">Taylor-Robinson 1994</LINK>), reductions in global and regional cerebral blood flow and metabolism (<LINK REF="REF-O_x0027_Carroll-1991" TYPE="REFERENCE">O'Carroll 1991</LINK>), and changes in cerebral fluid homeostasis (<LINK REF="REF-Haussinger-2000" TYPE="REFERENCE">Haussinger 2000</LINK>). In general, the degree of impairment in these parameters increases as the clinical condition worsens. The term <I>minimal </I>hepatic encephalopathy (in the older literature <I>subclinical</I> or <I>latent</I>) refers to people with cirrhosis who are 'clinically normal', but who show abnormalities in neuropsychometric or neurophysiological performance (<LINK REF="REF-Ferenci-2002" TYPE="REFERENCE">Ferenci 2002</LINK>).</P>
<P>The diagnosis of hepatic encephalopathy may present no problems, but without the background information and an obvious precipitating event, it may go unrecognised. We have no gold standard for the diagnosis (<LINK REF="REF-Montagnese-2004" TYPE="REFERENCE">Montagnese 2004</LINK>), but techniques that we can use singly or in combination. The diagnosis or exclusion of overt hepatic encephalopathy should include a careful and detailed neuropsychiatric history and examination (<LINK REF="REF-Montagnese-2004" TYPE="REFERENCE">Montagnese 2004</LINK>), with particular attention paid to changes in memory, concentration, cognition, and consciousness. Clinicians and researchers often use the West Haven Criteria to grade mental state (<LINK REF="REF-Conn-1977" TYPE="REFERENCE">Conn 1977</LINK>), and the Glasgow Coma Score to grade the level of consciousness (<LINK REF="REF-Teasdale-1974" TYPE="REFERENCE">Teasdale 1974</LINK>). The neurological examination should be comprehensive, looking particularly for evidence of subtle motor abnormalities. The assessment should consider and exclude other potential causes of neuropsychiatric abnormalities including concomitant neurological disorders and metabolic abnormalities such as those associated with diabetes, renal failure, drug, or alcohol intoxication. People with hepatic encephalopathy have impaired psychometric performance (<LINK REF="REF-Montagnese-2004" TYPE="REFERENCE">Montagnese 2004</LINK>; <LINK REF="REF-Randolph-2009" TYPE="REFERENCE">Randolph 2009</LINK>). Those with minimal hepatic encephalopathy show deficits in attention, visuo-spatial abilities, fine motor skills, and memory while their other cognitive functions are relatively well preserved. People with overt hepatic encephalopathy show additional disturbances in psychomotor speed, executive function, and concentration. Psychometric test batteries to assess cognitive function form part of the evaluation. The Psychometric Hepatic Encephalopathy Score has a high specificity for the diagnosis (<LINK REF="REF-Schomerus-1998" TYPE="REFERENCE">Schomerus 1998</LINK>; <LINK REF="REF-Weissenborn-2001" TYPE="REFERENCE">Weissenborn 2001</LINK>). The test employs five paper and pencil tests to assess attention, visual perception and visuo-constructive abilities. Test scores have to be normalised to take account of factors such as age, gender, and educational level. At present, normative databases are available in Germany, Italy, Denmark, Spain, Mexico, Korea, India, and Great Britain.</P>
<P>People with hepatic encephalopathy may have a number of neurophysiological abnormalities (<LINK REF="REF-Gu_x00e9_rit-2009" TYPE="REFERENCE">Guérit 2009</LINK>). The electroencephalogram, which primarily reflects cortical neuronal activity, may show progressive slowing of the background activity and abnormal wave morphology. Recent advances in electroencephalogram analysis should provide better quantifiable and more informative data. Other potential diagnostic techniques include the Critical Flicker Fusion Frequency (<LINK REF="REF-Kircheis-2002" TYPE="REFERENCE">Kircheis 2002</LINK>), and the Inhibitory Control Test (<LINK REF="REF-Bajaj-2008" TYPE="REFERENCE">Bajaj 2008</LINK>). The tests need further validation. Studies using structural and functional cerebral imaging techniques have helped to unravel the pathophysiology of hepatic encephalopathy, but they currently offer little diagnostically (<LINK REF="REF-Grover-2006" TYPE="REFERENCE">Grover 2006</LINK>; <LINK REF="REF-Berding-2009" TYPE="REFERENCE">Berding 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The non-absorbable disaccharides lactulose and lactitol are poorly absorbed sugars, which act as osmotic laxatives in the treatment of constipation (<LINK REF="REF-Johanson-2007" TYPE="REFERENCE">Johanson 2007</LINK>; <LINK REF="REF-Miller-2014" TYPE="REFERENCE">Miller 2014</LINK>). Lactulose (<LINK REF="REF-Montgomery-1929" TYPE="REFERENCE">Montgomery 1929</LINK>) is dispensed as a syrup, which is contaminated with other sugars; a pure crystalline preparation is also available. Lactitol, a second-generation disaccharide, is dispensed as a powder. The mode of administration is generally enteral.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-03-30 11:27:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The exact pathogenesis of hepatic encephalopathy is unknown. Ammonia plays a key role (<LINK REF="REF-Butterworth-2014" TYPE="REFERENCE">Butterworth 2014</LINK>). The main sources of ammonia include nitrogenous products in the diet, bacterial metabolism of urea and proteins in the colon, and deamination of glutamine in the small intestine. Non-absorbable disaccharides lower ammonia levels through a number of mechanisms: (i) <I>a laxative effect</I>: the colonic metabolism of lactulose and lactitol results in an increase in intraluminal gas formation, an increase in intraluminal osmolality, a reduction in intraluminal pH, and an overall decrease in transit time; (ii) <I>bacterial uptake of ammonia</I>: the intraluminal changes in pH result in a leaching of ammonia from the circulation into the colon. The colonic bacteria use the released volatile fatty acids as substrate and proliferate. In doing so, they use the trapped colonic ammonia as a nitrogen source for protein synthesis. The increase in bacterial numbers additionally 'bulks' the stool and contributes to the cathartic effect; (iii) <I>reduction of intestinal ammonia production</I>: non-absorbable disaccharides inhibit glutaminase activity and interfere with the intestinal uptake of glutamine and its subsequent metabolism to ammonia; (iv) <I>beneficial effects on the gut microbiome: </I>cirrhosis is associated with dysbiosis and changes in the colonic mucosal microbiome (<LINK REF="REF-Qin-2014" TYPE="REFERENCE">Qin 2014</LINK>). Further changes may be observed in patients with hepatic encephalopathy(<LINK REF="REF-Bajaj-2012" TYPE="REFERENCE">Bajaj 2012</LINK>). Non-absorbable disaccharides can beneficially affect microbiota composition (<LINK REF="REF-Riggio-1990b" TYPE="REFERENCE">Riggio 1990b</LINK>; <LINK REF="REF-Bajaj-2012" TYPE="REFERENCE">Bajaj 2012</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-03-30 11:27:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The prevalence of hepatic encephalopathy varies. About 10% to 14% have overt hepatic encephalopathy when first diagnosed with cirrhosis (<LINK REF="REF-Saunders-1981" TYPE="REFERENCE">Saunders 1981</LINK>). In studies in people with decompensated cirrhosis, about 20% have overt hepatic encephalopathy (<LINK REF="REF-D_x0027_Amico-1986" TYPE="REFERENCE">D'Amico 1986</LINK>; <LINK REF="REF-de-Jongh-1992" TYPE="REFERENCE">de Jongh 1992</LINK>; <LINK REF="REF-Zipprich-2012" TYPE="REFERENCE">Zipprich 2012</LINK>). The cumulated incidence of overt hepatic encephalopathy is as high as 40% (<LINK REF="REF-Randolph-2009" TYPE="REFERENCE">Randolph 2009</LINK>; <LINK REF="REF-Bajaj-2011a" TYPE="REFERENCE">Bajaj 2011a</LINK>). The prevalence of minimal hepatic encephalopathy varies in different studies, but it may be more than 50% or higher in people with previous overt hepatic encephalopathy (<LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>; <LINK REF="REF-Lauridsen-2011" TYPE="REFERENCE">Lauridsen 2011</LINK>). The presence of hepatic encephalopathy, whether minimal or overt, is associated with significant impairment in the performance of complex tasks, such as driving (<LINK REF="REF-Schomerus-1981" TYPE="REFERENCE">Schomerus 1981</LINK>; <LINK REF="REF-Bajaj-2009" TYPE="REFERENCE">Bajaj 2009</LINK>; <LINK REF="REF-Kircheis-2009" TYPE="REFERENCE">Kircheis 2009</LINK>). The condition is also associated with a detrimental effect on quality of life (<LINK REF="REF-Groeneweg-1998" TYPE="REFERENCE">Groeneweg 1998</LINK>) and safety (<LINK REF="REF-Roman-2011" TYPE="REFERENCE">Roman 2011</LINK>). In addition, the presence of overt hepatic encephalopathy in people with cirrhosis awaiting liver transplantation has a detrimental effect on neurocognitive function following the procedure (<LINK REF="REF-Sotil-2009" TYPE="REFERENCE">Sotil 2009</LINK>) and on overall survival (<LINK REF="REF-Bustamante-1999" TYPE="REFERENCE">Bustamante 1999</LINK>; <LINK REF="REF-D_x0027_Amico-2006" TYPE="REFERENCE">D'Amico 2006</LINK>; <LINK REF="REF-Stewart-2007" TYPE="REFERENCE">Stewart 2007</LINK>; <LINK REF="REF-Bajaj-2011a" TYPE="REFERENCE">Bajaj 2011a</LINK>; <LINK REF="REF-Patidar-2014" TYPE="REFERENCE">Patidar 2014</LINK>). The survival probability in people with cirrhosis after their first episode of hepatic encephalopathy is 42% at one year and 23% at three years (<LINK REF="REF-Bustamante-1999" TYPE="REFERENCE">Bustamante 1999</LINK>). Thus, more than 50% die within one year and more than 75% within three years. Overt hepatic encephalopathy also poses a substantial burden for the caregivers of affected people (<LINK REF="REF-Bajaj-2011b" TYPE="REFERENCE">Bajaj 2011b</LINK>), and a significant financial burden on healthcare systems (<LINK REF="REF-Poordad-2007" TYPE="REFERENCE">Poordad 2007</LINK>; <LINK REF="REF-Stepanova-2012" TYPE="REFERENCE">Stepanova 2012</LINK>).</P>
<P>Since 1966 (<LINK REF="REF-Bircher-1966" TYPE="REFERENCE">Bircher 1966</LINK>), when lactulose was first introduced into clinical practice, several RCTs have evaluated non-absorbable disaccharides for hepatic encephalopathy. Previous meta-analyses have found that lactitol may be more beneficial than lactulose (<LINK REF="REF-Blanc-1992" TYPE="REFERENCE">Blanc 1992</LINK>), or that lactulose and lactitol had comparable effects (<LINK REF="REF-Camma-1993" TYPE="REFERENCE">Camma 1993</LINK>). The previous versions of this review did not find sufficient evidence to recommend lactulose or lactitol for routine clinical use in people with cirrhosis and hepatic encephalopathy (<LINK REF="REF-Als_x002d_Nielsen-2000" TYPE="REFERENCE">Als-Nielsen 2000</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004b" TYPE="REFERENCE">Als-Nielsen 2004b</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2005" TYPE="REFERENCE">Als-Nielsen 2005</LINK>). Methodological issues including unclear bias control and lack of statistical power weakened the strength of the conclusions. A subsequent guideline from the European and American Association for the Study of Liver Diseases recommended lactulose as the intervention of choice for overt hepatic encephalopathy and its secondary prevention after an index event (<LINK REF="REF-EASL-and-AASLD-guideline-2014a" TYPE="REFERENCE">EASL and AASLD guideline 2014a</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014b" TYPE="REFERENCE">EASL and AASLD guideline 2014b</LINK>). The guideline did not recommend primary prevention of encephalopathy nor the routine treatment of minimal hepatic encephalopathy. Clinicians may consider treating minimal hepatic encephalopathy on a case by case basis under certain circumstances such as impaired driving skills, work performance, quality of life issues, or cognitive impairment. The original Cochrane review and the current European and American Associations for the Study of the Liver guidelines provide discrepant views about the role of lactulose. We therefore conducted this updated review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-03-30 11:27:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of i) non-absorbable disaccharides versus placebo/no intervention and ii) lactulose versus lactitol in people with cirrhosis and hepatic encephalopathy.</P>
<P>To avoid overlap with another planned Cochrane review, we did not evaluate non-absorbable disaccharides versus antibiotics (<LINK REF="REF-Kimer-2015" TYPE="REFERENCE">Kimer 2015</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2016-03-30 11:27:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2015-09-08 13:55:22 +0200" MODIFIED_BY="[Empty name]">
<P>We included RCTs, regardless of publication status, language, or blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-02-18 15:14:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included people with cirrhosis from RCTs on the prevention (primary or secondary) or treatment of hepatic encephalopathy, regardless of sex, age, aetiology of the underlying liver disease, type of hepatic encephalopathy, or precipitating factors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-02-18 15:14:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The intervention comparisons were i) non-absorbable disaccharides (lactulose or lactitol) versus placebo/no intervention and ii) lactulose versus lactitol. We included RCTs, irrespective of the doses, treatment durations, and modes of administration and allowed co-interventions if administered equally to allocation trial arms.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-03-30 11:27:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We assessed all outcomes at the maximum duration of follow-up (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>).<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-03-30 11:27:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>Mortality.</LI>
<LI>Hepatic encephalopathy. We based our assessment of hepatic encephalopathy on the definitions in included RCTs.</LI>
<LI>Serious adverse events defined as any untoward medical occurrence that led to death, was life threatening, or required hospitalisation or prolongation of hospitalisation (<LINK REF="REF-ICH_x002d_GCP-2007" TYPE="REFERENCE">ICH-GCP 2007</LINK>). We analysed serious adverse events as a composite outcome (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-03-15 17:11:03 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Quality of life.</LI>
<LI>Non-serious adverse events: all adverse events that did not fulfil the criteria for a serious adverse event.</LI>
<LI>Surrogate outcomes: Number Connection Test results and blood ammonia concentrations.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and Science Citation Index Expanded using the strategies described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The last search update was 19 October 2015.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We scanned the reference lists of relevant articles and proceedings from meetings of the British Society for Gastroenterology (BSG), the British Association for the Study of the Liver (BASL), the European Association for the Study of the Liver (EASL), the United European Gastroenterology Week (UEGW), the American Gastroenterological Association (AGA), the American Association for the Study of Liver Diseases (AASLD), and the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). We wrote to the principal authors of RCTs and the pharmaceutical companies involved in the production of non-absorbable disaccharides for additional information about completed RCTs and for information about any ongoing RCTs, and searched the database ClinicalTrials.gov (<A HREF="https://clinicaltrials.gov/">clinicaltrials.gov/</A>) and the World Health Organization (WHO) online trial meta-register (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_SELECTION MODIFIED="2016-03-15 16:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (Lise L Gluud and Marsha Y Morgan) read the electronic searches, performed additional manual searches, and listed potentially eligible RCTs. All authors read the potentially eligible trial reports and participated in the final selection of those to be included in the analyses. We reached the final selection through consensus. For RCTs reported in more than one publication, we selected the paper reporting the longest duration of follow-up as the primary reference. We listed details of all included RCTs (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and excluded studies (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-03-30 11:27:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors (Lise L Gluud and Marsha Y Morgan) independently collected data and resolved contrary opinions through discussion. The collected data included information on: i) RCTs: design (cross-over or parallel), settings (number of clinical sites; outpatient or inpatient; inclusion period), country of origin; ii) participants: mean age, proportion of men, aetiology of cirrhosis, type of hepatic encephalopathy, previous history of hepatic encephalopathy and iii) interventions: type, dose, duration of therapy, mode of administration. We gathered the primary and secondary outcome data, including the criteria used in the assessment of hepatic encephalopathy, and bias control information. A commercial translation services or medical personnel fluent in the language translated foreign language (non-English) papers (<LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>). We requested missing data and other information from authors of included RCTs.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-03-30 11:28:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We assessed bias control using the domains described in the Cochrane Hepato-Biliary (CHB) module and classified the risk of bias for each domain as high, unclear, or low and the overall assessment as high or low (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: sequence generation achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, or throwing dice are adequate if performed by an independent person not otherwise involved in the trial.</LI>
<LI>Unclear risk of bias: the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not random.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (for example, if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants, personnel, and outcome assessors</HEADING>
<UL>
<LI>Low risk of bias: blinding was performed adequately. We defined lack of blinding (detection and performance bias) as not likely to affect the assessment of the outcome mortality.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether blinding was likely to induce bias in the results.</LI>
<LI>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes was likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The investigators used sufficient methods, such as intention-to-treat analyses with multiple imputations or carry-forward analyses to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data induced bias in the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias: the trial reported clinically relevant outcomes (mortality, hepatic encephalopathy, and serious adverse events). If we had access to the original trial protocol, the outcomes selected were those called for in that protocol. If we obtained information from a trial registry (such as <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), we only used that information if the investigators registered the trial before inclusion of the first participant.</LI>
<LI>Unclear risk of bias: not all pre-defined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk of bias: one or more predefined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial was free of industry sponsorship or other type of for-profit support that may influence the trial design, conduct, or results.</LI>
<LI>Unclear risk of bias: no information on clinical trial support or sponsorship was available.</LI>
<LI>High risk of bias: the trial was sponsored by industry, received support in the form of lactulose, lactitol, or placebo, or received any other type of support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other biases including: medicinal dosing problems or follow-up (as defined below).</LI>
<LI>Unclear risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias such as the administration of inappropriate treatments being given to the controls (e.g. an inappropriate dose) or follow-up (e.g. the trial included different follow-up schedules for participants in the allocation groups).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall bias assessment</HEADING>
<UL>
<LI>Low risk of bias: all domains were low risk of bias using the definitions described above.</LI>
<LI>High risk of bias: one or more of the bias domains were of unclear or high risk of bias.</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-03-30 11:28:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We used risk ratios (RR) for dichotomous outcomes and the mean differences (MD) for continuous outcomes, both with 95% confidence intervals (CI). For primary outcomes, we calculated the number needed to treat to benefit (NNTB) as 1/ risk difference (RD) based on the highest quality evidence (RCTs with a low risk of bias where available).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-03-15 16:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>We included data from the first treatment period of cross-over trials (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-03-30 11:28:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We extracted data on all randomised participants in order to allow intention-to-treat analyses. To evaluate the importance of missing data, we conducted a worst-case scenario analysis with simple imputation (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>), with inclusion of missing outcomes as treatment failures. We also conducted an 'extreme' worst-case scenario analysis in which we included missing outcome data as treatment failures (intervention group) or successes (control group).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-03-30 11:28:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We expressed heterogeneity as I<SUP>2 </SUP>values using the following thresholds: 0% to 40% (unimportant), 40% to 60% (moderate), 60% to 80% (substantial), and &gt; 80% (considerable). This information is included in the 'Summary of findings' tables (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-03-30 11:28:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>For meta-analyses with at least 10 RCTs, we assessed reporting biases through regression analyses using the Harbord test (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>), which regresses Z/sqrt(V) against sqrt(V), where Z is the efficient score and V is Fisher's information (the variance of Z under the null hypothesis). All meta-analyses of continuous outcomes included fewer than 10 RCTs.<BR/>
</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We performed the analyses in Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), STATA (<LINK REF="REF-Stata" TYPE="REFERENCE">Stata</LINK>), and Trial Sequential Analysis (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Meta-analysis</HEADING>
<P>We undertook random-effects and fixed-effect meta-analyses. Although the conclusion of the two models concurred, the random-effects meta-analysis provides the most conservative estimate of intervention effects. Therefore, we report the random-effects meta-analyses in our results.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial Sequential Analysis</HEADING>
<P>We performed a Trial Sequential Analysis (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>), and defined the required information size (also known as the <I>heterogeneity adjusted required information size</I>) as the number of participants needed to detect or reject an intervention effect based on the relative risk reduction (RRR) and CGR. The analyses show firm evidence if the Z-curve crosses the monitoring boundary (also known as the <I>trial sequential monitoring boundary</I>) before reaching the required information size. We constructed futility boundaries to evaluate the uncertainty of obtaining a chance negative finding and performed the analyses with alpha set to 5%, power to 80%, and model-based diversity. Based on previous evidence (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014a" TYPE="REFERENCE">EASL and AASLD guideline 2014a</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014b" TYPE="REFERENCE">EASL and AASLD guideline 2014b</LINK>), we set the relative risk reduction (RRR) to 30% and the CGR to 15% (mortality), 45% (hepatic encephalopathy), and 30% (serious adverse events). In the analysis of mortality, we conducted the analysis with inclusion of i) all RCTs and ii) RCTs with a low risk of bias (only possible in mortality analyses). We repeated the analyses with the RRR reduced to 20% and with diversity increased by 20% (from 0% to 20% in the analyses of mortality and serious adverse events and from 30% to 50% in the analysis of hepatic encephalopathy).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-03-30 11:28:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We undertook subgroup analyses to investigate the effect of non-absorbable disaccharides in RCTs evaluating the prevention or treatment of hepatic encephalopathy. We also evaluated heterogeneity based on stratification of RCTs by:</P>
<UL>
<LI>primary or secondary prevention of hepatic encephalopathy;</LI>
<LI>overt or minimal hepatic encephalopathy;</LI>
<LI>acute or chronic hepatic encephalopathy.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-03-30 11:28:30 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We performed a sensitivity analysis including only RCTs with a low risk of bias (as described above) and worse-case scenario analysis as described above.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' tables</HEADING>
<P>We used the GRADE system to evaluate the quality of the evidence for outcomes reported in the review considering the within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimate, and risk of publication bias (<LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-07 10:51:57 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included 38 RCTs in our qualitative analyses (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and excluded 24 studies (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). We were able to gather data for our quantitative analyses from 34 RCTs.</P>
<SEARCH_RESULTS MODIFIED="2016-03-30 11:28:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified 1378 potentially relevant references in electronic databases and 10 additional records through manual searches (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After removing duplicates and references that were clearly irrelevant, we identified 38 RCTs described in 56 references that fulfilled our inclusion criteria (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
<P>We were unable to obtain outcome data from four RCTs (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>), and we included the remaining 34 RCTs, all published as full paper articles, in our quantitative analyses (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
<P>The countries of origin were India (<LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>), the USA (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>), China (<LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>), Italy (<LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>), the United Kingdom (<LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>), Spain (<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>), Mexico (<LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>), Belgium (<LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>), Egypt (<LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>), France (<LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>), Holland (<LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>), Pakistan (<LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>), Serbia (<LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>), and Taiwan (<LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>).<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The total number of participants was 1828. Their mean age ranged from 41 to 67 years and the proportion of men from 11% to 100%. The proportion of participants with cirrhosis secondary to hepatitis B/C infection ranged from 0% to 81%, while the proportion with alcohol-related cirrhosis ranged from 0% to 100%.</P>
<P>Seven RCTs evaluated the prevention of hepatic encephalopathy. Three RCTs evaluated primary (<LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>), or secondary prevention of hepatic encephalopathy (<LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>), in participants with no obvious risks. Four included participants with an increased risk of hepatic encephalopathy due to gastrointestinal bleeding (<LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>), recent insertion of a transjugular intrahepatic portosystemic shunt (<LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>), or portosystemic shunt surgery (<LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>). In 16 RCTs, participants had <I>overt</I> hepatic encephalopathy (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) classed as acute (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>), or chronic (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>). In 15 RCTs, participants had minimal hepatic encephalopathy (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-McClain-1984#STD-McClain-1984">McClain 1984</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Morgan-1989#STD-Morgan-1989">Morgan 1989</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Horsmans-1997#STD-Horsmans-1997">Horsmans 1997</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Quero-1997#STD-Quero-1997">Quero 1997</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Shi-1997#STD-Shi-1997">Shi 1997</A>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Li-1999#STD-Li-1999">Li 1999</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Dhiman-2000#STD-Dhiman-2000">Dhiman 2000</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Xing-2003#STD-Xing-2003">Xing 2003</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Zeng-2003#STD-Zeng-2003">Zeng 2003</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Prasad-2007#STD-Prasad-2007">Prasad 2007</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Mittal-2011#STD-Mittal-2011">Mittal 2011</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Jain-2013#STD-Jain-2013">Jain 2013</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#STD-Ziada-2013#STD-Ziada-2013">Ziada 2013</A>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Twenty-nine RCTs assessed non-absorbable disaccharides versus placebo/no intervention (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>). Of these, 25 assessed lactulose (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>), and four assessed lactitol (<LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>).</P>
<P>Nine RCTs compared lactulose versus lactitol (<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>We were unable to extract outcome data from four RCTs with 64 participants (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>).</P>
<P>In total, our quantitative analyses included 34 RCTs with 1764 participants (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
<P>Thirty-one RCTs followed participants to the end of the intervention (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>). Three parallel-arm RCTs followed participants for an additional 13 days (<LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>), one month (<LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>), or three months after the end of treatment (<LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>). The duration of the intervention depended on the type of hepatic encephalopathy. Overall, the RCTs followed participants for 89 days (range 4 to 360 days) after randomisation. In prevention RCTs, the duration was 207 days (range 5 to 360 days). For participants with overt hepatic encephalopathy, the mean duration was 49 days (range 4 to 360) with a shorter duration in RCTs on acute (mean 5 days; range 4 to 7 days) and chronic hepatic encephalopathy (mean 74 days; range 10 to 360 days). The mean duration was 70 days in RCTs on minimal hepatic encephalopathy (range 14 to 180).</P>
<P>Investigators assessed overt (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) and minimal hepatic encephalopathy using several different neuropsychiatric assessments and variables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Eight RCTs used the Portal Systemic Encephalopathy Index and Ratio (<LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>), which comprises mental status (West Haven Criteria), asterixis, Number Connection Test A results, blood ammonia concentrations, and the electroencephalogram mean cycle frequency. Two RCTs used a modified version of the test without the electroencephalogram (<LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>), while one additionally replaced Number Connection Test A with the Digit Symbol test (<LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>).</P>
<P>Ten of the remaining RCTs also used West Haven Criteria to assess mental status (<LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>). Three RCTs used the Conn Score, which is similar to the West Haven Criteria (<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>). Thirty-two RCTs employed the Number Connection Test (<LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>). Twenty-five RCTs measured blood ammonia in plasma, venous, or arterial blood (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>), and 22 assessed the electroencephalogram mean cycle frequency (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We excluded four RCTs and 20 observational studies (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Three RCTs compared lactulose versus probiotics (<LINK REF="STD-Sharma-2008" TYPE="STUDY">Sharma 2008</LINK>), polyethylene glycol followed by lactulose (<LINK REF="STD-Rahimi-2014" TYPE="STUDY">Rahimi 2014</LINK>), or a carbon adsorbent (<LINK REF="STD-Pockros-2009" TYPE="STUDY">Pockros 2009</LINK>), while one RCT compared mannitol lavage versus a combination of lactulose and the antibiotic kanamycin (<LINK REF="STD-Quinton-1982" TYPE="STUDY">Quinton 1982</LINK>). Five case series described the effects of lactulose on minimal (<LINK REF="STD-Salerno-1994" TYPE="STUDY">Salerno 1994</LINK>) or recurrent hepatic encephalopathy (<LINK REF="STD-Brown-1970" TYPE="STUDY">Brown 1970</LINK>; <LINK REF="STD-Rorsman-1970" TYPE="STUDY">Rorsman 1970</LINK>; <LINK REF="STD-Zeegen-1970" TYPE="STUDY">Zeegen 1970</LINK>; <LINK REF="STD-Bircher-1971" TYPE="STUDY">Bircher 1971</LINK>). One additional study looked at the differential effects of lactitol and lactulose on chronic hepatic encephalopathy (<LINK REF="STD-Lanthier-1985" TYPE="STUDY">Lanthier 1985</LINK>), while another looked at the effect of lactulose in preventing hepatic encephalopathy following insertion of a transjugular intrahepatic portosystemic shunt (<LINK REF="STD-Piotraschke-1996" TYPE="STUDY">Piotraschke 1996</LINK>). Three studies of participants with cirrhosis described compliance with non-absorbable disaccharides, the predictors of recurrence of hepatic encephalopathy, and the predictors of response (<LINK REF="REF-Bajaj-2010b" TYPE="REFERENCE">Bajaj 2010b</LINK>; <LINK REF="STD-Sharma-2009a" TYPE="STUDY">Sharma 2009a</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>). Three studies describe the prevalence and characteristics of participants with overt or minimal hepatic encephalopathy (<LINK REF="STD-Schomerus-1993" TYPE="STUDY">Schomerus 1993</LINK>; <LINK REF="STD-Sharma-2010a" TYPE="STUDY">Sharma 2010a</LINK>), or young people admitted with overt hepatic encephalopathy (<LINK REF="STD-Sharma-2011a" TYPE="STUDY">Sharma 2011a</LINK>). Six studies describe the effects of non-absorbable disaccharides on cerebral blood flow and metabolism (<LINK REF="STD-James-1971" TYPE="STUDY">James 1971</LINK>), fat excretion (<LINK REF="STD-Merli-1992" TYPE="STUDY">Merli 1992</LINK>), terminal ileal and colonic pH (<LINK REF="STD-Patil-1987" TYPE="STUDY">Patil 1987</LINK>), blood ammonia, atrial natriuretic peptide and amino acid concentrations (<LINK REF="STD-Trovato-1995" TYPE="STUDY">Trovato 1995</LINK>), blood ammonia, Number Connection Test results and lymphocyte subpopulations (<LINK REF="STD-Vendemiale-1992" TYPE="STUDY">Vendemiale 1992</LINK>), and benzodiazepine-like compounds (<LINK REF="STD-Venturini-2005" TYPE="STUDY">Venturini 2005</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-04-07 10:42:20 +0200" MODIFIED_BY="[Empty name]">
<P>We based our bias assessment on the published descriptions combined with additional information from investigators (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2016-03-30 11:28:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In 26 RCTs, investigators generated the allocation sequence based on a table of random numbers or computer-generated random numbers (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
<P>In 28 RCTs, the allocation concealment involved randomisation via a central independent unit, serially numbered, opaque, sealed envelopes, or blinded administration of identically appearing drug containers (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>).</P>
<P>We classified 23 RCTs as having low risk of selection bias (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>). </P>
<P>We classified 15 RCTs as having unclear risk of selection bias (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-03-30 11:28:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We classified five single-blind RCTs with blinded outcome assessment as having low risk of detection bias (<LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>), and 14 double-blind RCTs as having low risk of performance and detection bias (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>).</P>
<P>The remaining 19 RCTs were open and we classified them as having high risk of performance and detection bias (<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-03-30 11:29:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In 12 trials, the authors described missing outcome data and excluded participants who were dropouts or withdrawals from their analyses (<LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>). We classified these RCTs as having high risk of attrition bias and four RCTs as having unclear risk of attrition bias because the trial reports did not describe dropouts or withdrawals or the handling of missing outcome data in the analyses (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>).</P>
<P>The remaining 22 RCTs had no missing outcome data and the analyses included all participants based on the intention-to-treat principle using adequate methods including last observation carried forward or multiple imputation (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>). We classified these RCTs as having low risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-03-30 11:29:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Thirty-two RCTs reported predefined, clinically relevant outcome measures suggesting a low risk of selective reporting (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
<P>One trial reported different primary and secondary outcomes in the electronic trial register (<LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>). The remaining five RCTs did not report mortality (<LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>). We therefore classed these six RCTs as having a high risk of selective reporting.</P>
<SUBSECTION>
<HEADING LEVEL="3">For-profit funding</HEADING>
<P>Twenty RCTs did not receive funding or had other involvement with for-profit companies (<LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>).</P>
<P>In 10 RCTs, investigators received lactitol, lactulose, or placebo from a pharmaceutical company (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>).</P>
<P>Seven RCTs received financial or other support from a pharmaceutical company (<LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>).</P>
<P>One RCT did not report funding (<LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-03-30 11:29:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no other potential sources of bias and therefore classified all RCTs as having low risk of bias for this domain (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>; <LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>; <LINK REF="STD-Yao-2014" TYPE="STUDY">Yao 2014</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Overall bias assessment</HEADING>
<P>We classified eight RCTs as having low risk of bias in the assessment of mortality (<LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>), and none of the RCTs as having low risk of bias in the assessment of the remaining outcomes.<BR/>
</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-04-07 10:51:57 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Non-absorbable disaccharides versus placebo/no intervention</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>Our meta-analysis of mortality included 24 RCTs with 1487 participants (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Compared with placebo/no intervention, non-absorbable disaccharides were associated with a beneficial effect on mortality when including all randomised clinical trials (risk ratio (RR) 0.59, 95% confidence interval (CI) 0.40 to 0.87; I<SUP>2</SUP> = 0%) or the eight RCTs with a low risk of bias (RR 0.63, 95% CI 0.41 to 0.97; number needed to treat to benefit (NNTB) 19; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). </P>
<P>Our meta-analysis of hepatic encephalopathy included 22 RCTs with 1415 participants (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and showed that compared with placebo/no intervention, non-absorbable disaccharides were associated with a beneficial effect on hepatic encephalopathy (RR 0.58, 95% CI 0.48 to 0.69; I<SUP>2</SUP> = 43%; NNTB six participants). Twenty-four RCTs with 1487 participants reported serious adverse events (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) that reflected liver-related morbidity such as liver failure, hepatorenal syndrome, and variceal bleeding (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Non-absorbable disaccharides had a beneficial effect on serious adverse events (RR 0.47, 95% CI 0.36 to 0.60; I<SUP>2</SUP> = 0%; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). None of the RCTs evaluating hepatic encephalopathy or serious adverse events had a low risk of bias.</P>
<P>We conducted the Trial Sequential Analyses of primary outcomes with the relative risk reduction (RRR) downgraded to 30%. In the analysis of mortality, we set the CGR to 15%. When including all 24 RCTs (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), the cumulative Z-curve crossed the monitoring boundary after 1037 participants before reaching the heterogeneity adjusted information size. The cumulative Z-curve did not cross the monitoring boundary when we reduced the RRR to 20% and increased the diversity to 20%, or when we only included RCTs with a low risk of bias (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). When we conducted the Trial Sequential Analysis for the outcome hepatic encephalopathy, we initially set the CGR to 45% (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The analysis found that the Z-curve crossed the monitoring boundary before reaching the information size of 581 participants and the analysis was confirmed when we decreased the RRR to 20% (information size 1337 participants) and increased diversity from 30% (model based) to 50% (information size 814 participants). Likewise, when analysing serious adverse events with the CGR set to 30%, the Z-curve crossed the monitoring boundary before reaching the required information size (737 participants; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). We confirmed the result in an analysis with RRR of 20% and diversity 20% (information size 1719 participants).</P>
<P>Worst-case scenario analyses (missing outcome data counted as failures) showed that the non-absorbable disaccharides were associated with a beneficial effect on mortality (RR 0.61, 95% CI 0.42 to 0.88; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>), hepatic encephalopathy (RR 0.59, 95% CI 0.50 to 0.69; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>), and serious adverse events (RR 0.47, 95% CI 0.37 to 0.61; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). The 'extreme worst-case scenario' analyses (missing outcome data counted as failures in the non-absorbable disaccharide group and successes in the control group) reached the same conclusions (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>, and <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
<P>Regression analyses and funnel plots showed no evidence of small study effects in the analysis of mortality (P value = 0.73), hepatic encephalopathy (P value = 0.93), or serious adverse events (P value = 0.96).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Six RCTs included quality of life assessments (<LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>). Three RCTs, <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>, <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK> and <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>, evaluated 160 participants with minimal hepatic encephalopathy using the Sickness Impact Profile (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>), which includes 136 questions about health-related dysfunction (<LINK REF="REF-Gilson-1975" TYPE="REFERENCE">Gilson 1975</LINK>; <LINK REF="REF-SF-36-questionnaire" TYPE="REFERENCE">SF 36 questionnaire</LINK>). The responses to these questions are divided into 12 categories: ambulation, body care/movement, mobility, emotional behaviour, social interaction, alertness behaviour, communication, work, sleep and rest, eating, home management, and recreation/pastimes. These, in turn, are used to inform the two major summative domains physical and psychosocial health. Two RCTs defined the alteration in the total score after treatment as the change in the overall quality of life (<LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>). The third trial compared the end of treatment values (<LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>). The three RCTs individually found a beneficial effect of lactulose. However, the heterogeneity between RCTs was considerable so we did not conduct a meta-analysis (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>One trial, <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>, used an abbreviated version of the World Health Organization quality of life 100 questionnaire (<LINK REF="REF-WHOQOL-1998" TYPE="REFERENCE">WHOQOL 1998</LINK>), which evaluates the domains: physical health, psychological health, social relationships, and environment. The trial report includes a table showing a selection of subscores from the questionnaire (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). The analyses showed that lactulose improved the domains of physical and psychological health, and social relationships (P value &lt; 0.05 for all subscores).</P>
<P>One trial described the effect of lactulose on the quality of life without specifying the assessment method (<LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>). The abstract states that lactulose improved the quality of life without providing quantitative data. One further trial, <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>, assessed quality of life using the Katz functioning scale (<LINK REF="REF-Katz-1963" TYPE="REFERENCE">Katz 1963</LINK>), which evaluates the adjustment and social behaviour in the community. The investigators state that there were no differences between the intervention groups before or after treatment, but do not provide quantitative data.</P>
<P>The non-absorbable disaccharides increased the risk of gastrointestinal non-serious adverse events (RR 2.47, 95% CI 1.24 to 4.93; 739 participants; nine RCTs; I<SUP>2</SUP> = 64%; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), including diarrhoea, bloating, flatulence, and nausea. Participants allocated to placebo/no intervention had a higher risk of constipation.</P>
<P>The surrogate outcomes included Number Connection Test results (mean difference (MD) -5.56, 95% CI -11.59 to 0.47; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and blood ammonia concentrations assessed at the end of the trials (MD -11.64, 95% CI -21.14 to -2.14; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) and as the change from baseline to the end of follow-up (MD 18.97, 95% CI 8.86 to 29.09; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The analyses included a small number of participants and considerable heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prevention RCTs</HEADING>
<P>The meta-analysis evaluating primary or secondary prevention showed a beneficial effect on mortality when including all six RCTs (RR 0.63, 95% CI 0.40 to 0.98; 668 participants; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), or the five RCTs with a low risk of bias (RR 0.64, 95% CI 0.41 to 0.99; 538 participants; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The non-absorbable disaccharides also had beneficial effects on the prevention of hepatic encephalopathy (RR 0.47, 95% CI 0.33 to 0.68; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), and serious adverse events (RR 0.48, 95% CI 0.33 to 0.70, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Additional analyses including four RCTs showed that non-absorbable disaccharides increased the risk of non-serious adverse events (RR 2.78, 95% CI 1.50 to 5.13; 548 participants; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment RCTs</HEADING>
<P>The meta-analysis evaluating the treatment of overt or minimal hepatic encephalopathy showed no effect of non-absorbable disaccharides on mortality when including all 18 RCTs (RR 0.49, 95% CI 0.23 to 1.05; 819 participants; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), or the three RCTs with a low risk of bias (RR 0.56, 95% CI 0.12 to 2.68; 167 participants; three RCTs; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The analyses showed beneficial effect of non-absorbable disaccharides on mortality in RCTs evaluating acute, overt hepatic encephalopathy (RR 0.36, 95% CI 0.14 to 0.94; 172 participants; six RCTs), but not in RCTs evaluating minimal hepatic encephalopathy (RR 0.82, 95% CI 0.24 to 2.86; 647 participants; 12 RCTs). No events occurred in RCTs evaluating chronic hepatic encephalopathy (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>The non-absorbable disaccharides had beneficial effects on overt and minimal hepatic encephalopathy (RR 0.63, 95% CI 0.53 to 0.74; 747 participants; 16 RCTs; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). The effect was similar in RCTs evaluating acute or chronic hepatic encephalopathy (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). Non-absorbable disaccharides had a beneficial effect on serious adverse events (RR 0.42, 95% CI 0.26 to 0.69; 819 participants; 18 RCTs; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>) with no difference between the acute and chronic hepatic encephalopathy subgroups (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). Non-absorbable disaccharides did not increase the risk of non-serious adverse events (RR 2.12, 95% CI 0.62 to 7.28; 191 participants; five RCTs; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Lactulose versus lactitol</HEADING>
<P>Meta-analyses showed no difference between lactulose versus lactitol in the assessment of mortality (RR 1.30, 95% CI 0.59 to 2.85; 225 participants; eight RCTs; I<SUP>2</SUP> = 0%; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), hepatic encephalopathy (RR 1.00, 95% CI 0.84 to 1.19; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>), or serious adverse events (RR 1.56, 95% CI 0.84 to 2.88; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). All Trial Sequential Analyses ignored the monitoring boundaries because the information size was insufficient. None of the RCTs assessed the quality of life. The non-serious adverse events were mainly gastrointestinal (RR 1.55, 95% CI 0.88 to 2.74; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). We found no differences between interventions for the surrogate outcomes Number Connection Test (end of treatment <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK> or change from baseline <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>), or blood ammonia concentrations (end of treatment <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK> or change from baseline <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>). We found no differences between subgroups for any outcomes. We only found evidence of missing outcome data in two RCTs (<LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>). The trials did not provide information about the number of participants in the two groups (lactulose or lactitol) with missing outcome data. Therefore, we were unable to conduct worst-case scenario or extreme worst-case scenario analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' tables</HEADING>
<P>In the analyses comparing non-absorbable disaccharides versus placebo/no intervention (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#SOF-01#SOF-01">Summary of findings table 1</A>), we downgraded the quality of the evidence to '<I>moderate</I>' for the outcome mortality because the Trial Sequential Analysis of RCTs with a low risk of bias found no evidence to support or refute an intervention effect. Likewise, we downgraded the quality of evidence for the outcomes hepatic encephalopathy and serious adverse events one level to '<I>moderate</I>' because none of the included RCTs had a low risk of bias. We downgraded the outcome quality of life three levels to '<I>very low quality evidence</I>' because none of the included RCTs had a low risk of bias, the heterogeneity was considerable, and we were unable to combine the data in an overall analysis. We also downgraded the outcome non-serious adverse events three levels to '<I>very low quality evidence</I>' because none of the included RCTs had a low risk of bias, the confidence intervals were wide, and we were only able to include data from nine RCTs in our meta-analysis.</P>
<P>In the analyses comparing lactulose versus lactitol (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502110811122514315333345917702&amp;format=REVMAN&amp;download=true#SOF-02#SOF-02">Summary of findings table 2</A>), we downgraded the evidence three levels to '<I>very low quality</I>' due to imprecision, uncertainty, and a methodological quality (none of the included RCTs had a low risk of bias).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2016-03-30 11:29:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This review includes descriptive information from 38 randomised clinical trials (RCTs) with 1828 participants and quantitative data from 34 RCTs with 1764 participants. The primary analyses show that use of the non-absorbable disaccharides, lactulose and lactitol, is associated with reduced mortality compared with placebo/no intervention when including all RCTs and when including the RCTs with a low risk of bias. In subgroup analyses, we found no statistical differences between RCTs stratified by the type of hepatic encephalopathy. We found a beneficial effect on mortality in RCTs evaluating prevention and RCTs evaluating acute hepatic encephalopathy, but not in RCTs evaluating chronic or minimal hepatic encephalopathy (where the mortality rates overall were extremely low). The quality of the evidence was moderate.</P>
<P>Use of non-absorbable disaccharides is associated with a beneficial effect on the prevention and treatment of hepatic encephalopathy (<I>moderate quality evidence</I>). Additional analyses showed that non-absorbable disaccharides can help to reduce serious adverse events associated with the underlying liver disease including liver failure, variceal bleeding, and hepatorenal syndrome (<I>moderate quality evidence</I>). Six RCTs suggested a beneficial effect on quality of life, but we were unable to combine the results in a meta-analysis (<I>very low quality evidence</I>). As expected, the non-absorbable disaccharides increased the risk of non-serious gastrointestinal adverse events (<I>very low quality evidence</I>). None of the RCTs comparing lactulose versus lactitol assessed quality of life. Analyses of the remaining outcomes found no differences between the two interventions (<I>very low quality evidence</I>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The most important outcomes for people with cirrhosis and hepatic encephalopathy are mortality, morbidity, adverse events, and quality of life (<LINK REF="REF-Bajaj-2011a" TYPE="REFERENCE">Bajaj 2011a</LINK>). We included information on all of these outcomes. The RCTs evaluated improvement in hepatic encephalopathy using a variety of methods. This partly reflects that fact that the included RCTs were conducted between 1969 and 2014 during which time diagnostic criteria changed on more than one occasion. The included RCTs often used clinical or composite scoring systems and a categorical approach to define improvement (or lack thereof). The investigators did not use the same thresholds to define improvement, so we chose to use the definitions that they defined as clinically relevant. The diagnostic classification of hepatic encephalopathy also changed during the time period (<LINK REF="REF-EASL-and-AASLD-guideline-2014a" TYPE="REFERENCE">EASL and AASLD guideline 2014a</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014b" TYPE="REFERENCE">EASL and AASLD guideline 2014b</LINK>). Thus, we made a decision <I>a priori</I> to utilise the individual primary investigators' classification of the type of hepatic encephalopathy and the outcome criteria for hepatic encephalopathy, based on the argument that these decisions will have been made using the criteria that were most clinically relevant when the investigators conducted the trial.</P>
<P>The older RCTs often used co&#8211;interventions such as dietary protein restriction. Although the RCTs did not use the co-interventions consistently, participants randomised to experimental or control groups within a given RCT would have had equal access to them. This might result in heterogeneity, but not in systematic differences between groups.</P>
<P>Hepatic encephalopathy varies widely in its manifestations. The RCTs included in our review represent the entire spectrum of the syndrome encountered in people with cirrhosis. Thus, RCTs included people experiencing an acute episode of hepatic encephalopathy, chronic hepatic encephalopathy associated with advanced liver disease, spontaneous or surgically created portal-systemic shunts, and minimal hepatic encephalopathy. In addition, the included RCTs explored the use of non-absorbable disaccharides for primary and secondary prevention of hepatic encephalopathy. The fact that the RCTs address all the objectives of the review strengthens the completeness of the evidence. We included all RCTs with extractable data in our primary analyses. We also conducted subgroup, sensitivity, and regression analyses to determine the differential effects of intervention on the clinical variants. Our analyses showed that non-absorbable disaccharides are associated with stable beneficial effects on clinically important outcomes across the different groups. This supports the external validity of our findings.</P>
<P>This review includes the two commercially available disaccharides, lactulose and lactitol. However, only four of the 28 RCTs of non-absorbable disaccharides versus placebo/no treatment utilised lactitol (<LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>). Nine RCTs with a total of 248 participants compared lactulose versus lactitol (<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>). We found no differences between the two interventions, but the statistical power was insufficient.</P>
<P>People with non-cirrhotic portal hypertension and those with fulminant hepatic failure may also develop hepatic encephalopathy. They are encountered much less frequently in clinical practice and were not represented in the included trials. There is no reason to suppose that our results cannot be extrapolated to people with hepatic encephalopathy associated with non-cirrhotic portal hypertension, e.g. portal vein block. However, the situation in people with fulminant hepatic failure is much more complex and the result may not be directly applicable.</P>
<P>Episodes of hepatic encephalopathy often develop in response to a precipitating event such as infection, gastrointestinal bleeding, alcohol misuse, or electrolyte disturbances. Identification and treatment of these precipitating factors is key to the management of affected individuals although no obvious precipitating factor is identified in 50% of instances (<LINK REF="REF-EASL-and-AASLD-guideline-2014a" TYPE="REFERENCE">EASL and AASLD guideline 2014a</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014b" TYPE="REFERENCE">EASL and AASLD guideline 2014b</LINK>). Avoiding likely precipitants such as constipation, dietary indiscretion, and certain medications can also reduce the risk of developing hepatic encephalopathy in the longer term. It is not clear whether use of non-absorbable disaccharides provides additional benefit in situations where hepatic encephalopathy is precipitated by a treatable event. The RCTs included in our review do not provide detailed information on possible precipitating events, on the effects of interventions designed to ameliorate them, or on the effects, if any, of the addition of a non-absorbable disaccharide. However, in two of the included RCTs, non-absorbable disaccharides, used together with measures to manage upper gastrointestinal haemorrhage, prevented the development of hepatic encephalopathy (<LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>).</P>
<P>Non-adherence to non-absorbable disaccharides is generally ascribed to adverse gastrointestinal effects such as unpredictable diarrhoea, bloating, flatulence, and abdominal pain (<LINK REF="REF-Bajaj-2010c" TYPE="REFERENCE">Bajaj 2010c</LINK>; <LINK REF="REF-Volk-2012" TYPE="REFERENCE">Volk 2012</LINK>). Although we did find that treatment with lactulose or lactitol was associated with a higher risk of these non-serious adverse events, none of the RCTs included in our review evaluated compliance in a manner that allowed us to assess the potential influence of these gastrointestinal effects. Other factors may, however, be important in determining compliance with treatment both on the part of the person receiving treatment and the physician prescribing it. Thus, people with hepatic encephalopathy may be unaware of the need for long-term treatment, may be unable to effectively titrate the dosage, and may find the side effects inconvenient especially when away from home. The physician may fail to explain the multiple ways in which non-absorbable disaccharides produce their beneficial effects and by placing undue focus on the need for them to pass two semi-soft stools/day may foster the belief that as long as this is achieved, there is no real need to take the medication. They may also erroneously assume that people will comply with treatment and hence fail to check adherence.</P>
<P>Hepatic encephalopathy imposes a significant burden on healthcare systems and the resource utilisation associated with the management of people with hepatic encephalopathy is increasing (<LINK REF="REF-Poordad-2007" TYPE="REFERENCE">Poordad 2007</LINK>). The increased costs do not seem to reflect the duration of hospitalisation, which has decreased, but a combination of direct and indirect factors such as the costs of treatment and rehabilitation after hospitalisation (<LINK REF="REF-Neff-2010" TYPE="REFERENCE">Neff 2010</LINK>). None of the RCTs included in the present review assessed the costs associated with hospitalisation, but we found a clear beneficial effect of non-absorbable disaccharides in preventing the development and recurrence of hepatic encephalopathy that would generally require hospitalisation. Use of non-absorbable disaccharides is also associated with a reduction in the occurrence of serious liver-related complications. This will also result in reduced hospitalisations and lengths of hospital stay.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-03-30 11:30:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The previous version of this review identified several potential biases in included RCTs (Als-Nielsen 2004). In this updated review, we identified a larger number of RCTs and additional information on essential aspects of bias control. As recommended, we combined the individual bias domains in an overall assessment (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>). We also included an assessment of individual domains, focusing on RCTs with a low risk of selection bias (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>). Based on previous evidence (<LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>), we defined mortality, but not serious adverse events, as an outcome that is robust to performance and detection bias. This decision can be questioned as lack of blinding is not likely to influence the assessment of events such as variceal bleeding, hepatorenal syndrome, and liver failure. We included 14 double-blind RCTs and cannot exclude the possibility that our analyses overestimate the effect of non-absorbable disaccharides on hepatic encephalopathy due to lack of blinding. In contrast to the previous version of this review, we included any type of for-profit funding as a bias domain (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>). The decision to include this domain is debatable (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). The fact that we included gratuitous supply of interventions or placebo was the main reason why we did not identify RCTs comparing lactulose versus lactitol with a low risk of bias in the overall assessment. Based on the revised assessment of bias control combined with the assessment of the directness of evidence, heterogeneity, precision of effect estimate, and risk of publication bias we classified the quality of the evidence as <I>moderate </I>for the assessment of our primary outcomes mortality, hepatic encephalopathy, and serious adverse events.</P>
<P>The included RCTs were conducted world-wide. The country/continent of origin included India/Pakistan (<LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>), the USA (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-McClain-1984" TYPE="STUDY">McClain 1984</LINK>), the Far-East (<LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Xing-2003" TYPE="STUDY">Xing 2003</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; <LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>), Europe (<LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>; <LINK REF="STD-Horsmans-1997" TYPE="STUDY">Horsmans 1997</LINK>; <LINK REF="STD-Quero-1997" TYPE="STUDY">Quero 1997</LINK>; <LINK REF="STD-Riggio-2005" TYPE="STUDY">Riggio 2005</LINK>), Mexico (<LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>), and Egypt (<LINK REF="STD-Ziada-2013" TYPE="STUDY">Ziada 2013</LINK>). A single centre in India conducted eight of the RCTs (<LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>). Four of these RCTs involved participants with minimal hepatic encephalopathy (<LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>; <LINK REF="STD-Prasad-2007" TYPE="STUDY">Prasad 2007</LINK>; <LINK REF="STD-Mittal-2011" TYPE="STUDY">Mittal 2011</LINK>; <LINK REF="STD-Jain-2013" TYPE="STUDY">Jain 2013</LINK>), and four evaluated primary and secondary prophylaxis (<LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Sharma-2011" TYPE="STUDY">Sharma 2011</LINK>; <LINK REF="STD-Agrawal-2012" TYPE="STUDY">Agrawal 2012</LINK>; <LINK REF="STD-Sharma-2012" TYPE="STUDY">Sharma 2012</LINK>). The results of the RCTs evaluating minimal hepatic encephalopathy did not differ substantially from those in the similar RCTs undertaken in centres outside of India. We found no comparable prevention studies undertaken outside of India. Two prevention RCTs conducted in Italy looked at the effects of non-absorbable disaccharides following transjugular intrahepatic portosystemic shunt insertion (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1509082134496188549514681110678&amp;format=REVMAN#STD-Riggio-1989#STD-Riggio-1989">Riggio 1989</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1509082134496188549514681110678&amp;format=REVMAN#STD-Riggio-2005#STD-Riggio-2005">Riggio 2005</A>). The RCTs found no benefit on mortality, hepatic encephalopathy, or serious adverse events. However, this is a notoriously difficult situation to manage and one that depends more on careful pre-selection of candidates than on <I>post-hoc</I> exhibition of pharmacotherapy. One RCT conducted in China looked at the effect of lactulose in the prevention of hepatic encephalopathy following an acute upper gastrointestinal bleed and observed significant benefit (<LINK REF="STD-Wen-2013" TYPE="STUDY">Wen 2013</LINK>). We observed clinical variation in participant demographics between the prevention RCTs conducted in India and those conducted elsewhere, but variables such as age, gender, and the aetiology of the cirrhosis did not confound the results. RCTs evaluating the effects of non-absorbable disaccharides for primary and secondary prevention conducted in countries outside of India would strengthen the external validity of our findings.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-03-30 11:31:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>A recent methodological review drew attention to outcome reporting bias in systematic reviews (<LINK REF="REF-Page-2014" TYPE="REFERENCE">Page 2014</LINK>). Changes between the outcomes in protocols and published systematic reviews include the statistical significance of the results for those outcomes. We updated this review to incorporate current recommendations (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>; <LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>). The methods used in this update differ from those in the previous version (<LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004b" TYPE="REFERENCE">Als-Nielsen 2004b</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2005" TYPE="REFERENCE">Als-Nielsen 2005</LINK>). As part of the update, we changed the definition of our primary outcomes to provide information on benefits as well as harms. Accordingly, we now include serious adverse events as a primary rather than a secondary outcome measure.</P>
<P>The selective publication of RCTs with a positive result increases the risk of outcome reporting bias (<LINK REF="REF-Dwan-2008" TYPE="REFERENCE">Dwan 2008</LINK>). The RCTs included in the present review were all published as full paper articles and this might be interpreted as a potential publication bias. However, we combined our electronic searches with extensive manual searches of reference lists and conference proceedings. We identified a large number of abstracts, but all were published subsequently as full papers. We found no evidence of publication bias or other small study effects and very few RCTs showed evidence of outcome reporting bias. Of the 29 RCTs on non-absorbable disaccharides versus placebo or no intervention, we were unable to include data for primary outcomes from four RCTs with 64 participants (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>). The RCTs are small and the narrative information in the published reports suggested that the intervention had a beneficial effect on hepatic encephalopathy. Exclusion of these four RCTs is unlikely to change our conclusions.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-03-30 11:31:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The previous version of this review assessed the effect of non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol based on a total of 19 RCTs (Als-Nielsen 2004). Eleven RCTs compared lactulose or lactitol versus placebo/no intervention (<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>; <LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>; <LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>; <LINK REF="STD-Shi-1997" TYPE="STUDY">Shi 1997</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>), and eight RCTs compared lactulose versus lactitol (<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>; <LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>; <LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>; <LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>; <LINK REF="STD-Morgan-1989" TYPE="STUDY">Morgan 1989</LINK>; <LINK REF="STD-Riggio-1989" TYPE="STUDY">Riggio 1989</LINK>; <LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>; <LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>). Based on a meta-analyses including four RCTs with 85 participants, the review found no effect of non-absorbable disaccharides on mortality compared with placebo/no intervention (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>). A meta-analysis including six RCTs with 207 participants showed a beneficial effect on hepatic encephalopathy (<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>; <LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>; <LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>; <LINK REF="STD-Watanabe-1997" TYPE="STUDY">Watanabe 1997</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Dhiman-2000" TYPE="STUDY">Dhiman 2000</LINK>), but the effect was not confirmed in an analysis that only included RCTs with a low risk of bias. We included 38 RCTs (1828 participants) in our qualitative evaluation and 34 RCTs in our qualitative analyses. Our analyses include several different groups of participants from several countries. In spite of the clinical differences, our analyses showed negligible or moderate statistical heterogeneity. Our findings disagree with previous evidence, mainly because previous reviews included fewer RCTs.</P>
<P>The joint guidelines from the European and American Associations for the Study of the Liver made four recommendations of relevance to this review (<LINK REF="REF-EASL-and-AASLD-guideline-2014a" TYPE="REFERENCE">EASL and AASLD guideline 2014a</LINK>; <LINK REF="REF-EASL-and-AASLD-guideline-2014b" TYPE="REFERENCE">EASL and AASLD guideline 2014b</LINK>). <I>First</I>, that lactulose should be the first-choice treatment for an acute episode of overt hepatic encephalopathy in people with cirrhosis. <I>Second</I>, that lactulose should be used for prevention of recurrent episodes of hepatic encephalopathy after the initial episode. <I>Third</I>, that minimal hepatic encephalopathy should not be treated routinely. <I>Fourth</I>, that primary prophylaxis for prevention of the development of hepatic encephalopathy is not required in people with cirrhosis except if they are known to be at high risk.</P>
<P>In agreement with the guideline recommendations, we found a beneficial effect of non-absorbable disaccharides on clinical outcomes in RCTs evaluating secondary prevention and treatment. The guidelines do not recommend routine treatment of minimal hepatic encephalopathy or primary prevention of hepatic encephalopathy. Our analyses provide a large body of evidence showing that people with minimal hepatic encephalopathy benefit from non-absorbable disaccharides in relation to cognitive functioning and probably quality of life, and some evidence that non-absorbable disaccharides may be considered in primary prevention.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-03-30 11:31:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2016-03-30 11:31:13 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This review includes randomised clinical trials (RCTs) evaluating the prevention and treatment of hepatic encephalopathy in people with cirrhosis. The analyses found that non-absorbable disaccharides are associated with beneficial effects on mortality and hepatic encephalopathy and that non-absorbable disaccharides can help to reduce serious adverse events associated with the underlying liver disease including liver failure, hepatorenal syndrome, and variceal bleeding. The quality of the evidence was moderate. The interventions may also have a beneficial effect on quality of life, but we were unable to combine the data in meta-analyses. The non-serious gastrointestinal adverse events are well known and include diarrhoea, bloating, and flatulence. The quality of the evidence was very low for the secondary outcomes (quality of life and non-serious adverse events). The mean treatment duration depended on the type of encephalopathy, with five days for acute, 74 days for chronic, 70 days for minimal, and 207 days for prevention of hepatic encephalopathy. None of the RCTs comparing lactulose versus lactitol evaluated quality of life. The review found no differences between lactulose and lactitol for the remaining outcomes. The quality of the evidence was very low.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-03-30 11:31:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We used the EPICOT format (<LINK REF="REF-Brown-2006" TYPE="REFERENCE">Brown 2006</LINK>) in the definition of implications for research:</P>
<P>
<B>E</B>vidence (what is the current state of the evidence?): this review includes 38 RCTs and provides moderate quality evidence that non-absorbable disaccharides have a beneficial effect on clinical outcomes. Additional research may be needed to further evaluate the effect of the intervention in specific subgroups.</P>
<P>
<B>P</B>articipants (what is the population of interest?): the largest body of evidence evaluated prevention of hepatic encephalopathy and people with minimal hepatic encephalopathy. Only a relatively small proportion of participants had chronic hepatic encephalopathy or an acute episode of hepatic encephalopathy. Future research may address the effect of non-absorbable disaccharides in these groups.</P>
<P>
<B>I</B>nterventions (what are the interventions of interest?): the interventions assessed include lactulose and lactitol.</P>
<P>
<B>C</B>omparisons (what are the comparisons of interest?): placebo-controlled RCTs as well as RCTs comparing lactulose versus lactitol seem relevant. Future RCTs should also evaluate the effect of co-interventions.</P>
<P>
<B>O</B>utcomes (what are the outcomes of interest?): RCTs should include an assessment of mortality, hepatic encephalopathy, and adverse events. Additional evidence evaluating the effect on quality of life is also needed.</P>
<P>
<B>T</B>ime stamp (date of literature search): October 2015.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-03-30 11:31:46 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We would like to thank Mr Ee Teng Goh, Dr Jian Ping Liu, Dr Srdan Novovic, and Ms Grith Block who translated the non-English language papers (Chinese, French, Serbian, Italian, and Spanish). We also thank Ms. Sarah Klingenberg from the Cochrane Hepato-Biliary Group for her help with the electronic searches and Dr. Bodil Als-Nielsen and Christian Gluud who contributed to the previous version of this review.</P>
<P>Peer reviewers: Goran Bjelakovic, Serbia; Arun Sanyal, USA.<BR/>Contact editors: Kurinchi S Gurusamy, UK; Janus Christian Jakobsen, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-03-30 11:31:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lise L Gluud received payment for presentations given at scientific meetings sponsored by Norgine.</P>
<P>All review authors have conducted previous reviews on hepatic encephalopathy and two authors (Hendrik Vilstrup and Marsha Morgan) have conducted RCTs on hepatic encephalopathy. These previous research activities are an academic bias based on the definitions given in the Cochrane Hepato-Biliary Group module.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-03-30 11:38:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>LL Gluud drafted the revised review, identified and selected RCTs, contributed to the data extraction, analyses, and interpretation of the results, and revised the review. H Vilstrup identified and selected RCTs, contributed to the data extraction, analyses, and interpretation of the results, and revised the review. MY Morgan identified and selected RCTs, contributed to the data extraction, analyses, and interpretation of the results, and revised the review.</P>
<P>All authors agreed to the publication of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-03-30 11:31:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We have revised the methods used in the original protocol and the previous version of this review (<LINK REF="REF-Als_x002d_Nielsen-2000" TYPE="REFERENCE">Als-Nielsen 2000</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2004b" TYPE="REFERENCE">Als-Nielsen 2004b</LINK>; <LINK REF="REF-Als_x002d_Nielsen-2005" TYPE="REFERENCE">Als-Nielsen 2005</LINK>) with:</P>
<UL>
<LI>exclusion of RCTs assessing non-absorbable disaccharides versus antibiotics;</LI>
<LI>redefinition of primary and secondary outcomes (serious adverse events was previously a secondary outcome and is now a primary outcome);</LI>
<LI>revised assessment of bias control based on the Cochrane Hepato-Biliary Group module (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>). The changes include the addition of the domains missing outcome data; outcome reporting bias; other bias; for-profit funding; overall bias assessment.</LI>
<LI>additional statistical analyses including regression analyses of small study effects; trial sequential analyses; worst-case scenario analyses; random-effects meta-regression.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-04-19 13:45:31 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2016-03-30 11:50:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<INCLUDED_STUDIES MODIFIED="2016-03-30 11:50:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="MIX" ID="STD-Agrawal-2012" MODIFIED="2015-06-16 12:06:24 +0200" MODIFIED_BY="[Empty name]" NAME="Agrawal 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-04-03 13:56:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Agrawal A, Sharma BC, Sharma P, Sarin SK</AU>
<TI>Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2012</YR>
<VL>107</VL>
<PG>1043-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22710579"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-16 12:06:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Agrawal A, Sharma P, Sharma B, Sarin S</AU>
<TI>Secondary prophylaxis of hepatic encephalopathy in cirrhosis: An open label, randomized controlled trial of lactulose, probiotics and no-therapy [abstract]</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2010</YR>
<VL>105</VL>
<PG>S105</PG>
<IDENTIFIERS MODIFIED="2015-06-16 12:06:24 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-16 12:06:12 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1038/ajg.2010.320-5"/>
<IDENTIFIER MODIFIED="2015-06-16 12:06:24 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CN-01004953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1971" MODIFIED="2015-03-04 17:43:20 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 1971" YEAR="1971">
<REFERENCE MODIFIED="2015-03-04 17:43:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown H, Trey C, McDermott WV Jr</AU>
<TI>Lactulose treatment of hepatic encephalopathy in outpatients</TI>
<SO>Archives of Surgery</SO>
<YR>1971</YR>
<VL>102</VL>
<PG>25-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="5538764"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corazza-1982" MODIFIED="2015-06-16 10:54:05 +0200" MODIFIED_BY="[Empty name]" NAME="Corazza 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-06-16 10:54:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corazza GR, Tacconi C, Zoli G</AU>
<TI>Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>Suppl 1</NO>
<PG>7-13</PG>
<IDENTIFIERS MODIFIED="2015-01-07 16:46:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00189390"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhiman-2000" MODIFIED="2015-06-22 13:55:12 +0200" MODIFIED_BY="[Empty name]" NAME="Dhiman 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-06-22 13:55:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB</AU>
<TI>Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2000</YR>
<VL>45</VL>
<PG>1549-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20460170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elkington-1969" MODIFIED="2015-06-22 13:55:16 +0200" MODIFIED_BY="[Empty name]" NAME="Elkington 1969" YEAR="1969">
<REFERENCE MODIFIED="2015-06-22 13:55:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elkington SG, Floch MH, Conn HO</AU>
<TI>Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial</TI>
<SO>New England Journal of Medicine</SO>
<YR>1969</YR>
<VL>281</VL>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69242833"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Germain-1973" MODIFIED="2015-06-22 13:55:20 +0200" MODIFIED_BY="[Empty name]" NAME="Germain 1973" YEAR="1973">
<REFERENCE MODIFIED="2015-06-22 13:55:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Germain L, Frexinos J, Louis A, Ribet A</AU>
<TI>Double blind study of lactulose in 18 patients with chronic hepatic encephalopathy after portocaval shunt</TI>
<TO>Étude en double aveugle du lactulose chez 18 malades atteints d'encéphalopathie hépatique chronique après shunt porto-cave</TO>
<SO>Archives Francaises des Maladies de L'appareil Digestif</SO>
<YR>1973</YR>
<VL>62</VL>
<PG>293-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74133808"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grandi-1991" MODIFIED="2015-06-22 13:55:25 +0200" MODIFIED_BY="[Empty name]" NAME="Grandi 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-06-22 13:55:25 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Grandi M, Sacchetti C, Pederzoli S, Celani MF. A clinical comparative study of crystaline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients. Minerva Gastroenterol Dietol 1991;37(4):225-30.&lt;/p&gt;" NOTES_MODIFIED="2015-06-22 13:55:25 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grandi M, Sacchetti C, Pederzoli S, Celani MF</AU>
<TI>A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portosystemic encephalopathy in cirrhotic patients</TI>
<TO>Studio clinico di confronto tra lattulosio puro in cristalli e lactitolo puro in polvere nella encefalopatia porto-sistemica del paziente cirrotico</TO>
<SO>Minerva Gastroenterologica e Dietologica</SO>
<YR>1991</YR>
<VL>37</VL>
<PG>225-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 1805974"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heredia-1987" MODIFIED="2015-04-03 13:58:31 +0200" MODIFIED_BY="[Empty name]" NAME="Heredia 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-04-03 13:58:31 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Heredia D, Caballeria J, Arroyo V, Ravelli G, Rodes J. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial. J Hepatol 1987;4(3):293-8.&lt;/p&gt;" NOTES_MODIFIED="2015-04-03 13:58:31 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heredia D, Caballeria J, Arroyo V, Ravelli G, Rodès J</AU>
<TI>Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial</TI>
<SO>Journal of Hepatology</SO>
<YR>1987</YR>
<VL>4</VL>
<PG>293-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1989035379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heredia-1988" MODIFIED="2015-04-03 13:58:05 +0200" MODIFIED_BY="[Empty name]" NAME="Heredia 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-04-03 13:58:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heredia D, Teres J, Orteu N, Rodès J</AU>
<TI>Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy</TI>
<SO>Journal of Hepatology</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>106-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3053887"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horsmans-1997" MODIFIED="2016-02-26 12:12:40 +0100" MODIFIED_BY="[Empty name]" NAME="Horsmans 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-03-04 17:46:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geubel AP, Solbreux PM, Horsmans Y, Desager JP, Harvengt C, Dive C</AU>
<TI>Effect of lactulose in cirrhotic patients with portalsystemic shunting and without clinical encephalopathy: A randomized controlled trial [abstract]</TI>
<SO>Acta Gastroenterologica Belgica</SO>
<YR>1991</YR>
<VL>54</VL>
<PG>C8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00266808"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-26 12:12:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP</AU>
<TI>Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>165-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9042989"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jain-2013" MODIFIED="2015-03-04 17:47:48 +0100" MODIFIED_BY="[Empty name]" NAME="Jain 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-04 17:47:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain L, Sharma BC, Srivastava S, Puri SK, Sharma P, Sarin S</AU>
<TI>Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2013</YR>
<VL>28</VL>
<PG>1187-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="23425082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jankovic-1996" MODIFIED="2015-03-04 17:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="Jankovic 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-03-04 17:48:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic G, Pavicevic V, Pavlovic A, Krstic M, Cabric I, Crnobaric M, et al</AU>
<TI>Lactitol in the treatment of acute hepatic encephalopathy in liver cirrhosis</TI>
<TO>Laktitol u therapiji akutne hepati&#269;ke encephalopatije</TO>
<SO>Archives of Gastroenterohepatology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>22-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00182347"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1999" MODIFIED="2016-03-30 11:49:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Li 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-03-30 11:49:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Z, Zhang H, Hong Y, Yu D, Gui X</AU>
<TI>Clinical effect of lactulose in the treatment of subclinical hepatic encephalopathy</TI>
<SO>Chinese Journal of Integrated Traditional &amp; Western Medicine on Liver Diseases</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>13-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClain-1984" MODIFIED="2015-03-04 17:50:41 +0100" MODIFIED_BY="[Empty name]" NAME="McClain 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-03-04 17:50:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClain CJ, Potter TJ, Kromhout JP, Zieve L</AU>
<TI>The effect of lactulose on psychomotor performance tests in alcoholic cirrhotics without overt hepatic encephalopathy</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1984</YR>
<VL>6</VL>
<PG>325-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="6481115"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mittal-2011" MODIFIED="2015-06-16 10:55:15 +0200" MODIFIED_BY="[Empty name]" NAME="Mittal 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-04 17:51:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mittal VV, Sharma BC, Sharma P, Sarin SK</AU>
<TI>A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2011</YR>
<VL>23</VL>
<PG>725-32</PG>
<IDENTIFIERS MODIFIED="2014-10-23 22:57:38 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21646910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-16 10:55:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mittal VV, Sharma P, Sharma B, Sarin SK</AU>
<TI>Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics &amp; L-ornithine L-aspartate with placebo [abstract]</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>Suppl 2</NO>
<PG>471A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00739663"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Morgan-1987a" MODIFIED="2016-03-23 12:32:29 +0100" MODIFIED_BY="[Empty name]" NAME="Morgan 1987a" YEAR="1987">
<REFERENCE MODIFIED="2015-02-05 21:54:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hawley KE, Morgan MY</AU>
<TI>A randomised controlled double-blind trial of lactitol and lactulose in acute hepatic encephalopathy in cirrhotic patients [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1986</YR>
<VL>3</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-05 21:54:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawley KE, Morgan MY</AU>
<TI>Lactitol vs lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind randomised trial [abstract]</TI>
<SO>Hepatology</SO>
<YR>1986</YR>
<VL>6</VL>
<PG>1148</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-05 21:54:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawley KE, Morgan MY</AU>
<TI>Randomised controlled double blind trial of lactitol and lactulose in acute hepatic encephalopathy in cirrhotic patients [abstract]</TI>
<SO>Gut</SO>
<YR>1986</YR>
<VL>27</VL>
<PG>A1266</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-23 12:32:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morgan MY, Hawley KE</AU>
<TI>Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial</TI>
<SO>Hepatology</SO>
<YR>1987</YR>
<VL>7</VL>
<PG>1278-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="88056766"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Morgan-1987b" MODIFIED="2015-06-22 13:55:43 +0200" MODIFIED_BY="[Empty name]" NAME="Morgan 1987b" YEAR="1987">
<REFERENCE MODIFIED="2015-06-22 13:55:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan MY, Hawley KE, Stambuk D</AU>
<TI>Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study</TI>
<SO>Journal of Hepatology</SO>
<YR>1987</YR>
<VL>4</VL>
<PG>236-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87223884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Morgan-1989" MODIFIED="2015-03-04 17:55:14 +0100" MODIFIED_BY="[Empty name]" NAME="Morgan 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-03-04 17:55:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomized cross-over study. J Hepatol 1989;8(2):208-17.&lt;/p&gt;" NOTES_MODIFIED="2015-03-04 17:55:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morgan MY, Alonso M, Stanger LC</AU>
<TI>Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomized cross-over study</TI>
<SO>Journal of Hepatology</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>208-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2654285"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanger LC, Alonso M, Morgan MY</AU>
<TI>Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy: a randomised cross-over study [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>179</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pai-1995" MODIFIED="2015-06-22 13:55:48 +0200" MODIFIED_BY="[Empty name]" NAME="Pai 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-06-22 13:55:48 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD. Treatment of porto-systemic encephalopathy with lactulose: a randomized controlled study. Chung Hua Tsa Chih Taipei 1995;55(1):31-6.&lt;/p&gt;" NOTES_MODIFIED="2015-06-22 13:55:48 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD</AU>
<TI>Treatment of porto-systemic encephalopathy with lactulose: a randomized controlled study</TI>
<SO>Chinese Medical Journal</SO>
<YR>1995</YR>
<VL>55</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Prasad-2007" MODIFIED="2015-03-04 17:56:35 +0100" MODIFIED_BY="[Empty name]" NAME="Prasad 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-03-04 17:56:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R</AU>
<TI>Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy</TI>
<SO>Hepatology</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>549-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17326150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quero-1997" MODIFIED="2015-06-16 10:58:22 +0200" MODIFIED_BY="[Empty name]" NAME="Quero 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-06-16 10:58:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Quero JC, Groeneweg M, Meulstee J, Hop WCJ, Schalm SW</AU>
<TI>Does a low-dose of lactulose improve quality of life in patients with liver cirrhosis?</TI>
<SO>Advances in Hepatic Encephalopathy &amp; Metabolism in Liver Disease: Proceedings of the 9th International Symposium on Ammonia</SO>
<YR>1997</YR>
<VL>64</VL>
<PG>459-65</PG>
<ED>Record C, Al-Mardini H</ED>
<PB>Ipswich Book Company Ltd</PB>
<CY>Newcastle upon Tyne, UK</CY>
<IDENTIFIERS MODIFIED="2014-11-04 22:24:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00363147"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-04 18:45:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quero JC, Groeneweg M, Meulstee J, Schalm SW</AU>
<TI>Does a low-dose of lactulose improve quality of life in patients with liver cirrhosis? [abstract]</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1996</YR>
<VL>18</VL>
<PG>A19</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00250860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raza-2004" MODIFIED="2015-03-04 18:49:57 +0100" MODIFIED_BY="[Empty name]" NAME="Raza 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-03-04 18:49:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raza MA, Bhatti RS, Akram J</AU>
<TI>Effect of rectal lactulose administration with oral therapy on time to recovery from hepatic encephalopathy: a randomized study</TI>
<SO>Annals of Saudi Medicine</SO>
<YR>2004</YR>
<VL>24</VL>
<PG>374-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15573853"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Riggio-1989" MODIFIED="2015-03-04 18:51:40 +0100" MODIFIED_BY="[Empty name]" NAME="Riggio 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-01-15 18:20:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Riggio O, Balducci G, Ariosto F, Merli M, Pieche U, Pinto G, et al</AU>
<TI>Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1989</YR>
<VL>34</VL>
<PG>823-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1989250975"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-15 18:21:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Riggio O, Balducci G, Ariosto F, Merli M, Romiti A, Tremiterra S, et al</AU>
<TI>Lactitol in the treatment of severe chronic hepatic encephalopathy. A randomized cross-over comparison with lactulose [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>168</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-15 18:20:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riggio O, Balducci G, Ariosto F, Merli M, Tremiterra S, Ziparo V, et al</AU>
<TI>Lactitol in the treatment of chronic hepatic encephalopathy - a randomized cross-over comparison with lactulose</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>1990</YR>
<VL>37</VL>
<PG>524-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2253931"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Riggio-2005" MODIFIED="2015-03-04 18:52:20 +0100" MODIFIED_BY="[Empty name]" NAME="Riggio 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-03-04 18:52:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al</AU>
<TI>Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study</TI>
<SO>Journal of Hepatology</SO>
<YR>2005</YR>
<VL>42</VL>
<PG>674-9</PG>
<IDENTIFIERS MODIFIED="2014-10-07 11:34:00 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15826716"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-05 21:57:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riggio O, Masini A, Efrati C, Nicolao F, Attili AF, Merli M</AU>
<TI>Randomized controlled trial for the prevention of early post-tips hepatic encephalopathy: comparison between rifaximin, lactitol and no treatment [abstract]</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>1510</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodgers-1973" MODIFIED="2015-06-22 13:56:06 +0200" MODIFIED_BY="[Empty name]" NAME="Rodgers 1973" YEAR="1973">
<REFERENCE MODIFIED="2015-06-22 13:56:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodgers JB Jr, Kiley JE, Balint JA</AU>
<TI>Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1973</YR>
<VL>60</VL>
<PG>459-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 4587191"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sharma-2009" MODIFIED="2015-02-05 21:58:40 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-10-11 20:18:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma BC, Sharma P, Agrawal A, Sarin SK</AU>
<TI>Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>137</VL>
<PG>885-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19501587"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sharma-2011" MODIFIED="2015-03-04 18:52:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-04 18:52:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Agrawal A, Sharma BC, Sarin SK</AU>
<TI>Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>996-1003</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:23:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21129028"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sharma-2012" MODIFIED="2016-02-26 12:20:03 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-02-26 12:19:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agrawal A, Sharma P, Sharma BC, Sarin SK</AU>
<TI>Primary prophylaxis of hepatic encephalopathy in patients with cirrhosis: an open labelled randomized controlled trial of lactulose versus no lactulose [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>Suppl 2</NO>
<PG>S238</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00844674"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-26 12:19:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Chander SB, Praveen S, Amit A, Kumar SS</AU>
<TI>Primary prophylaxis of hepatic encephalopathy in patients with cirrhosis: A open labelled randomized controlled trial of lactulose versus no lactulose [abstract]</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2010</YR>
<VL>25</VL>
<PG>A13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1111/j.1440-1746.2009.06493.x"/>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00789741"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-26 12:20:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sharma BC, Agrawal A, Sarin SK</AU>
<TI>Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labelled randomized controlled trial of lactulose versus no lactulose</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2012</YR>
<VL>27</VL>
<PG>1329-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22606978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-1997" MODIFIED="2015-06-22 13:56:14 +0200" MODIFIED_BY="[Empty name]" NAME="Shi 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-06-22 13:56:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi H, Liu HY, Fu Z, Zhu L, Chen WZ</AU>
<TI>Lactitol in treatment of subclinical hepatic encephalopathy: a double blind placebo-controlled randomised trial</TI>
<SO>Chinese Journal of Digestion</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>221-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simmons-1970" MODIFIED="2015-06-22 13:56:18 +0200" MODIFIED_BY="[Empty name]" NAME="Simmons 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-06-22 13:56:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Simmons F, Goldstein H, Boyle JD</AU>
<TI>A controlled clinical trial of lactulose in hepatic encephalopathy</TI>
<SO>Gastroenterology</SO>
<YR>1970</YR>
<VL>59</VL>
<PG>827-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71054874"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Uribe-1987a" MODIFIED="2015-04-03 13:38:23 +0200" MODIFIED_BY="[Empty name]" NAME="Uribe 1987a" YEAR="1987">
<REFERENCE MODIFIED="2015-04-03 13:38:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L, et al</AU>
<TI>Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial</TI>
<SO>Hepatology</SO>
<YR>1987</YR>
<VL>7</VL>
<PG>639-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-04 19:00:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uribe M, Gil S, Perez F, Toledo H, Ballesteros A, Garcia-Ramos G</AU>
<TI>Successful use of lactitol in acute portal systemic encephalopathy. A double blind controlled trial [abstract]</TI>
<SO>Hepatology</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>765</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Uribe-1987b" MODIFIED="2015-06-22 13:56:26 +0200" MODIFIED_BY="[Empty name]" NAME="Uribe 1987b" YEAR="1987">
<REFERENCE MODIFIED="2015-06-22 13:56:26 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Uribe M, Toledo H, Perez F, Vargas F, Gil S, Garcia-Ramos G, Ravelli GP, Guevara L. Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Dig Dis Sci 1987;32(12):1345-53.&lt;/p&gt;" NOTES_MODIFIED="2015-06-22 13:56:26 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uribe M, Toledo H, Perez F, Vargas F, Gil S, Garcia-Ramos G, et al</AU>
<TI>Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>1345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watanabe-1997" MODIFIED="2016-03-30 11:50:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Watanabe 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-03-30 11:50:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="OTHER">
<AU>Suzuki H, Sato S, Suzuki K, Muto Y, Watanabe A, Kuriyama K</AU>
<TI>Phase III study with lactitol (NS-4) for the patients of hyperammonemia: comparative study with lactulose</TI>
<SO>Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)</SO>
<YR>1995</YR>
<VL>11</VL>
<PG>1439-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00542601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-04 19:05:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, et al</AU>
<TI>Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>1410-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9397979"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-11 23:00:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe A, Sakai T, Sato S</AU>
<TI>Does lactulose improve psychometric tests and quality of life in cirrhotic patients with subclinical hepatic encephalopathy? [abstract]</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>452A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2013" MODIFIED="2015-02-05 22:01:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wen 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-02-05 22:01:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen J, Liu Q, Song J, Tong M, Peng L, Liang H</AU>
<TI>Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial</TI>
<SO>Digestion</SO>
<YR>2013</YR>
<VL>87</VL>
<PG>132-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="23485720"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xing-2003" MODIFIED="2014-11-16 20:58:35 +0100" MODIFIED_BY="[Empty name]" NAME="Xing 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-11-16 20:58:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xing Q, Liu L</AU>
<TI>Research of lactulose in the treatment of minimal hepatic encephalopathy</TI>
<SO>World Chinese Journal of Digestion</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>108-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2014" MODIFIED="2016-03-23 12:34:58 +0100" MODIFIED_BY="[Empty name]" NAME="Yao 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-03-23 12:34:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao C, Huang G, Wang M, Xia M, Yao F, Niu D, et al</AU>
<TI>Chinese herbal medicine formula Jieduhuayu granules improves cognitive and neurophysiological functions in patients with cirrhosis who have minimal hepatic encephalopathy: a randomized controlled trial</TI>
<SO>Complementary Therapies in Medicine</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>977-85</PG>
<IDENTIFIERS MODIFIED="2015-05-19 10:07:16 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="25453517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2003" MODIFIED="2016-03-30 11:50:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Zeng 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-03-30 11:50:07 +0200" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nie YQ, Zeng Z, Li YY, Sha WH, Ping L, Dai SJ</AU>
<TI>Long-term efficacy of lactulose in patients with subclinical hepatic encephalopathy</TI>
<SO>Zhonghua Nei Ke Za Zhi</SO>
<YR>2003</YR>
<VL>42</VL>
<PG>261-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="12887812"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-02 20:14:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zeng Z, Li YY, Jia L, Nie Y-Q</AU>
<TI>Influence of lactulose on the cognitive level and quality of life in patients with minimal hepatic encephalopathy</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>165-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00613050"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-30 11:50:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zeng Z, Li YY</AU>
<TI>Effects of lactulose treatment on the course of subclinical hepatic encephalopathy</TI>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>2003</YR>
<VL>83</VL>
<PG>1126-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="12921628"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziada-2013" MODIFIED="2015-03-04 19:09:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ziada 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-04 19:09:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziada DH, Soliman HH, El Yamany SA, Hamisa MF, Hasan AM</AU>
<TI>Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy</TI>
<SO>Arab Journal of Gastroenterology</SO>
<YR>2013</YR>
<VL>14</VL>
<PG>116-22</PG>
<IDENTIFIERS MODIFIED="2014-10-28 08:45:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="24206740"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-06-16 11:10:14 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bajaj-2010a" MODIFIED="2015-03-18 12:45:51 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2010a" YEAR="2010">
<REFERENCE MODIFIED="2015-03-04 19:10:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM</AU>
<TI>Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2010</YR>
<VL>31</VL>
<PG>1012-7</PG>
<IDENTIFIERS MODIFIED="2014-10-27 19:47:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20136802"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bircher-1971" MODIFIED="2015-03-04 19:11:18 +0100" MODIFIED_BY="[Empty name]" NAME="Bircher 1971" YEAR="1971">
<REFERENCE MODIFIED="2015-03-04 19:11:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bircher J, Haemmerli UP, Scollo-Lavizzari G, Hoffmann K</AU>
<TI>Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature</TI>
<SO>American Journal of Medicine</SO>
<YR>1971</YR>
<VL>51</VL>
<PG>148-59</PG>
<IDENTIFIERS MODIFIED="2014-10-27 19:50:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="5095524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1970" MODIFIED="2015-03-04 19:12:01 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-03-04 19:12:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown H, Trey C, McDermott WV Jr</AU>
<TI>Encephalopathy after portacaval shunting managed with lactulose</TI>
<SO>American Journal of Surgery</SO>
<YR>1970</YR>
<VL>119</VL>
<PG>132-7</PG>
<IDENTIFIERS MODIFIED="2014-11-16 20:33:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="5440784"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-1971" MODIFIED="2014-11-02 20:39:06 +0100" MODIFIED_BY="[Empty name]" NAME="James 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-11-02 20:39:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James IM, Garassini M</AU>
<TI>Effect of lactulose on cerebral metabolism in patients with chronic portosystemic encephalopathy</TI>
<SO>Gut</SO>
<YR>1971</YR>
<VL>12</VL>
<PG>702-4</PG>
<IDENTIFIERS MODIFIED="2014-10-27 20:10:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="5098325"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanthier-1985" MODIFIED="2014-11-02 20:39:12 +0100" MODIFIED_BY="[Empty name]" NAME="Lanthier 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-11-02 20:39:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanthier PL, Morgan MY</AU>
<TI>Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose</TI>
<SO>Gut</SO>
<YR>1985</YR>
<VL>26</VL>
<PG>415-20</PG>
<IDENTIFIERS MODIFIED="2014-10-27 20:55:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3979914"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merli-1992" MODIFIED="2015-03-04 19:12:46 +0100" MODIFIED_BY="[Empty name]" NAME="Merli 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-03-04 19:12:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Merli M, Caschera M, Piat C, Pinto G, Diofebi M, Riggio O</AU>
<TI>The effect of lactulose and lactitol administration on fecal fat excretion in patients with liver cirrhosis</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>125-7</PG>
<IDENTIFIERS MODIFIED="2014-11-04 23:22:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00087562"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patil-1987" MODIFIED="2014-11-02 20:39:32 +0100" MODIFIED_BY="[Empty name]" NAME="Patil 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-11-02 20:39:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patil DH, Westaby D, Mahida YR, Palmer KR, Rees R, Clark ML, et al</AU>
<TI>Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy</TI>
<SO>Gut</SO>
<YR>1987</YR>
<VL>28</VL>
<PG>255-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="3570029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piotraschke-1996" MODIFIED="2015-03-04 19:13:20 +0100" MODIFIED_BY="[Empty name]" NAME="Piotraschke 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-03-04 19:13:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piotraschke J, Berger E, Haag K, Ochs A, Görtelmeyer R, Rössle M</AU>
<TI>Effect of lactulose on latent hepatic encephalopathy and plasma ammonia concentration in outpatients with TIPS [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pockros-2009" MODIFIED="2015-03-04 19:13:59 +0100" MODIFIED_BY="[Empty name]" NAME="Pockros 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-04 19:13:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pockros P, Hassanein T, Vierling J, Heuman D, Hillebrand D, Chojkier M</AU>
<TI>Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy (HE) [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2009</YR>
<VL>50</VL>
<PG>S43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00715816"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quinton-1982" MODIFIED="2015-03-04 19:14:31 +0100" MODIFIED_BY="[Empty name]" NAME="Quinton 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-03-04 19:14:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinton A, Lamouliatte H, Plane D, Delteil L</AU>
<TI>Randomized study of mannitol lavage and of a combination of lactulose and kanamycin in prevention and treatment of posthemorrhagic encephalopathy in patients with cirrhosis [abstract]</TI>
<SO>Gastroenterologie Clinique et Biologique</SO>
<YR>1982</YR>
<VL>6</VL>
<PG>124A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rahimi-2014" MODIFIED="2015-03-04 19:15:31 +0100" MODIFIED_BY="[Empty name]" NAME="Rahimi 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-03-04 19:15:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rahimi RS, Singal AG, Cuthbert JA, Rockey DC</AU>
<TI>Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: The HELP Randomized Clinical Trial</TI>
<SO>JAMA Internal Medicine</SO>
<YR>2014</YR>
<VL>174</VL>
<PG>1727-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riggio-1990" MODIFIED="2015-03-04 19:16:13 +0100" MODIFIED_BY="[Empty name]" NAME="Riggio 1990" YEAR="">
<REFERENCE MODIFIED="2015-03-04 19:16:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, et al</AU>
<TI>Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>433-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2398251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rorsman-1970" MODIFIED="2015-03-04 19:16:27 +0100" MODIFIED_BY="[Empty name]" NAME="Rorsman 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-03-04 19:16:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rorsman G, Sulg I</AU>
<TI>Lactulose treatment of chronic hepatoportal encephalopathy. A clinical and electroencephalographic study</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1970</YR>
<VL>187</VL>
<PG>337-46</PG>
<IDENTIFIERS MODIFIED="2014-11-04 21:54:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="5526951"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salerno-1994" MODIFIED="2015-03-04 19:16:48 +0100" MODIFIED_BY="[Empty name]" NAME="Salerno 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-03-04 19:16:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salerno F, Moser P, Maggi A, Vitaliani G, Benetti G</AU>
<TI>Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy</TI>
<SO>Journal of Hepatology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>1092-6</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:07:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="7699233"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schomerus-1993" MODIFIED="2015-03-04 19:17:02 +0100" MODIFIED_BY="[Empty name]" NAME="Schomerus 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-03-04 19:17:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schomerus H, Schreiegg J</AU>
<TI>Prevalence of latent portasystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice</TI>
<SO>Zeitschrift fur Gastroenterologie</SO>
<YR>1993</YR>
<VL>31</VL>
<PG>231-4</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:10:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8493802"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2008" MODIFIED="2015-03-04 19:17:44 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-03-04 19:17:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sharma BC, Puri V, Sarin SK</AU>
<TI>An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2008</YR>
<VL>20</VL>
<PG>506-11</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:13:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18467909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2009a" MODIFIED="2015-03-04 19:18:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2009a" YEAR="2009">
<REFERENCE MODIFIED="2015-03-04 19:18:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sharma BC, Sarin SK</AU>
<TI>Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>1365-71</PG>
<IDENTIFIERS MODIFIED="2014-11-02 21:57:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19555401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2010" MODIFIED="2015-03-04 19:18:44 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-03-04 19:18:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sharma BC, Sarin SK</AU>
<TI>Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2010</YR>
<VL>22</VL>
<PG>526-31</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:15:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20009938"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2010a" MODIFIED="2014-11-02 21:59:40 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2010a" YEAR="2010">
<REFERENCE MODIFIED="2014-11-02 21:59:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sharma BC, Sarin SK</AU>
<TI>Prevalence of abnormal psychometric tests and critical flicker frequency after clinical recovery of overt hepatic encephalopathy</TI>
<SO>Neurology India</SO>
<YR>2010</YR>
<VL>58</VL>
<PG>220-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20508339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2011a" MODIFIED="2015-03-04 19:19:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2011a" YEAR="2011">
<REFERENCE MODIFIED="2015-03-04 19:19:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sharma BC</AU>
<TI>Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose</TI>
<SO>Saudi Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>17</VL>
<PG>138-41</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:26:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21372353"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trovato-1995" MODIFIED="2015-02-05 22:18:01 +0100" MODIFIED_BY="[Empty name]" NAME="Trovato 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-02-05 22:18:01 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trovato GM, Catalano D, Carpinteri G, Runcio N, Mazzone O. Effects of lactitol (correction of lactilol) on hepatic encephalopathy and plasma amino-acid imbalance. Recenti Prog Med 1995;86(7-8):299-303.&lt;/p&gt;" NOTES_MODIFIED="2015-02-05 22:18:01 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trovato GM, Catalano D, Carpinteri G, Runcio N, Mazzone O</AU>
<TI>Effects of lactitol on hepatic encephalopathy and plasma amino-acid imbalance</TI>
<SO>Recenti Progressi in Medicina</SO>
<YR>1995</YR>
<VL>86</VL>
<PG>299-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7569287"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vendemiale-1992" MODIFIED="2015-01-14 12:07:43 +0100" MODIFIED_BY="[Empty name]" NAME="Vendemiale 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-01-14 12:07:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vendemiale G, Palasciano G, Cirelli F, Altamura M, De Vincentiis A, Altomare E</AU>
<TI>Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1992</YR>
<VL>42</VL>
<PG>969-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 1418064"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venturini-2005" MODIFIED="2015-03-04 19:21:42 +0100" MODIFIED_BY="[Empty name]" NAME="Venturini 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-03-04 19:21:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Venturini I, Ferrieri A, Farina F, Cosenza F, Avallone R, Corsi L, et al</AU>
<TI>Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study</TI>
<SO>Drugs under Experimental and Clinical Research</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>161-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16223206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeegen-1970" MODIFIED="2015-06-16 11:10:14 +0200" MODIFIED_BY="[Empty name]" NAME="Zeegen 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-06-16 11:10:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeegen R, Drinkwater JE, Fenton JC, Vince A, Dawson AM</AU>
<TI>Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1970</YR>
<VL>39</VL>
<PG>245-63</PG>
<IDENTIFIERS MODIFIED="2014-10-27 21:33:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="5449591"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-11-16 20:58:35 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2014-10-23 20:37:30 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Salih-2007" MODIFIED="2014-10-07 17:54:21 +0200" MODIFIED_BY="[Empty name]" NAME="Salih 2007" YEAR="2007">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wang-2012" MODIFIED="2014-10-07 17:54:25 +0200" MODIFIED_BY="[Empty name]" NAME="Wang 2012" YEAR="2012">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-19 13:45:31 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Bajaj-2008" MODIFIED="2016-03-30 11:50:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Bajaj 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al</AU>
<TI>Inhibitory control test for the diagnosis of minimal hepatic encephalopathy</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>135</VL>
<PG>1591-600</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18723018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2009" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Bajaj 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Wade JB, Sanyal AJ</AU>
<TI>Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>50</VL>
<PG>2014-21</PG>
<IDENTIFIERS MODIFIED="2014-10-21 12:34:41 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19787808"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2010b" MODIFIED="2015-03-18 12:45:58 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al</AU>
<TI>Persistence of cognitive impairment after resolution of overt hepatic encephalopathy</TI>
<SO>Gastroenterology</SO>
<YR>2010</YR>
<VL>138</VL>
<PG>2332-40</PG>
<IDENTIFIERS MODIFIED="2015-03-04 19:32:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20178797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2010c" MODIFIED="2015-06-16 11:11:21 +0200" MODIFIED_BY="[Empty name]" NAME="Bajaj 2010c" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM</AU>
<TI>Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2010</YR>
<VL>31</VL>
<PG>1012-7</PG>
<IDENTIFIERS MODIFIED="2015-06-03 15:17:38 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-03 15:17:38 +0200" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20136802"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2011a" MODIFIED="2015-10-26 14:20:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al</AU>
<TI>Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>33</VL>
<PG>739-47</PG>
<IDENTIFIERS MODIFIED="2014-10-21 11:25:53 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21306407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2011b" MODIFIED="2016-02-26 12:35:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, et al</AU>
<TI>The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>106</VL>
<PG>1646-53</PG>
<IDENTIFIERS MODIFIED="2015-10-26 14:18:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21556040"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2012" MODIFIED="2016-03-23 12:38:36 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Gillevet PM, Patel NR, Ahluwalia V, Ridlon JM, Kettenmann B, et al</AU>
<TI>A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy</TI>
<SO>Metabolic Brain Disease</SO>
<YR>2012</YR>
<VL>27</VL>
<PG>205-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22527995"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berding-2009" MODIFIED="2015-03-08 12:11:01 +0100" MODIFIED_BY="[Empty name]" NAME="Berding 2009" TYPE="JOURNAL_ARTICLE">
<AU>Berding G, Banati RB, Buchert R, Chierichetti F, Grover VP, Kato A, et al</AU>
<TI>Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>621-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19413665"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bircher-1966" MODIFIED="2015-06-03 18:36:17 +0200" MODIFIED_BY="[Empty name]" NAME="Bircher 1966" TYPE="JOURNAL_ARTICLE">
<AU>Bircher J, Müller J, Guggenheim P, Haemmerli UP</AU>
<TI>Treatment of chronic portal-systemic encephalopathy with lactulose</TI>
<SO>Lancet</SO>
<YR>1966</YR>
<VL>1</VL>
<PG>890</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blanc-1992" MODIFIED="2015-03-04 19:53:39 +0100" MODIFIED_BY="[Empty name]" NAME="Blanc 1992" TYPE="JOURNAL_ARTICLE">
<AU>Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, et al</AU>
<TI>Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis</TI>
<SO>Hepatology</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>222-8</PG>
<IDENTIFIERS MODIFIED="2014-10-27 19:59:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="1531204"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2006" MODIFIED="2016-02-26 12:36:43 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al</AU>
<TI>How to formulate research recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2006</YR>
<VL>333</VL>
<PG>804-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bustamante-1999" MODIFIED="2015-03-08 12:11:07 +0100" MODIFIED_BY="[Empty name]" NAME="Bustamante 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al</AU>
<TI>Prognostic significance of hepatic encephalopathy in patients with cirrhosis</TI>
<SO>Journal of Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>890-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="10365817"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Butterworth-2014" MODIFIED="2015-03-04 19:53:54 +0100" MODIFIED_BY="[Empty name]" NAME="Butterworth 2014" TYPE="JOURNAL_ARTICLE">
<AU>Butterworth RF</AU>
<TI>Hepatic encephalopathy in alcoholic cirrhosis</TI>
<SO>Handbook of Clinical Neurology</SO>
<YR>2014</YR>
<VL>125</VL>
<PG>589-602</PG>
<IDENTIFIERS MODIFIED="2014-10-21 13:30:46 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="25307598"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cadranel-2001" MODIFIED="2015-04-03 14:00:16 +0200" MODIFIED_BY="[Empty name]" NAME="Cadranel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, Tourbah A, et al</AU>
<TI>Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>515-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11232699"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Camma-1993" MODIFIED="2015-03-04 19:54:07 +0100" MODIFIED_BY="[Empty name]" NAME="Camma 1993" TYPE="JOURNAL_ARTICLE">
<AU>Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L</AU>
<TI>Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1993</YR>
<VL>38</VL>
<PG>916-22</PG>
<IDENTIFIERS MODIFIED="2014-10-27 20:06:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8482191"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chu-1997" MODIFIED="2015-03-08 12:28:53 +0100" MODIFIED_BY="[Empty name]" NAME="Chu 1997" TYPE="JOURNAL_ARTICLE">
<AU>Chu NS, Yang SS, Liaw YF</AU>
<TI>Evoked potentials in liver diseases</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>S288-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9407349"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Conn-1977" MODIFIED="2015-03-08 12:29:13 +0100" MODIFIED_BY="[Empty name]" NAME="Conn 1977" TYPE="JOURNAL_ARTICLE">
<AU>Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al</AU>
<TI>Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1977</YR>
<VL>72</VL>
<PG>573-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="14049"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-1986" MODIFIED="2015-03-04 19:56:21 +0100" MODIFIED_BY="[Empty name]" NAME="D'Amico 1986" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G, Morabito A, Pagliaro L, Marubini E</AU>
<TI>Survival and prognostic indicators in compensated and decompensated cirrhosis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1986</YR>
<VL>31</VL>
<PG>468-75</PG>
<IDENTIFIERS MODIFIED="2014-10-21 12:47:36 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3009109"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2006" MODIFIED="2015-03-08 13:54:50 +0100" MODIFIED_BY="[Empty name]" NAME="D'Amico 2006" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G, Garcia-Tsao G, Pagliaro L</AU>
<TI>Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies</TI>
<SO>Journal of Hepatology</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>217-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Jongh-1992" MODIFIED="2015-03-04 19:56:28 +0100" MODIFIED_BY="[Empty name]" NAME="de Jongh 1992" TYPE="JOURNAL_ARTICLE">
<AU>de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M</AU>
<TI>Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver</TI>
<SO>Gastroenterology</SO>
<YR>1992</YR>
<VL>103</VL>
<PG>1630-5</PG>
<IDENTIFIERS MODIFIED="2014-10-21 12:47:36 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="1426884"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dwan-2008" MODIFIED="2016-03-23 12:39:35 +0100" MODIFIED_BY="[Empty name]" NAME="Dwan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al</AU>
<TI>Systematic review of the empirical evidence of study publication bias and outcome reporting bias</TI>
<SO>PloS One</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>e3081</PG>
<IDENTIFIERS MODIFIED="2014-10-29 22:17:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="CMR-12056"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EASL-and-AASLD-guideline-2014a" MODIFIED="2015-03-04 19:59:07 +0100" MODIFIED_BY="[Empty name]" NAME="EASL and AASLD guideline 2014a" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases</TI>
<SO>Journal of Hepatology</SO>
<YR>2014</YR>
<VL>61</VL>
<PG>642-59</PG>
<IDENTIFIERS MODIFIED="2014-10-14 09:54:15 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="25015420"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EASL-and-AASLD-guideline-2014b" MODIFIED="2015-03-04 19:57:05 +0100" MODIFIED_BY="[Empty name]" NAME="EASL and AASLD guideline 2014b" TYPE="JOURNAL_ARTICLE">
<AU>Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al</AU>
<TI>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver</TI>
<SO>Hepatology</SO>
<YR>2014</YR>
<VL>60</VL>
<PG>715-35</PG>
<IDENTIFIERS MODIFIED="2014-10-14 09:54:15 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="25042402"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferenci-2002" MODIFIED="2015-03-04 20:00:05 +0100" MODIFIED_BY="[Empty name]" NAME="Ferenci 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT</AU>
<TI>Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<PG>716-21</PG>
<IDENTIFIERS MODIFIED="2014-10-21 11:22:04 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11870389"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilson-1975" MODIFIED="2015-03-04 20:00:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gilson 1975" TYPE="JOURNAL_ARTICLE">
<AU>Gilson BS, Gilson JS, Bergner M, Bobbit RA, Kressel S, Pollard WE, et al</AU>
<TI>The sickness impact profile. Development of an outcome measure of health care</TI>
<SO>American Journal of Public Health</SO>
<YR>1975</YR>
<VL>65</VL>
<PG>1304-10</PG>
<IDENTIFIERS MODIFIED="2014-11-06 21:07:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="1200192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2015" MODIFIED="2016-02-26 13:20:52 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2015" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About Cochrane (Cochrane Review Groups (CRGs)) 2015, Issue 2. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2015-03-04 20:00:54 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Grade Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groeneweg-1998" MODIFIED="2015-03-08 12:29:39 +0100" MODIFIED_BY="[Empty name]" NAME="Groeneweg 1998" TYPE="JOURNAL_ARTICLE">
<AU>Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, et al</AU>
<TI>Subclinical hepatic encephalopathy impairs daily functioning</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>45-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9657095"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grover-2006" MODIFIED="2015-03-08 12:30:15 +0100" MODIFIED_BY="[Empty name]" NAME="Grover 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grover VP, Dresner MA, Forton DM, Counsell S, Larkman DJ, Patel N, et al</AU>
<TI>Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>2969-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16718775"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gu_x00e9_rit-2009" MODIFIED="2015-10-19 14:21:07 +0200" MODIFIED_BY="[Empty name]" NAME="Guérit 2009" TYPE="JOURNAL_ARTICLE">
<AU>Guérit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, et al</AU>
<TI>Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>789-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19638107"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2015-03-04 20:01:03 +0100" MODIFIED_BY="[Empty name]" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>3443-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16345038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haussinger-2000" MODIFIED="2015-03-08 12:31:12 +0100" MODIFIED_BY="[Empty name]" NAME="Haussinger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S</AU>
<TI>Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>1035-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="10898326"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2014-10-06 16:56:54 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Higgins J, White IR, Wood AM</AU>
<TI>Imputation methods for missing outcome data in meta-analysis of clinical trials</TI>
<SO>Clinical Trials</SO>
<YR>2008</YR>
<VL>5</VL>
<PG>225-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2015-06-16 11:23:29 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2015-03-18 12:47:33 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-2007" MODIFIED="2015-06-16 11:24:27 +0200" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 2007" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>Pennsylvania</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-2007" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Johanson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF</AU>
<TI>Review of the treatment options for chronic constipation</TI>
<SO>MedGenMed: Medscape General Medicine</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>25</PG>
<IDENTIFIERS MODIFIED="2014-10-21 13:14:35 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17955081"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Katz-1963" MODIFIED="2014-11-06 20:55:33 +0100" MODIFIED_BY="[Empty name]" NAME="Katz 1963" TYPE="JOURNAL_ARTICLE">
<AU>Katz MM, Lyerly SB</AU>
<TI>Methods for measuring adjustment and social behavior in the community: i. Rationale, description, discriminative validity and scale development</TI>
<SO>Psychological Reports</SO>
<YR>1963</YR>
<VL>13</VL>
<PG>503-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kimer-2015" MODIFIED="2015-04-03 16:10:17 +0200" MODIFIED_BY="[Empty name]" NAME="Kimer 2015" TYPE="COCHRANE_PROTOCOL">
<AU>Kimer N, Krag A, Møller S, Bendtsen F, Gluud L</AU>
<TI>Rifaximin for people with hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-04-03 14:11:00 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-04-03 14:10:59 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD011585"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kircheis-2002" MODIFIED="2015-03-08 12:32:16 +0100" MODIFIED_BY="[Empty name]" NAME="Kircheis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D</AU>
<TI>Critical flicker frequency for quantification of low-grade hepatic encephalopathy</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<PG>357-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11826409"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kircheis-2009" MODIFIED="2015-03-08 12:32:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kircheis 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kircheis G, Knoche A, Hilger N, Manhart F, Schnitzler A, Schulze H, et al</AU>
<TI>Hepatic encephalopathy and fitness to drive</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>137</VL>
<PG>1706-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19686744"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lauridsen-2011" MODIFIED="2015-03-05 10:38:25 +0100" MODIFIED_BY="[Empty name]" NAME="Lauridsen 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lauridsen MM, Jepsen P, Vilstrup H</AU>
<TI>Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease</TI>
<SO>Metabolic Brain Disease</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>135-9</PG>
<IDENTIFIERS MODIFIED="2014-10-21 11:49:14 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21484318"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2014" MODIFIED="2015-03-08 11:56:02 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2014" TYPE="JOURNAL_ARTICLE">
<AU>Miller LE, Tennila J, Ouwehand AC</AU>
<TI>Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis</TI>
<SO>Clinical and Experimental Gastroenterology</SO>
<YR>2014</YR>
<VL>7</VL>
<PG>241-8</PG>
<IDENTIFIERS MODIFIED="2014-10-14 09:51:46 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="25050074"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Montagnese-2004" MODIFIED="2015-03-08 12:33:12 +0100" MODIFIED_BY="[Empty name]" NAME="Montagnese 2004" TYPE="JOURNAL_ARTICLE">
<AU>Montagnese S, Amodio P, Morgan MY</AU>
<TI>Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach</TI>
<SO>Metabolic Brain Disease</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>281-312</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15554423"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1929" MODIFIED="2015-06-03 18:34:49 +0200" MODIFIED_BY="[Empty name]" NAME="Montgomery 1929" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery E, Hudson CS</AU>
<TI>Transformation of lactose to a new disaccharide, lactulose</TI>
<SO>Science</SO>
<YR>1929</YR>
<VL>69</VL>
<PG>556</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neff-2010" MODIFIED="2015-03-08 11:57:42 +0100" MODIFIED_BY="[Empty name]" NAME="Neff 2010" TYPE="JOURNAL_ARTICLE">
<AU>Neff G</AU>
<TI>Pharmacoeconomics of hepatic encephalopathy</TI>
<SO>Pharmacotherapy</SO>
<YR>2010</YR>
<VL>30</VL>
<PG>28S-32S</PG>
<IDENTIFIERS MODIFIED="2014-10-29 23:02:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20412038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Carroll-1991" MODIFIED="2015-03-08 12:33:26 +0100" MODIFIED_BY="[Empty name]" NAME="O'Carroll 1991" TYPE="JOURNAL_ARTICLE">
<AU>O'Carroll RE, Hayes PC, Ebmeier KP, Dougall N, Murray C, Best JJ, et al</AU>
<TI>Regional cerebral blood flow and cognitive function in patients with chronic liver disease</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>1250-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="1674063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Page-2014" MODIFIED="2016-02-26 13:16:50 +0100" MODIFIED_BY="[Empty name]" NAME="Page 2014" TYPE="COCHRANE_REVIEW">
<AU>Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, et al</AU>
<TI>Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2014-10-29 22:04:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.MR000035.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="MR000035"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parsons_x002d_Smith-1957" MODIFIED="2015-03-08 12:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Parsons-Smith 1957" TYPE="JOURNAL_ARTICLE">
<AU>Parsons-Smith BG, Summerskill WH, Dawson AM, Sherlock S</AU>
<TI>The electroencephalograph in liver disease</TI>
<SO>Lancet</SO>
<YR>1957</YR>
<VL>273</VL>
<PG>867-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="13482229"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patidar-2014" MODIFIED="2016-02-26 13:17:23 +0100" MODIFIED_BY="[Empty name]" NAME="Patidar 2014" TYPE="JOURNAL_ARTICLE">
<AU>Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqui MS, et al</AU>
<TI>Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2014</YR>
<VL>109</VL>
<NO>11</NO>
<PG>1757-63</PG>
<IDENTIFIERS MODIFIED="2015-10-26 14:17:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="25178701"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poordad-2007" MODIFIED="2015-03-08 12:00:30 +0100" MODIFIED_BY="[Empty name]" NAME="Poordad 2007" TYPE="JOURNAL_ARTICLE">
<AU>Poordad FF</AU>
<TI>Review article: the burden of hepatic encephalopathy</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>3-9</PG>
<IDENTIFIERS MODIFIED="2014-10-29 22:59:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17295846"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qin-2014" MODIFIED="2016-03-15 16:30:35 +0100" MODIFIED_BY="[Empty name]" NAME="Qin 2014" TYPE="JOURNAL_ARTICLE">
<AU>Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al</AU>
<TI>Alterations of the human gut microbiome in liver cirrhosis</TI>
<SO>Nature</SO>
<YR>2014</YR>
<VL>513</VL>
<NO>7516</NO>
<PG>59-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="25079328"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Randolph-2009" MODIFIED="2015-03-17 18:42:39 +0100" MODIFIED_BY="[Empty name]" NAME="Randolph 2009" TYPE="JOURNAL_ARTICLE">
<AU>Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al</AU>
<TI>Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>629-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19302444"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-06-16 12:06:51 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riggio-1990b" MODIFIED="2016-03-23 12:42:41 +0100" MODIFIED_BY="[Empty name]" NAME="Riggio 1990b" TYPE="JOURNAL_ARTICLE">
<AU>Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, et al</AU>
<TI>Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>4</NO>
<PG>433-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2398251"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roman-2011" MODIFIED="2015-06-16 11:52:27 +0200" MODIFIED_BY="[Empty name]" NAME="Roman 2011" TYPE="JOURNAL_ARTICLE">
<AU>Roman E, Córdoba J, Torrens M, Torras X, Villanueva C, Vargas V, et al</AU>
<TI>Minimal hepatic encephalopathy is associated with falls</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>106</VL>
<PG>476-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saunders-1981" MODIFIED="2015-03-08 12:02:13 +0100" MODIFIED_BY="[Empty name]" NAME="Saunders 1981" TYPE="JOURNAL_ARTICLE">
<AU>Saunders JB, Walters JR, Davies AP, Paton A</AU>
<TI>A 20-year prospective study of cirrhosis</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1981</YR>
<VL>282</VL>
<PG>263-6</PG>
<IDENTIFIERS MODIFIED="2014-10-21 12:45:54 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6779978"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012" MODIFIED="2015-03-08 12:03:50 +0100" MODIFIED_BY="[Empty name]" NAME="Savovic 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<PG>429-38</PG>
<IDENTIFIERS MODIFIED="2014-10-29 20:33:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22945832"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schomerus-1981" MODIFIED="2016-03-30 11:52:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Schomerus 1981" TYPE="JOURNAL_ARTICLE">
<AU>Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dolle W</AU>
<TI>Latent portosystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1981</YR>
<VL>26</VL>
<PG>622-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="7249898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schomerus-1998" MODIFIED="2015-03-08 12:38:07 +0100" MODIFIED_BY="[Empty name]" NAME="Schomerus 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schomerus H, Hamster W</AU>
<TI>Neuropsychological aspects of portal-systemic encephalopathy</TI>
<SO>Metabolic Brain Disease</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>361-77</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="10206827"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SF-36-questionnaire" MODIFIED="2015-06-16 12:03:04 +0200" MODIFIED_BY="[Empty name]" NAME="SF 36 questionnaire" TYPE="OTHER">
<TI>Short Form 36 questionnaire (SF 36)</TI>
<SO>www.sf-36.org (accessed 20 November 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sotil-2009" MODIFIED="2015-03-08 13:58:46 +0100" MODIFIED_BY="[Empty name]" NAME="Sotil 2009" TYPE="JOURNAL_ARTICLE">
<AU>Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT</AU>
<TI>Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation</TI>
<SO>Liver Transplantation</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>184-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stata" MODIFIED="2014-10-06 17:15:30 +0200" MODIFIED_BY="[Empty name]" NAME="Stata" TYPE="COMPUTER_PROGRAM">
<TI>Stata 13</TI>
<YR>2007</YR>
<PB>Stata Corp, Texas, USA</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stepanova-2012" MODIFIED="2015-03-08 12:05:10 +0100" MODIFIED_BY="[Empty name]" NAME="Stepanova 2012" TYPE="JOURNAL_ARTICLE">
<AU>Stepanova M, Mishra A, Venkatesan C, Younossi ZM</AU>
<TI>In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2012</YR>
<VL>10</VL>
<PG>1034-41</PG>
<IDENTIFIERS MODIFIED="2014-10-29 22:56:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22642955"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stewart-2007" MODIFIED="2015-03-08 13:58:16 +0100" MODIFIED_BY="[Empty name]" NAME="Stewart 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stewart CA, Malinchoc M, Kim WR, Kamath PS</AU>
<TI>Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease</TI>
<SO>Liver Transplantation</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>1366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor_x002d_Robinson-1994" MODIFIED="2015-03-08 12:38:29 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor-Robinson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Taylor-Robinson SD, Sargentoni J, Marcus CD, Morgan MY, Bryant DJ</AU>
<TI>Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy</TI>
<SO>Metabolic Brain Disease</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>347-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="7898401"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Teasdale-1974" MODIFIED="2015-03-08 12:38:56 +0100" MODIFIED_BY="[Empty name]" NAME="Teasdale 1974" TYPE="JOURNAL_ARTICLE">
<AU>Teasdale G, Jennett B</AU>
<TI>Assessment of coma and impaired consciousness. A practical scale</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>81-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="4136544"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 6 June 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2015-06-16 11:15:03 +0200" MODIFIED_BY="[Empty name]" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Victor-1965" MODIFIED="2015-03-08 12:39:20 +0100" MODIFIED_BY="[Empty name]" NAME="Victor 1965" TYPE="JOURNAL_ARTICLE">
<AU>Victor M, Adams RD, Cole M</AU>
<TI>The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration</TI>
<SO>Medicine</SO>
<YR>1965</YR>
<VL>44</VL>
<PG>345-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="5318075"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Volk-2012" MODIFIED="2015-06-03 15:20:28 +0200" MODIFIED_BY="[Empty name]" NAME="Volk 2012" TYPE="JOURNAL_ARTICLE">
<AU>Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS</AU>
<TI>Hospital readmissions among patients with decompensated cirrhosis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2012</YR>
<VL>107</VL>
<PG>247-52</PG>
<IDENTIFIERS MODIFIED="2015-06-03 15:20:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-03 15:20:28 +0200" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21931378"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weissenborn-1998" MODIFIED="2015-06-16 12:02:26 +0200" MODIFIED_BY="[Empty name]" NAME="Weissenborn 1998" TYPE="JOURNAL_ARTICLE">
<AU>Weissenborn K</AU>
<TI>Diagnosis of encephalopathy</TI>
<SO>Digestion</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>Suppl 2</NO>
<PG>22-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weissenborn-2001" MODIFIED="2015-03-08 12:39:25 +0100" MODIFIED_BY="[Empty name]" NAME="Weissenborn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H</AU>
<TI>Neuropsychological characterization of hepatic encephalopathy</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>768-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11434627"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHOQOL-1998" MODIFIED="2016-02-26 13:19:48 +0100" MODIFIED_BY="[Empty name]" NAME="WHOQOL 1998" TYPE="JOURNAL_ARTICLE">
<AU>The WHOQOL Group</AU>
<TI>Development of the World Health Organization WHOQOL-BREF quality of life assessment</TI>
<SO>Psychological Medicine</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>551-8</PG>
<IDENTIFIERS MODIFIED="2014-11-13 22:35:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="9626712"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zipprich-2012" MODIFIED="2015-03-08 12:07:21 +0100" MODIFIED_BY="[Empty name]" NAME="Zipprich 2012" TYPE="JOURNAL_ARTICLE">
<AU>Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM</AU>
<TI>Prognostic indicators of survival in patients with compensated and decompensated cirrhosis</TI>
<SO>Liver International</SO>
<YR>2012</YR>
<VL>32</VL>
<PG>1407-14</PG>
<IDENTIFIERS MODIFIED="2014-10-21 12:47:36 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22679906"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-04-19 13:45:31 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Als_x002d_Nielsen-2000" MODIFIED="2016-02-25 14:32:24 +0100" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2000" TYPE="COCHRANE_REVIEW">
<AU>Als-Nielsen B, Gluud LL, Gluud C</AU>
<TI>Nonabsorbable disaccharides for hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-02-25 14:31:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-02-25 14:31:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003044"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2004a" MODIFIED="2016-03-15 14:14:41 +0100" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2004a" TYPE="COCHRANE_REVIEW">
<AU>Als-Nielsen B, Gluud LL, Gluud C</AU>
<TI>Non-absorbable disaccharides for hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-02-25 14:29:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-02-25 14:29:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003044.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2004b" MODIFIED="2016-03-15 14:14:30 +0100" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Als-Nielsen B, Gluud LL, Gluud C</AU>
<TI>Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7447</NO>
<PG>1046</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:41:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2005" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Als-Nielsen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Als-Nielsen BE, Gluud LL, Gluud CN</AU>
<TI>Nonabsorbable disaccharides for the treatment of hepatic encephalopathy--a systemic review of randomized clinical trials--a secondary publication</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2005</YR>
<VL>167</VL>
<PG>179-82</PG>
<IDENTIFIERS MODIFIED="2016-02-25 14:36:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2016" MODIFIED="2016-04-19 13:45:31 +0200" MODIFIED_BY="[Empty name]" NAME="Gluud 2016" TYPE="OTHER">
<AU>Gluud LL, Vilstrup H, Morgan MY</AU>
<TI>Non-absorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis</TI>
<SO>Hepatology</SO>
<YR>2016 Apr 15 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2016-04-19 13:45:31 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-04-19 13:45:31 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/hep.28598"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-03-08 12:39:25 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-04-07 11:47:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-04-07 11:47:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Outcomes included in meta-analyses" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Inclusion period" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Country of origin">
<INCLUDED_CHAR MODIFIED="2016-03-30 11:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Agrawal-2012">
<CHAR_METHODS MODIFIED="2016-03-30 11:31:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:31:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 158 participants (see notes) with cirrhosis and a history, but no current evidence, of overt hepatic encephalopathy. In total, 71% of participants in the lactulose group and 73% in the control group had minimal hepatic encephalopathy at inclusion.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 41 ± 10.7 years</LI>
<LI>Control group 46.0 ± 11.2 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 85.0%</LI>
<LI>Control group 78.2%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 40.0%</LI>
<LI>Hepatitis B 20.9%</LI>
<LI>Hepatitis C 15.3%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:31:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:31:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Number Connection Tests A and B</LI>
<LI>Figure Connection Tests A and B</LI>
<LI>Block design test</LI>
<LI>Digit symbol test</LI>
<LI>Critical Flicker Frequency</LI>
<LI>Arterial blood ammonia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and blood ammonia concentrations assessed after 12 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>October 2008 to December 2009</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:32:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial includes 158 participants randomly allocated to lactulose or no intervention and a third intervention arm with 77 participants allocated to a probiotic. The probiotic group is not included in our analyses.</LI>
<LI>The diagnosis of minimal hepatic encephalopathy was based on the presence of at least 2 abnormal psychometric tests.</LI>
<LI>The primary outcome of the trial was the development of overt hepatic encephalopathy, graded using the West Haven Criteria, at 12 months.</LI>
<LI>Secondary prophylaxis was defined as the prevention of recurrence of hepatic encephalopathy during the follow-up period in participants who had recovered from a previous episode of overt hepatic encephalopathy.</LI>
<LI>The model of end stage liver disease (MELD) score (mean ± SD) at inclusion was 19.2 ± 5.5 in the lactulose group and 18.5 ± 4.2 in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:32:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Brown-1971">
<CHAR_METHODS MODIFIED="2016-03-30 11:32:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, cross-over, single-centre inpatient/outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:32:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 20 participants with advanced cirrhosis stabilised in hospital on a low protein diet and then given increasing amounts of protein until they developed overt hepatic encephalopathy. They were then randomised to treatment with lactulose or placebo (sorbitol), which they received for prescribed, but not standardised periods of time in rotation</P>
<UL>
<LI>Patient characteristics: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:32:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus placebo (sorbitol) for a maximum of 30 months (see notes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:32:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Clinical status (no specific overall score)</LI>
<LI>Subjective improvement e.g. ability to return to work</LI>
<LI>Blood ammonia</LI>
<LI>Electroencephalogram</LI>
<LI>Number of hospitalisations</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:32:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>No outcomes included in meta-analyses (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:32:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:32:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>USA</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:32:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators initially evaluated participants in hospital, but continued follow-up on an outpatient basis. Based on the text, we estimated that the maximum treatment duration was 30 months.</LI>
<LI>The published report excludes 11 participants for the following reasons: i) follow-up too short (n = 2); ii) non-compliant with treatment (n = 3); iii) managed with protein restriction alone (n = 3); iv) died due to acute alcoholic hepatitis (n = 2) or lymphoma (n = 1). The authors report that 9 of the remaining participants responded well with a reduction in the number of hospitalisations during treatment with lactulose. Illustrative narrative data are provided on 5 of these 9 participants.</LI>
<LI>We were unable to extract qualitative outcome data.</LI>
<LI>The investigators did not assess the quality of life directly, but indirectly via the subjective overall assessment of improvement (e.g. return to work).</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:32:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Corazza-1982">
<CHAR_METHODS MODIFIED="2016-03-30 11:32:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:32:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 32 participants with cirrhosis and chronic hepatic encephalopathy</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 53.7 ± 2.6 years</LI>
<LI>Control group 54.1 ± 2.9 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 37.5%</LI>
<LI>Control group 50.0%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 87.5%</LI>
<LI>Hepatitis B 12.5%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:32:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus placebo for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:32:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (Encephalopathy Intensity Score)</LI>
<LI>Blood ammonia</LI>
<LI>Electroencephalogram</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:32:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, adverse events, and blood ammonia concentrations assessed after 10 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:32:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:32:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Italy</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-10-22 16:38:08 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>The trial includes 32 participants allocated to lactulose or placebo and a third allocation arm with 20 participants allocated to pyridoxine-alpha-ketoglutarate. The pyridoxine-alpha-ketoglutarate group is not included in our analyses.</LI>
<LI>The trial describes the effects of the interventions on hepatic encephalopathy based on an overall score, but does not provide an assessment of the changes in the score from basal (improved or not improved); thus, we were unable to include the post-intervention scores in our analyses.</LI>
<LI>The authors give the impression that none of the included participants died.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Dhiman-2000">
<CHAR_METHODS MODIFIED="2016-03-30 11:33:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:33:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 26 participants with cirrhosis and minimal hepatic encephalopathy. None had a past history of overt hepatic encephalopathy (see notes).</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 44.1 ± 18.0 years</LI>
<LI>Control group 47.8 ± 13.5 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 85.7%</LI>
<LI>Control group 33.3%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 36%</LI>
<LI>Hepatitis B 23%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Tests A and B</LI>
<LI>Figure Connection Tests A and B</LI>
<LI>Block Design Test</LI>
<LI>Picture Completion Test</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 3 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:33:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators screened 40 people with cirrhosis and no past history or current evidence of overt hepatic encephalopathy using a battery of psychometric tests. The trial includes the 26 participants diagnosed as having minimal hepatic encephalopathy on the basis of impaired performance on at least 2 of the 6 psychometric tests administered. These 26 participants received lactulose (n = 14) or no treatment (n = 12). The paper also provides data on the remaining 14 people who did not have minimal hepatic encephalopathy (6 of whom were tested at baseline and after 3 months). We included data for participants with minimal hepatic encephalopathy in our analyses.</LI>
<LI>The report provides the mean number of abnormal tests in the lactulose and control group post intervention.</LI>
<LI>The proportion of participants with Child's Grade B/C at baseline was 71% in the lactulose group and 67% in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:33:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Elkington-1969">
<CHAR_METHODS MODIFIED="2016-03-30 11:33:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, cross-over, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:33:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 7 participants with cirrhosis and chronic hepatic encephalopathy (25%) or previous overt hepatic encephalopathy (75%). All participants had advanced decompensated liver disease.</P>
<UL>
<LI>Participant's characteristics are not reported (the paper states that participants had decompensated cirrhosis).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:33:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus placebo (sorbitol) for 15 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:33:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (modified Parson-Smith criteria)</LI>
<LI>Arterial blood ammonia</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-02-03 15:23:38 +0100" MODIFIED_BY="[Empty name]">
<P>No outcomes included in our primary meta-analyses. Mortality and hepatic encephalopathy assessed after 15 days included in sensitivity analyses.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:33:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:33:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>USA</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:33:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial describes 7 participants who were randomised to lactulose or placebo (sorbitol) and then after a wash-out period crossed over to the other treatment. We were unable to extract data on the individual treatment periods. We therefore excluded the trial from our analyses.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:33:38 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Germain-1973">
<CHAR_METHODS MODIFIED="2016-03-30 11:33:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:33:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 18 participants with cirrhosis who developed overt hepatic encephalopathy after portal-systemic shunt surgery.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 47.0 ± 14.2 years</LI>
<LI>Control group 46.2 ± 16.6 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 77.7%</LI>
<LI>Control group 66.6%</LI>
</UL>
<P>Aetiology of cirrhosis not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-08 19:54:13 +0100" MODIFIED_BY="[Empty name]">
<P>Lactulose syrup versus placebo (saccharose&#8211;based) for 15 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:33:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental state (modified Parson-Smith criteria)</LI>
<LI>Venous blood ammonia</LI>
<LI>Psychometric tests</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:33:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 15 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:33:37 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:33:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>France</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:33:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Published in French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:34:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Grandi-1991">
<CHAR_METHODS MODIFIED="2016-03-30 11:34:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, cross-over, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:34:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 40 participants with cirrhosis and chronic hepatic encephalopathy</P>
<P>Age (median)</P>
<UL>
<LI>Both groups 59.3 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups 62.5%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:34:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Crystalline lactulose versus lactitol for 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:34:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Modified Portal Systemic Encephalopathy Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:34:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events (see notes) assessed after 60 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:34:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:34:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Italy</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:34:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Published in Italian</LI>
<LI>All participants had Child's class B or C cirrhosis</LI>
<LI>The trial does not describe the number of participants with or without an overall improvement in manifestations of hepatic encephalopathy, but describes the intervention effect using the overall score. We were therefore not able to include the trial in the analyses evaluating hepatic encephalopathy.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Heredia-1987">
<CHAR_METHODS MODIFIED="2015-04-03 11:29:22 +0200" MODIFIED_BY="[Empty name]">
<P>Open, parallel-arm, single-centre, inpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 40 participants with cirrhosis and an acute episode of hepatic encephalopathy. In total, 65% had a previous history of overt hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 59.3 ± 3 years</LI>
<LI>Lactitol group 60.0 ± 3 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 55%</LI>
<LI>Lactitol group 45%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 48%</LI>
<LI>Hepatitis B/C not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus lactitol for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental state (modified Conn Scale)</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, adverse events, and blood ammonia assessed after 5 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:34:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>4 participants (10%) had undergone portal systemic shunt surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:36:13 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Heredia-1988">
<CHAR_METHODS MODIFIED="2016-03-30 11:35:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, cross-over, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:35:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 20 participants with cirrhosis and previous portal-systemic shunt surgery with chronic hepatic encephalopathy</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Both groups 54.5 ± 2.1 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups 70%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 60%</LI>
<LI>Hepatitis B/C 24%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:35:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus lactitol for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:35:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Quantified neurological status</LI>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:36:13 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality and adverse events assessed after 3 months (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:36:13 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:36:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:36:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial includes 25 participants. 2 died and 3 dropped out of the study. The trial report does not provide information about the allocation arm (lactulose or lactitol) of the participants who dropped out.</LI>
<LI>The authors reports the effect on hepatic encephalopathy using the overall Portal Systemic Encephalopathy Sum, but do not describe the number of participants with (or without) an overall improvement in hepatic encephalopathy.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:36:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Horsmans-1997">
<CHAR_METHODS MODIFIED="2016-03-30 11:36:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:36:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 14 participants with cirrhosis and minimal hepatic encephalopathy. None of the included participants had a history of overt hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 59.0 ± 8.7 years</LI>
<LI>Control group 56.1 ± 14.2 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 42.9%</LI>
<LI>Control group 57.1%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 35.7%</LI>
<LI>Hepatitis B/C not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:36:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Crystalline lactulose versus placebo (lactose) for 15 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:36:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Test A</LI>
<LI>Race Track Test</LI>
<LI>Automated sinusoid and psychomotor tests</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:36:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and Number Connection Test results assessed after 15 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:36:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:36:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Belgium</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:36:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Participants were not lactose intolerant</LI>
<LI>The criteria for the diagnosis of minimal hepatic encephalopathy were not specified; all participants were clinically normal and had normal electroencephalograms, but had impaired psychometric performance.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:41:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Jain-2013">
<CHAR_METHODS MODIFIED="2016-03-30 11:41:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:41:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 60 participants with cirrhosis and minimal hepatic encephalopathy</P>
<P>Age (median and range)</P>
<UL>
<LI>Lactulose group 42 (15 to 70) years</LI>
<LI>Control group 41 (17 to 68) years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 66.7%</LI>
<LI>Control group 63.3%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 58.3%</LI>
<LI>Hepatitis B 18.3%</LI>
<LI>Hepatitis C 15.0%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:41:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:41:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Arterial blood ammonia</LI>
<LI>Psychometric Hepatic Encephalopathy Score (PHES) comprising:</LI>
</UL>
<UL>
<OL>
<LI>Number Connection Tests A and B</LI>
<LI>Digit symbol test</LI>
<LI>Serial dotting test</LI>
<LI>Line drawing test</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:41:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 3 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:41:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>October 2011 to February 2012</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:41:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:41:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators used the Psychometric Hepatic Encephalopathy Score to diagnose minimal hepatic encephalopathy.</LI>
<LI>The paper also includes follow-up data on 20 participants who did not have evidence of minimal hepatic encephalopathy.</LI>
<LI>The median (range) Model of End-stage Liver Disease score at inclusion was 19 (14 to 34) for the lactulose and 20 (14 to 32) for the control group.</LI>
<LI>The paper also describes plasma cytokines and cerebral magnetic resonance spectroscopy, which are not included in our analyses.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Jankovic-1996">
<CHAR_METHODS MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-06 19:08:00 +0200" MODIFIED_BY="[Empty name]">
<P>The trial includes 16 participants with cirrhosis admitted with an acute episode of hepatic encephalopathy. Participant characteristics not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus lactitol for 5 to 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Number Connection Test A</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality and adverse events assessed after 5 to 7 days and 13 days after the end of treatment (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:41:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Serbia</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-04-03 11:41:38 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>The authors reported the intervention effect on the mean values for the measured variables, but did not report the number with (or without) overall improvement in hepatic encephalopathy. We were therefore unable to include the data in our analysis for the outcome hepatic encephalopathy.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Li-1999">
<CHAR_METHODS MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, multicentre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 86 participants with cirrhosis and minimal hepatic encephalopathy (see notes).</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 47.6 ± 10.9 years</LI>
<LI>Control group 41.5 ± 13.0 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 77.1%</LI>
<LI>Control group 89.5%</LI>
</UL>
<P>Aetiology of cirrhosis not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 30 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Test A</LI>
<LI>Digit Symbol Test</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 30 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>January 1997 to January 1998</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:41:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Published in Chinese</LI>
<LI>The participants had minimal hepatic encephalopathy diagnosed on the basis of impaired performance on the Number Connection Test results or Digit Symbol Test</LI>
<LI>The proportion of participants with Child's Grades B/C in the lactulose group was 79.2% and in the control group 84.2%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:42:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-McClain-1984">
<CHAR_METHODS MODIFIED="2016-03-30 11:42:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:42:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 32 participants with cirrhosis and minimal hepatic encephalopathy (see notes).</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 55 ± 6.5 years</LI>
<LI>Control group 54.0 ± 9.1 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups 96.9%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 100%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:42:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus placebo (sucrose) for 3 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:42:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Tests A and B</LI>
<LI>Digit Symbol Test</LI>
<LI>Speed of writing words</LI>
<LI>Speed of writing numbers</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:42:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Adverse events assessed after 3 months (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:42:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:42:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>USA</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:42:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>All included participants had minimal hepatic encephalopathy (psychometric testing shows impaired cognitive function).</LI>
<LI>The report describes the characteristics of participants who completed the trial (lactulose 10 participants, placebo 12).</LI>
<LI>The investigators assessed the quality of life based on the Katz social functioning score. The publication does not include quantitative data, but the authors comment that they saw no changes in the Katz score in response to treatment.</LI>
<LI>We were unable to gather data on the number with (or without) improvement in hepatic encephalopathy because the results are expressed as percentage change over baseline.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:42:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Mittal-2011">
<CHAR_METHODS MODIFIED="2016-03-30 11:42:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:42:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 80 participants with cirrhosis and minimal hepatic encephalopathy</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 43.9 ± 10.9 years</LI>
<LI>Control group 41.2 ± 11.9 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 80%</LI>
<LI>Control group 75%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 37.5%</LI>
<LI>Hepatitis B/C 35.0%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:42:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:42:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Number Connection Tests A and B</LI>
<LI>Figure Connection Tests A and B</LI>
<LI>Picture Completion Test</LI>
<LI>Block Design Test</LI>
<LI>Arterial blood ammonia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:42:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, quality of life, and blood ammonia concentration assessed after 3 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-01-21 20:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>October 2007 to October 2009</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:42:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:42:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial includes 160 participants randomised to lactulose (n = 40), probiotics (n = 40), L-ornithine L-aspartate (n = 40), or no treatment (n = 40). The L-ornithine L-aspartate and probiotic groups are not included in our analyses.</LI>
<LI>The investigators based the diagnosis of minimal hepatic encephalopathy on the presence of at least 2 abnormal psychometric tests. They expressed the psychometric test results as a Z score equating to the difference between the observed result and the population norm. They defined a Z score of &lt;-2 as abnormal.</LI>
<LI>The investigators assessed quality of life with the Sickness Impact Profile questionnaire, which assessed the influence of disease and treatment on daily functioning. The questionnaire consists of 136 items, which are grouped into 12 scales such as sleep and rest, eating, work, and home management. Scores range from 0 (best score) to 100 (worst score). Changes in the score were calculated. The scores were comparable at baseline. After treatment, the score was lower in the lactulose group compared with controls.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:42:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Morgan-1987a">
<CHAR_METHODS MODIFIED="2016-03-30 11:42:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:42:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 25 participants with cirrhosis and acute hepatic encephalopathy (see notes).</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 48.3 ± 15.8 years</LI>
<LI>Lactitol group 48.4 ± 12.5 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 46.7%</LI>
<LI>Lactitol group 61.5%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 53.7%</LI>
<LI>Hepatitis B/C 0%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:42:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose versus lactitol as identically presented liquids for 5 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:42:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:42:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and Number Connection Test results assessed after 5 days (end of treatment). Additional information retrieved for clinical outcomes 1 month after the end of treatment (see notes).</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:42:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>July 1984 to December 1985</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:42:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>United Kingdom</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:42:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Initially, the investigators evaluated 27 potentially eligible participants, but excluded 2 with fulminant hepatic failure before treatment. The investigators randomised 25 participants, who experienced between them 28 episodes of hepatic encephalopathy.</LI>
<LI>3 participants discontinued treatment with lactitol because they developed severe nausea (n = 1), profuse gastrointestinal bleeding (n = 1), or ileus (n = 1). All 3 participants died after the end of treatment.</LI>
<LI>None of the participants died during the trial. Participants who died after the completion of the trial had severely decompensated cirrhosis.</LI>
<LI>The investigators reported that the time to improved manifestations of hepatic encephalopathy was shorter in the group of participants allocated to lactitol.</LI>
<LI>Participants with autoimmune hepatitis made up 23.1% of the lactulose group and 13.3% of the lactitol group.</LI>
<LI>All participants had Child's Grade B/C cirrhosis.</LI>
<LI>One of the review authors (Marsha Y Morgan) was the primary investigator on the trial.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:43:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Morgan-1987b">
<CHAR_METHODS MODIFIED="2016-03-30 11:43:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, cross-over, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:43:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 12 participants with cirrhosis and chronic hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Both groups 57.3 ± 11.5 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups 55.6%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 44%</LI>
<LI>Hepatitis B/C 0%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:43:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose versus lactitol as identically presented liquids for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:43:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:43:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, Number Connection Test results, and blood ammonia concentrations assessed after 3 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:43:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>November 1985 to February 1986</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:43:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>United Kingdom</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:43:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>3 of 9 participants had surgical portal-systemic shunts.</LI>
<LI>In total, 56% of participants had cryptogenic cirrhosis.</LI>
<LI>3 of 12 participants did not complete the trial because they died (n = 1) or began to abuse alcohol and were non-compliant in the early phase of the first treatment period (n = 2). Data on all participants are included in our analyses.</LI>
<LI>One of the review authors (Marsha Y Morgan) was primary investigator on the trial.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:43:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Morgan-1989">
<CHAR_METHODS MODIFIED="2016-03-30 11:43:41 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Single-blind, cross-over, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:43:41 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 20 participants with cirrhosis, minimal hepatic encephalopathy, and no history of previous overt hepatic encephalopathy (see notes).</P>
<P>Age (mean and range)</P>
<UL>
<LI>Both groups 52.0 (37 to 66) years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups 78.6%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 100%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-09 12:18:22 +0100" MODIFIED_BY="[Empty name]">
<P>Lactulose syrup versus lactitol for 2 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:43:46 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (Modified Conn Score)</LI>
<LI>Number Connection Tests A and B</LI>
<LI>Digit Symbol Test</LI>
<LI>Digit Copying Test</LI>
<LI>Computer-based visual reaction time</LI>
<LI>Computer-based perceptual maze test</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:43:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and Number Connection Test results assessed after 2 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:43:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>October 1986 to April 1988</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:43:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>United Kingdom</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:43:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>All participants were abstinent from alcohol.</LI>
<LI>6 of the initially randomised participants did not complete 2 weeks of treatment because of non-serious adverse events (lactitol n = 1) or for reasons unrelated to the trial (lactulose: n = 2; lactitol: n = 3). 14 participants completed the trial. None died. We included data on all randomised participants in our analyses.</LI>
<LI>One of the review authors (Marsha Y Morgan) was the primary investigator on the trial.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:44:11 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pai-1995">
<CHAR_METHODS MODIFIED="2016-03-30 11:44:07 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Single-blind, parallel-arm, single-centre, inpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:44:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 41 participants with cirrhosis and acute hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 65.9 ± 9.8 years</LI>
<LI>Lactitol group 67.5 ± 4.9 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 75.0%</LI>
<LI>Lactitol group 95.0%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 18%.</LI>
<LI>Hepatitis B/C 69%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:43:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus lactitol for 5 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:43:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:43:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 5 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:43:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>April 1993 to April 1994</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:43:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Taiwan</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:43:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>All participants had Child's Grade B/C cirrhosis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:44:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Prasad-2007">
<CHAR_METHODS MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 61 participants with cirrhosis and minimal hepatic encephalopathy (see notes).</P>
<P>Age (mean and range)</P>
<UL>
<LI>Lactulose group 48.3 (38.4 to 58.2) years</LI>
<LI>Control group 50.6 (39.1 to 62.1) years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 87.1%</LI>
<LI>Control group 93.3%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 65%</LI>
<LI>Hepatitis B/C 30%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mini Mental State Examination</LI>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Number Connection Tests A and B</LI>
<LI>Figure Connection Tests A and B</LI>
<LI>Picture Completion Test</LI>
<LI>Block Design Test</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and quality of life assessed after 3 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>January 2004 to March 2005</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:44:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:44:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators based the diagnosis of minimal hepatic encephalopathy on the presence of at least 2 abnormal psychometric tests. They expressed the psychometric test results as a Z score equating to the difference between the observed result and the population norm. They defined a Z score of &lt;-2 as abnormal. The investigators calculated a mean Z score (mZS) for each patient and referred to changes in the number of abnormal tests AbnNP and the mZS at the end of treatment or follow-up as &#916;AbnNP and &#916;mZS</LI>
<LI>The proportion with Child's Grade B/C was 66.7% in the lactulose group and 55.2% in the control group.</LI>
<LI>The investigators describe 29 participants who were neuropsychiatrically unimpaired and followed them for 3 months in the same way as the participants in the randomised clinical trial.</LI>
<LI>The investigators assessed the quality of life based on the Sickness Impact Profile. They defined the change in the total score after follow-up as the estimated change in the overall quality of life. At baseline, participants with minimal hepatic encephalopathy had impairment in 11 of the 12 scales in the score (in particular the social interaction, alertness, emotional behaviour, sleep, work, home management, recreation and pastime).</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Quero-1997">
<CHAR_METHODS MODIFIED="2016-03-30 11:44:55 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 40 participants with cirrhosis and minimal hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 51.9 ± 13.0 years</LI>
<LI>Control group 49.7 ± 12 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 73.7%</LI>
<LI>Control group 71.4%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 27.5%</LI>
<LI>Hepatitis B/C 30.0%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Crystalline lactulose versus placebo (lactose) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (criteria not specified)</LI>
<LI>Number Connection Test A</LI>
<LI>Symbol Digit Test</LI>
<LI>Electroencephalogram</LI>
<LI>Arterial ammonia concentration</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and quality of life assessed after a maximum of 9 months (3 months after the end of therapy)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>October 1992 to September 1994</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Holland</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:44:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators diagnosed participants with at least 2 abnormal psychometric tests scores as having minimal hepatic encephalopathy.</LI>
<LI>All participants had elevated blood ammonia levels.</LI>
<LI>Proportion with Child's Grade B/C was 21.0% in the lactulose group and 9.5% in the control group.</LI>
<LI>The investigators assessed quality of life using the Sickness Impact Profile and defined the change in the total score after follow-up as the estimated change in the overall quality of life. At baseline, participants with minimal hepatic encephalopathy had impairment in 11 of the 12 scales in the score (in particular social interaction, alertness, emotional behaviour, sleep, work, home management, recreation and pastime).</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:45:14 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Raza-2004">
<CHAR_METHODS MODIFIED="2016-03-30 11:45:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, inpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:45:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 31 participants with cirrhosis experiencing an acute episode of hepatic encephalopathy.</P>
<P>Age (mean)</P>
<UL>
<LI>Lactulose group 55.1 years</LI>
<LI>Control group 52.4 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 27.8%.</LI>
<LI>Control group 46.2%.</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Hepatitis B/C 100%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:45:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose enemata versus tap water enemata administered for a mean of 4.5 days depending on clinical response<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:45:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Clinical scoring (Jones and Gammal)</LI>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Digit Symbol Test (replacing Number Connection Test A)</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:45:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality and hepatic encephalopathy assessed after a mean duration of 4.5 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:45:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:45:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Pakistan</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-22 18:56:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The primary outcome was the time to improvement.</LI>
<LI>The investigators made the assessments at 48 hours and then at the end of treatment, which was on average 4.5 days.</LI>
<LI>Both allocation groups also received oral lactulose syrup.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:45:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Riggio-1989">
<CHAR_METHODS MODIFIED="2016-03-30 11:45:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Single-blind, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:45:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 31 participants with cirrhosis who had undergone portal-systemic shunt surgery and evaluates the prevention of hepatic encephalopathy. In total, 46.7% in the lactulose group and 37.5% in the lactitol group had experienced at least 1 episode of hepatic encephalopathy within 1 year of inclusion of the trial.<BR/>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 49 ± 13 years</LI>
<LI>Lactitol group 59 ± 6 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 73.3%</LI>
<LI>Lactitol group 68.8%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 19%</LI>
<LI>Hepatitis B/C 19%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:45:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus lactitol for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:45:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:45:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:45:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not described</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:45:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Italy</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-10-22 17:03:09 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>The proportion of participants with Grade B/C cirrhosis was 13.3% in the lactulose and 12.5% in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:46:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Riggio-2005">
<CHAR_METHODS MODIFIED="2016-03-30 11:46:07 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Single-blind, parallel-arm, single-centre, inpatient/outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:46:07 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 50 participants with cirrhosis randomised immediately after transjugular intrahepatic portosystemic shunt (TIPS) placement. 15% (8% in the lactitol group and 24% in the control group) had experienced a previous episode of hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactitol group 60.6 ± 9.0 years</LI>
<LI>Control group 54.9 ± 11.7 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactitol group 56%</LI>
<LI>Control group 84%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 34%</LI>
<LI>Hepatitis B/C not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:46:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactitol versus no intervention for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:46:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment </B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:46:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, and blood ammonia concentrations assessed after 6 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:46:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>November 1998 to September 2003</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:46:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Italy</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:46:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial includes 75 participants randomised to no treatment (n = 25), lactitol (n = 25), or rifaximin (n = 25). The rifaximin group is not included in our analyses.</LI>
<LI>The proportion of participants with Child's B/C cirrhosis was 76% in the lactitol group and 64% in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Rodgers-1973">
<CHAR_METHODS MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, cross-over, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 6 participants with cirrhosis and chronic hepatic encephalopathy. 3 are described in detail.</P>
<P>Age (mean)</P>
<UL>
<LI>Both groups: 65 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups: 66%</LI>
</UL>
<P>Aetiology of cirrhosis not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus placebo (sorbitol) (see notes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Clinical grading (criteria not described)</LI>
<LI>Blood ammonia</LI>
<LI>Electroencephalography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>None (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>1967 to 1970</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>USA</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:46:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators randomised 6 participants to treatment with lactulose or placebo (sorbitol) alternatively for 2-month periods. The paper describes 3 of these participants in detail. We were unable to extract quantitative data from the trial publication.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sharma-2009">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 140 participants with cirrhosis who had recovered from an episode of overt hepatic encephalopathy. The trial evaluates secondary prevention. In total, 57% of included participants had minimal hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 48.2 ± 8.4 years</LI>
<LI>Control group 44.9 ± 10.2 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 77.1%</LI>
<LI>Control group 71.4%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 39.2%</LI>
<LI>Hepatitis B/C 39.2%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Number Connection Tests A and B</LI>
<LI>Figure Connection Tests A and B</LI>
<LI>Digit Symbol Test</LI>
<LI>Object Assembly Test</LI>
<LI>Critical flicker frequency</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 12 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>January 2006 to June 2008</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators defined the primary endpoint as the development of an episode of overt hepatic encephalopathy 6 months after randomisation.</LI>
<LI>The Model for End-Stage Liver Disease (MELD) score (mean ± SD) at inclusion was 21.8 ± 3.4 in the lactulose group and 20.6 ± 2.4 in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sharma-2011">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 70 participants with cirrhosis who were stable after an acute variceal bleed. In total, the trial included 16% with a previous episode of hepatic encephalopathy (17.1% in the lactulose group and 14.3% in the control group). The trial evaluates prevention of hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 41.6 ± 12.9 years</LI>
<LI>Control group 37.2 ± 16.0 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 86%</LI>
<LI>Control group 80%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 47%</LI>
<LI>Hepatitis B/C 37%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 120 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Arterial blood ammonia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 120 hours</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>December 2008 to January 2010</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial report describes the blood ammonia concentrations for participants who did not did not develop hepatic encephalopathy, but not the values for participants in the 2 allocation groups.</LI>
<LI>The Model for End-Stage Liver Disease (MELD) score (mean ± SD) at inclusion was 16.7 ± 5.7 in the lactulose group and 15.8 ± 3.8 in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sharma-2012">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 120 participants with cirrhosis and no history of overt hepatic encephalopathy. Of these, 57% had minimal hepatic encephalopathy at inclusion. The trial evaluates prevention of hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 43.4 ± 12.5 years</LI>
<LI>Control group 42.2 ± 11.5 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 80.0%</LI>
<LI>Control group 88.3%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 30.8%</LI>
<LI>Hepatitis B 30.0%</LI>
<LI>Hepatitis C 12.5%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West Haven Criteria)</LI>
<LI>Number Connection Tests A and B</LI>
<LI>Figure Connection Tests A and B</LI>
<LI>Picture Completion Test</LI>
<LI>Digit Symbol Test</LI>
<LI>Serial Dotting Test</LI>
<LI>Line Tracing Test</LI>
<LI>Critical flicker frequency</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 12 months</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>January 2008 to September 2009</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>India</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators based the diagnosis of minimal hepatic encephalopathy on the finding of 2 or more abnormal psychometric tests.</LI>
<LI>The investigators switched 4 participants from the control to the intervention group. These participants are included in their original allocation group in our analyses.</LI>
<LI>The Model for End-Stage Liver Disease (MELD) score (mean ± SD) at inclusion was 13.4 ± 4.8 in the lactulose group and 12.3 ± 4.8 in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Shi-1997">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 31 participants with cirrhosis and minimal hepatic encephalopathy.</P>
<P>Mean age</P>
<UL>
<LI>Both groups 54 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Both groups 87%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 0%</LI>
<LI>Hepatitis B/C not described</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactitol versus placebo (glucose) for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Test</LI>
<LI>Digit Symbol Test</LI>
<LI>Somatosensory evoked potentials</LI>
<LI>Blood ammonia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>No outcomes (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-10-22 17:10:32 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>The authors do not describe the criteria used to diagnose minimal hepatic encephalopathy.</LI>
<LI>No numerical data are provided.</LI>
<LI>Published in Chinese.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Simmons-1970">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, parallel-arm, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 26 participants with cirrhosis and acute hepatic encephalopathy</P>
<P>Age (mean ± SD)</P>
<P>Lactulose group 50.4 ± 7.6 years</P>
<P>Control group 51.8 ± 6.7 years</P>
<P>Proportion of men</P>
<UL>
<LI>Both groups 100%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 100%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus placebo (glucose) for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental function tests (Sherlock)</LI>
<LI>Venous blood ammonia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 10 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>USA</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Uribe-1987a">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, cross-over, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-22 19:06:01 +0100" MODIFIED_BY="[Empty name]">
<P>The trial includes 37 participants with cirrhosis and acute hepatic encephalopathy</P>
<P>Participant characteristics not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Rectal lactitol enemata versus rectal placebo enemata (lactose or tap water) for 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>N<B>europsychiatric assessment </B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, Number Connection Test results, and blood ammonia concentrations assessed after 4 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mexico</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial includes 37 participants with cirrhosis experiencing 45 episodes of acute overt hepatic encephalopathy.</LI>
<LI>The investigators undertook a pre-agreed group sequential analysis of response after randomisation of the first 20 participants to enemata of lactitol (n = 10), lactose (n = 5), or tap water (n = 5). The investigators discontinued the tap water arm because the mortality rate was high; the trial continued with the randomisation of participants to lactitol or lactose.</LI>
<LI>In our analyses, we combined participants randomised to the tap water and lactose groups (n = 23).</LI>
<LI>None of the participants in the trial was lactose intolerant.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Uribe-1987b">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Double-blind, cross-over, single-centre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 20 participants with cirrhosis and chronic hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactitol group 41.0 ± 1.5 years</LI>
<LI>Control group 40.8 ± 2.5 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactitol group 62.5%</LI>
<LI>Control group 40.0%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 44%</LI>
<LI>Hepatitis B/C 55%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactitol versus placebo (lactose) for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>N<B>europsychiatric assessment </B>
</P>
<UL>
<LI>Portal Systemic Encephalopathy Sum and Index comprising:</LI>
</UL>
<UL>
<OL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Asterixis</LI>
<LI>Number Connection Test A</LI>
<LI>Venous blood ammonia</LI>
<LI>Electroencephalogram</LI>
</OL>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events, Number Connection Test results, and blood ammonia concentrations assessed after 2 weeks</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mexico</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>None of the participants in the control group was lactose intolerant</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Watanabe-1997">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, multicentre, outpatient trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 75 participants with cirrhosis and previous overt hepatic encephalopathy. In total, 48% had minimal hepatic encephalopathy and 52% were unimpaired based on neuropsychiatric assessment.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group (unimpaired) 56.7 ± 9.5 years</LI>
<LI>Control group (unimpaired) 58.6 ± 6.2 years</LI>
<LI>Lactulose group (minimal hepatic encephalopathy) 62.0 ± 7.3 years</LI>
<LI>Control group (minimal hepatic encephalopathy) 65.6 ± 7.1 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose and control group (unimpaired) 62%</LI>
<LI>Lactulose and control group (minimal hepatic encephalopathy) 47%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 11%</LI>
<LI>Hepatitis B/C 78%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 8 weeks (see notes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental state (Conn)</LI>
<LI>Number Connection Test part A</LI>
<LI>Symbol Digit Test</LI>
<LI>Block Design Test</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events assessed after 8 weeks (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Japan</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The primary publication (full paper article) does not describe quality of life, but an earlier published abstract, reporting the same trial, states that the investigators assessed quality of life "quantitatively according to the reported criteria" without information about the specific method. The abstract reports that participants randomised to lactulose had improved quality of life (general fatigue and abdominal distension) although no quantitative data are provided.</LI>
<LI>The investigators diagnosed 39 participants as neuropsychiatrically unimpaired and 36 participants as having minimal hepatic encephalopathy on the basis of psychometric testing. We combined the outcomes for the 2 groups in our primary analysis.</LI>
<LI>The investigators followed 62 of the 75 participants for 6 months after the trial and registered that 18 participants with minimal hepatic encephalopathy and 11 participants diagnosed as unimpaired continued lactulose. 5 participants with minimal hepatic encephalopathy and 4 participants who were unimpaired started de novo lactulose after completing the trial.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Wen-2013">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, inpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 130 participants with cirrhosis experiencing an acute upper gastrointestinal haemorrhage. None had overt or minimal hepatic encephalopathy at inclusion. The trial evaluates prevention of hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 53.0 ± 13.3 years</LI>
<LI>Control group 50,4 ± 10.2 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 48.4%</LI>
<LI>Control group 51.5%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 8%</LI>
<LI>Hepatitis B/C 75%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental state (West Haven Criteria)</LI>
<LI>Number Connection Test</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 7 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>May 2007 to July 2011</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The proportion of participants with Child's B/C was 39.7% in the lactulose group and 49.2% in the control group</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Xing-2003">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 45 participants with cirrhosis and minimal hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 33.6 ± 9.6 years</LI>
<LI>Control group 38.5 ± 6.8 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 66.7%</LI>
<LI>Control group 58.3%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 20.0%</LI>
<LI>Hepatitis B/C 68.9%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Test</LI>
<LI>Verbal and Performance Intelligence Quotient tests</LI>
<LI>Blood ammonia</LI>
<LI>Electroencephalogram</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 4 weeks</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>February 2000 to March 2002</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Published in Chinese.</LI>
<LI>The method used to diagnose minimal hepatic encephalopathy is not described.</LI>
<LI>Participants in the intervention and control group also received vitamin B and silymarin.</LI>
<LI>Of the 48 participants randomised, 3 (1 assigned to lactulose and 2 to no intervention) did not complete the trial according to the protocol. The outcome of these participants is described in the publication.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Yao-2014">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 40 participants with cirrhosis and minimal hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 45.52 ± 6.34 years</LI>
<LI>Control group 45.23 ± 7.46 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose and control group 67.5%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol not described</LI>
<LI>Hepatitis not described</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Test</LI>
<LI>Digit Symbol Test</LI>
<LI>Mini Mental State Examination</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality and Number Connection Test results assessed after 15 days</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>May 2011 to July 2013</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-05-20 14:46:59 +0200" MODIFIED_BY="[Empty name]">
<P>The trial report describes the effects on lactulose using surrogate outcomes and does not include information about the number of participants with (or without) an overall improvement of hepatic encephalopathy. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Zeng-2003">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Open, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 60 participants with cirrhosis and minimal hepatic encephalopathy with no previous history of overt hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Short &#8211;term lactulose 50 ± 16 years</LI>
<LI>Long-term lactulose 49 ± 17 years</LI>
<LI>Control 49 ± 13 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>All groups 85%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Alcohol 17%</LI>
<LI>Hepatitis B/C 63%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for eight or 24 weeks (see notes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Number Connection Test</LI>
<LI>Digit Symbol Test</LI>
<LI>Electroencephalography</LI>
<LI>Venous blood ammonia</LI>
<LI>Sensory Evoked Potentials</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, adverse events assessed after a maximum of 24 weeks (see notes)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>July 1998 to March 2002</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The investigators assess quality of life using the World Health Organization quality of life BREF (WHOQOL-BREF) including the domains physical health, psychological health, social relationships, and environment.</LI>
<LI>The method for diagnosing minimal hepatic encephalopathy is not specified.</LI>
<LI>The trial includes the following 3 allocation arms: lactulose for 8 weeks, lactulose for 24 weeks, and no intervention. We combined the results of the 2 lactulose arms in our analyses.</LI>
<LI>All participants in the intervention and control groups also received vitamin B and silymarin.</LI>
<LI>The proportion of participants with Child's B/C cirrhosis was 75% in the short&#8211;term lactulose arm, 60% in the long-term lactulose arm, and 60% in the control arm.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Ziada-2013">
<CHAR_METHODS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Single-blind, parallel-arm, single-centre, outpatient trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The trial includes 60 participants with cirrhosis and minimal hepatic encephalopathy.</P>
<P>Age (mean ± SD)</P>
<UL>
<LI>Lactulose group 48.8 ± 8.2 years</LI>
<LI>Control group 51.2 ± 7.5 years</LI>
</UL>
<P>Proportion of men</P>
<UL>
<LI>Lactulose group 75.0%</LI>
<LI>Control group 72.0%</LI>
</UL>
<P>Aetiology of cirrhosis</P>
<UL>
<LI>Not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose syrup versus no intervention for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Neuropsychiatric assessment</B>
</P>
<UL>
<LI>Mental status (West-Haven Criteria)</LI>
<LI>Number Connection Test A</LI>
<LI>Block Design Test</LI>
<LI>Digit Symbol Test</LI>
<LI>Serial-dotting test</LI>
<LI>Line tracing test</LI>
<LI>Blood ammonia</LI>
<LI>Cerebral magnetic resonance spectroscopy</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality, hepatic encephalopathy, and adverse events assessed after 4 weeks</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>March 2010 to January 2012</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Egypt</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>The trial includes 90 participants randomised to lactulose (n = 30), a probiotic (n = 30), or to no treatment (n = 30). We did not include the probiotics group in our analyses.</LI>
<LI>The investigators based the diagnosis of minimal hepatic encephalopathy on the finding of at least 2 abnormal psychometric tests.</LI>
<LI>The proportion of participants with Child's B/C cirrhosis was 91.7% in the lactulose group and 88.0% in the control group.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised clinical trial<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Bajaj-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Observational study. Retrospective review of participants with cirrhosis maintained on lactulose following an index episode of hepatic encephalopathy. The outcomes included recurrence of hepatic encephalopathy, precipitating factors, and compliance with lactulose treatment. The analyses compared participants with/without a recurrence of hepatic encephalopathy and identified the predictors of recurrence.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Bircher-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Case series reporting the effects of protein intake, lactulose, and neomycin on clinical grading, electroencephalography, and blood ammonia levels in 6 participants with cirrhosis and chronic hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Brown-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Case series reporting neuropsychiatric status and associated variables in 4 participants with cirrhosis and post-shunt hepatic encephalopathy during alternating periods of treatment with lactulose and sorbitol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-James-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Observational study. Careful documentation of the effects of treatment with lactulose over 10 days on cerebral blood flow and metabolism in 6 participants with cirrhosis and chronic hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Lanthier-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Observational cross-over study comparing the effects of 3 months of treatment with lactulose and lactitol on mental status, psychometric performance, venous blood ammonia levels, electroencephalography mean cycle frequency, and cerebral blood flow and metabolism in 5 participants with chronic hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-07 23:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Merli-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-07 23:52:07 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study on the effects of treatment with lactulose or lactitol on faecal fat excretion in 18 participants with cirrhosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Patil-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Observational study detailing the differential effects of lactulose and lactitol on (i) an in vitro faecal incubation system and (ii) on terminal ileal and colonic pH in 6 normal participants using radiotelemetry.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-09 16:01:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piotraschke-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-09 16:01:11 +0100" MODIFIED_BY="[Empty name]">
<P>Observational open study published in abstract form describing the non-comparative effect of lactulose on preventing hepatic encephalopathy in participants with cirrhosis following insertion of a transjugular intrahepatic portosystemic shunt.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pockros-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial of lactulose versus AST-120 (spherical carbon adsorbent). The trial includes 47 participants with cirrhosis and overt hepatic encephalopathy. The trial did not include a placebo or no intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Quinton-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial of mannitol lavage versus a combination of lactulose and the antibiotic kanamycin for the prevention of hepatic encephalopathy following gastrointestinal haemorrhage in participants with cirrhosis. The trial did not include a placebo/no intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Rahimi-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial on lactulose versus polyethylene glycol for the treatment of acute hepatic encephalopathy. The trial did not include a placebo/no intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-03 13:53:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riggio-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-03 13:53:17 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study comparing the effect of lactulose or lactitol on the faecal flora of 21 participants with cirrhosis and no evidence of hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Rorsman-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Case series reporting the responses of 3 participants with cirrhosis and post-shunt hepatic encephalopathy to treatment with lactulose.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:47:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Salerno-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:47:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Observational study on the differential effects of 2 different doses of lactitol on neuropsychiatric status in participants with cirrhosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-07 23:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schomerus-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-07 23:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>A field study documenting the prevalence of minimal hepatic encephalopathy in ambulatory participants with cirrhosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sharma-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised trial of lactulose versus probiotics for the treatment of minimal hepatic encephalopathy. The trial does not include a placebo or no intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-07 23:52:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-07 23:52:09 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study to identify the predictors of minimal hepatic encephalopathy in participants with cirrhosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-09 16:03:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-09 16:03:59 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study evaluating predictors of non-response to lactulose in participants with cirrhosis and overt hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-09 16:03:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-09 16:03:34 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study evaluating the prevalence of abnormal psychometric tests and critical flicker frequency after clinical recovery of overt hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-03 23:49:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-03 23:49:06 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective review of the efficacy of lactulose for the treatment of hepatic encephalopathy in young people with hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:47:11 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Trovato-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:47:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Observational study of the effects of lactitol on clinical status and blood ammonium, atrial natriuretic peptide, and amino acid concentrations in 10 participants with cirrhosis and hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:47:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Vendemiale-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:47:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>An open comparison of the effects of 10 days treatment with lactulose or no treatment on blood ammonia levels, Number Connection Test results, and lymphocyte sub-populations in people with cirrhosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Venturini-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial of the effect of rifaximin, lactulose, and placebo on circulating benzodiazepine-like compounds in 18 participants with cirrhosis. None of the included participants had hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-30 11:46:58 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Zeegen-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-30 11:46:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Case series describes the effects of treatment with lactulose in 5 participants with cirrhosis and overt hepatic encephalopathy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-11-16 20:58:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Trial registration number" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-03-30 11:47:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Salih-2007">
<CHAR_STUDY_NAME MODIFIED="2016-03-30 11:47:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose for the prevention of hepatic encephalopathy in participants with cirrhosis and upper gastrointestinal haemorrhage</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-30 11:47:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:47:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Participants with cirrhosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:47:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:47:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Hepatic encephalopathy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-10-07 17:31:23 +0200" MODIFIED_BY="[Empty name]">
<P>2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-03-30 11:47:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Aga Kahn University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2014-10-07 17:59:56 +0200" MODIFIED_BY="[Empty name]">
<P>NCT00553423</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-03-30 11:47:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Investigators contacted via email October 2014. No reply</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Wang-2012">
<CHAR_STUDY_NAME MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Impact of lactulose treatment on cognition, assessment of quality of life and changes of intestinal flora in minimal hepatic encephalopathy participants: a multicentre, randomised, open-label and controlled clinical study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cirrhosis and minimal hepatic encephalopathy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Lactulose versus no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Recovery from minimal hepatic encephalopathy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-10-07 17:43:02 +0200" MODIFIED_BY="[Empty name]">
<P>2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Zhong Shan Hospital, Shanghai, China</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2014-10-07 18:00:01 +0200" MODIFIED_BY="[Empty name]">
<P>ChiCTR-TRC-12002342</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-03-30 11:47:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Investigators contacted via email October 2014 and reported that the final analyses will take place in October 2014</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-04-07 11:47:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-04-07 11:43:00 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:40:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:43:00 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Random number table<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:58 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:09 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-06 21:19:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>The investigators described the allocation as 1:1, but the allocation sequence generation is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-04-07 11:44:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:40:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Blinded administration of interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Blinded administration of interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:44:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Numbered opaque sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Blinded allocation of interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Numbered, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Numbered, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-12 20:16:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Numbered sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Central independent unit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Central independent unit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Central independent unit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Centrally prepared, numbered drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Centrally prepared, numbered drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Serially numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Administration of coded, identical drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Blinded administration of coded drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Blinded administration of coded drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-20 14:56:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>The authors specify that allocation was concealed, but do no specify the method of concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-03-19 17:23:39 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-04-07 11:44:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Non-mortality outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-07 11:39:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-03-30 11:32:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:30:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-03-30 11:33:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-07 11:44:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-03-30 11:33:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:31:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:31:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:31:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:32:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:32:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:33:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:33:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>Open trial. This trial is registered on clinicaltrials.gov as placebo-controlled, but is conducted and reported as an open trial in which the control group received no intervention. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:34:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:34:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:35:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:35:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Double-blind trial with administration of the interventions as identically appearing solutions. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Double-blind trial with administration of the interventions as identically appearing solutions. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-03-30 11:43:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Open, single-blind trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>Open, single-blind trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:38:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:39:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:49:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Open, single-blind trial. No blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-03-30 11:45:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:49:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Open trial. No blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:49:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-10-22 17:06:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:50:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:51:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-04-03 13:33:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:41:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:52:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:52:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:53:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-20 14:56:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-20 14:56:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:53:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Open trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-17 16:53:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Open, single-blind trial. No blinding of participants or personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-03-18 13:35:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Performance bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-04-07 11:46:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Non-mortality outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:29:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Open trial. No blinding of the outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-07 11:40:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-04-07 11:40:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:30:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:36:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-07 11:46:28 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-04-07 11:46:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:31:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:36:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:31:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:36:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:32:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:37:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:32:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:36:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:32:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:41:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>No blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-03 13:10:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:34:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:35:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-03 13:10:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:42:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:38:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:37:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Open, single-blind trial. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>Open, single-blind trial. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:38:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:39:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:39:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Open trial. No blinding of the outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:49:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Open, single-blind trial. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-03 13:18:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Open, single-blind trial. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:50:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-03 13:24:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Open trial. The investigators describe the trial as placebo-controlled, but the placebo intervention is not described in the methods section describes the trial as open. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:51:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:51:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Double-blind, placebo-controlled. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:52:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:52:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Open trial. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:53:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-20 14:56:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Open trial. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-20 14:56:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-17 16:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Open trial. No blinding of the outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:40:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-18 13:41:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Open, single-blind trial. Blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-18 13:41:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Detection bias unlikely to influence the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-04-07 11:46:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>The investigators account for all participants randomised and report intention-to-treat analyses that included all participants. Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-07 11:40:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>The investigators do not account for all participants randomised (see notes).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 12:04:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Unclear outcome data for participants who did not complete the trial. The trial does not appear to have post-randomisation exclusions although this is not specifically stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-07 11:46:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>The investigators account for all participants randomised and include all participants randomised in the analyses. Missing outcome data unlikely to affect the analyses or be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>No losses to follow-up or dropouts seemed to occur post-randomisation (clinical outcome data are presented for all participants). The trial report does not include information about the number of participants allocated to the intervention and control group during the first period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>The investigators account for all participants randomised. There are no missing outcome data and no dropouts or losses to follow-up post-randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:34:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>The investigators account for all participants randomised and there are no post-randomisation dropouts or losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>The investigators account for all participants randomised and there are no post-randomisation dropouts or losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:36:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Participants who died or dropped out are excluded from the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 12:51:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>The investigators account for all participants randomised. All participants completed the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:41:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>The investigators account for all participants randomised. 2 participants were lost to follow-up and excluded from the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:06:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Participants with missing outcome data are not described and the analyses do not account for participants with missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:07:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>The investigators account for all participants randomised. All participants completed the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-19 13:54:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>The paper does not account for participants who did not complete the trial and the analyses exclude participants with missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:42:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>The investigators account for all participants randomised and used sufficient methods to handle missing data in the analyses of clinical outcomes (but not in the analyses of surrogate outcomes). Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:42:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>The investigators account for all participants randomised. There are no post-randomisation exclusions (follow-up assessments and clinical monitoring continued for all participants, including those who discontinued the interventions).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>The investigators account for all participants randomised and there are no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-20 11:47:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>The investigators account for all participants randomised and there are no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:38:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>The investigators account for all participants randomised, but do not include participants who died or dropped out in the reported analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>The investigators account for all participants randomised and used sufficient methods to handle missing data in the analyses of clinical outcomes. 5 participants in the control group and none in the lactulose group were lost to follow-up. Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>The investigators account for all participants randomised, but the trial report excludes participants with missing outcomes (2 from both intervention groups) from the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Participants who were excluded or lost to follow-up are not described. The handling of participants with missing outcomes is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:46:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>The investigators account for all participants randomised; there are no missing outcome data and all participants are included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>The investigators account for all participants randomised and used sufficient methods to handle missing data. Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 13:55:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>The investigators do not account for all participants randomised in the trial report or analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-26 17:45:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Open trial. The investigators describe the trial as placebo-controlled in the trial registry, but the placebo intervention is not mentioned in the methods section of the published RCT. No blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:01:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>The investigators account for all participants randomised. There are no participants with post-randomisation missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>The investigators account for all participants randomised and used sufficient methods to handle missing data. Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-19 13:57:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Patient with missing outcome data are not described and the handling of participants with missing outcomes in the analyses is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:26:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>The investigators account for all participants randomised. There are no missing outcomes and all participants are included in the analyses. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:28:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>The investigators account for all participants randomised and there are no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>The investigators account for all participants randomised. There are no missing data for clinical outcomes, but trial authors exclude 2 participants from the reported analyses. The 2 participants developed complications requiring antibiotics and never received the trial medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:32:09 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Participants with missing outcome data are excluded from the analyses. The authors do not include information about the allocation group for participants with missing outcomes. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>The investigators account for all participants randomised. There are no missing clinical outcomes, but the trial authors exclude 2 participants who were intolerant to lactulose from the reported analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>The investigators account for all participants randomised and used sufficient methods to handle missing data. Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-20 14:56:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>All participants are described and there are no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>The investigators account for all participants randomised and used sufficient methods to handle missing data. Missing outcome data are unlikely to affect the analyses or to be associated with the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-09 15:59:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Participants with missing outcomes are excluded from the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-04-07 11:46:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:40:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>Mortality data incomplete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:46:57 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>Predefined outcomes described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>Mortality data incomplete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>In the trial registration, the primary outcome measure was 'improvement of minimal hepatic encephalopathy'. In the published report the primary outcome was the change in arterial blood ammonia, inflammatory mediators, serum endotoxins, and cerebral magnetic resonance spectroscopy. The published report describes "improvement in minimal hepatic encephalopathy" as a secondary outcome measure (reported for participants receiving lactulose).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>The trial report does not include information about the allocation group of participants who died within the first 5 days after randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>Predefined outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>Predefined outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Predefined outcomes are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>Predefined outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>Predefined outcomes are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-22 19:12:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Predefined outcomes are reported (see notes).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>Predefined outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-04-07 11:47:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="9">
<NAME>For-profit funding</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:41:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>The trial received support in the form of a grant from a pharmaceutical company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:47:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>A pharmaceutical company provided financial support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-22 18:32:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>A pharmaceutical company was involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>Pharmaceutical companies supplied the interventions, but were not otherwise involved in the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:09:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>A pharmaceutical company supplied the study drugs, but were not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>A pharmaceutical company supplied lactitol, but was not otherwise involved in the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:14:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>A pharmaceutical company supplied the interventions, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:09:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>A pharmaceutical company supplied the interventions, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:10:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>A pharmaceutical company supplied lactitol, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>A pharmaceutical company supplied lactitol, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:11:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>A pharmaceutical company supplied lactitol, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>The trial received funding from a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>A pharmaceutical company supplied the drug, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-22 17:03:25 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>A pharmaceutical company supplied the lactitol, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 13:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>A pharmaceutical company supported the trial with a grant and supplied the drug and placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 16:07:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>A pharmaceutical company supplied lactulose, but was not otherwise involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 15:13:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>One of the trial investigators was an employee of a pharmaceutical company, which manufactured the trial drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 15:16:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>One of the trial investigators was an employee of a pharmaceutical company, which manufactured the trial drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>Funding not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-04-07 11:47:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:41:48 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>No for-profit funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:47:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:56 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>No other biases identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>No other biases identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>No other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-04-07 11:47:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="10">
<NAME>Overall assessment (mortality)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:23 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:41:51 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:47:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:00 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>Low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2016-04-07 11:47:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="11">
<NAME>Overall assessment (non-mortality outcomes)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:32:17 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Agrawal-2012">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:41:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Brown-1971">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Corazza-1982">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-07 11:47:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Dhiman-2000">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Elkington-1969">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:33:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Germain-1973">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Grandi-1991">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:34:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1987">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:27 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Heredia-1988">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:36:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Horsmans-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jain-2013">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Jankovic-1996">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:41:58 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-McClain-1984">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:42:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Mittal-2011">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Morgan-1987a">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Morgan-1987b">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:43:54 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Morgan-1989">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:24 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Pai-1995">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:44:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Prasad-2007">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Quero-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:45:21 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Raza-2004">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Riggio-1989">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:46:20 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Riggio-2005">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Rodgers-1973">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Sharma-2009">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Sharma-2011">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Sharma-2012">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Shi-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Simmons-1970">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Uribe-1987a">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Uribe-1987b">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Watanabe-1997">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Wen-2013">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Xing-2003">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yao-2014">
<DESCRIPTION>
<P>High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Ziada-2013">
<DESCRIPTION>
<P>High risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-10-27 16:15:04 +0100" MODIFIED_BY="Grade Profiler">Non-absorbable disaccharides versus placebo/no intervention for the prevention and treatment of hepatic encephalopathy in people with cirrhosis</TITLE>
<TABLE COLS="7" ROWS="24">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Non-absorbable disaccharides versus placebo/no intervention for the prevention and treatment of hepatic encephalopathy in people with cirrhosis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Population:</B> prevention and treatment of hepatic encephalopathy in people with cirrhosis<BR/>
<B>Intervention: </B>non-absorbable disaccharides (lactulose and lactitol)<BR/>
<B>Control:</B> placebo/no intervention</P>
<P>
<B>Setting:</B> in-hospital (overt hepatic encephalopathy) and outpatient (minimal hepatic encephalopathy and prevention trials)</P>
<P>
<B>Duration of follow-up:</B> the duration depended on the type of encephalopathy with 5 days for acute, 74 days for chronic, 70 days for minimal, and 207 days for prevention of hepatic encephalopathy</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Non-absorbable disaccharides versus placebo/no intervention</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.59 </B>(0.40 to 0.87) when including all RCTs; <B>RR 0.63 </B>(0.41 to 0.97) when including RCTs with a low risk of bias</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1487<BR/>(24 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trial Sequential Analysis:</B>
</P>
<P>The Trial Sequential Analysis found a beneficial effect of the intervention including all RCTs, but when the analysis only included RCTs with a low risk of bias.</P>
<P>
<B>Assessment method: </B>Assessed based on the total number of participants who died.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>88 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>49 per 1000</B>
<BR/>(32 to 75)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(7 to 17)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hepatic encephalopathy</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.58 </B>
<BR/>(0.5 to 0.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1415<BR/>(22 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trial Sequential Analysis:</B>
</P>
<P>The Trial Sequential Analysis found a beneficial effect of the intervention including all RCTs, but when the analysis only included RCTs with a low risk of bias.</P>
<P>
<B>Assessment method: </B>Assessed based on the definitions in included RCTs (number of participants without a clinically relevant improvement of hepatic encephalopathy).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>469 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>272 per 1000</B>
<BR/>(234 to 323)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>423 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>245 per 1000</B>
<BR/>(211 to 292)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.47 </B>
<BR/>(0.36 to 0.6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1487<BR/>(24 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trial Sequential Analysis:</B>
</P>
<P>The Trial Sequential Analysis found a beneficial effect of the intervention including all RCTs, but when the analysis only included RCTs with a low risk of bias.</P>
<P>
<B>Assessment method: </B>Assessed and defined as any untoward medical occurrence that led to death, was life threatening, or required hospitalisation or prolongation of hospitalisation (<LINK REF="REF-ICH_x002d_GCP-2007" TYPE="REFERENCE">ICH-GCP 2007</LINK>).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
<BR/>(75 to 124)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
<BR/>(51 to 85)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life (secondary outcome)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No overall estimate available</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>We were unable to combine the data into an overall analysis due to unacceptably high heterogeneity.</P>
<P>
<B>Assessment method:</B>
</P>
<P>Based on the quality of life questionnaires.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Non-serious adverse events (secondary outcome)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.47 </B>
<BR/>(1.24 to 4.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>739<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Assessment method: </B>The outcome includes all adverse events that do not fulfil the criteria for 'serious' (<LINK REF="REF-ICH_x002d_GCP-2007" TYPE="REFERENCE">ICH-GCP 2007</LINK>).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>106 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>261 per 1000</B>
<BR/>(131 to 521)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>63 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>156 per 1000</B>
<BR/>(78 to 311)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RCT: </B>randomised clinical trial; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Mortality is downgraded one level to '<I>moderate quality evidence</I>' because the Trial Sequential Analysis found insufficient evidence when we limited the analysis to include only RCTs with a low risk of bias.<BR/>
<SUP>2</SUP>Hepatic encephalopathy is downgraded one level to '<I>moderate quality evidence</I>' because none of the RCTs had a low risk of bias in the overall assessment.</P>
<P>
<SUP>3</SUP>Serious adverse events is downgraded one level to '<I>moderate quality evidence</I>' because none of the RCTs had a low risk of bias in the overall assessment.</P>
<P>
<SUP>4</SUP>Quality of life is downgraded three levels to '<I>very low quality evidence</I>' because i) none of the included RCTs had a low risk of bias, ii) the heterogeneity was considerable, and iii) we were unable to combine the data in an overall analysis.</P>
<P>
<SUP>5</SUP>Non-serious adverse events is downgraded three levels to '<I>very low quality evidence</I>' because i) none of the included RCTs had a low risk of bias, ii) the confidence intervals were wide (uncertainty), and iii) we were only able to include data from nine RCTs in our meta-analysis.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-03-30 11:49:06 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-10-27 16:13:57 +0100" MODIFIED_BY="Grade Profiler">Lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis</TITLE>
<TABLE COLS="7" ROWS="24">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Population:</B> prevention and treatment of hepatic encephalopathy in people with cirrhosis<BR/>
<B>Intervention: </B>lactulose<BR/>
<B>Control:</B> lactitol</P>
<P>
<B>Setting:</B> in-hospital (overt hepatic encephalopathy) and outpatient (minimal hepatic encephalopathy and prevention trials)</P>
<P>
<B>Duration of follow-up:</B> the duration depended on the type of encephalopathy with 5 days for acute, 74 days for chronic, 70 days for minimal, and 207 days for prevention of hepatic encephalopathy<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Lactulose versus lactitol</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.3 </B>
<BR/>(0.59 to 2.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>225<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trial Sequential Analysis:</B>
</P>
<P>The Trial Sequential Analysis found no evidence to support or refute a difference between the 2 interventions being compared.</P>
<P>
<B>Assessment method: </B>Assessed based on the total number of participants who died.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
<BR/>(42 to 202)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hepatic encephalopathy</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.84 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>194<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trial Sequential Analysis:</B>
</P>
<P>The Trial Sequential Analysis found no evidence to support or refute a difference between the 2 interventions being compared.</P>
<P>
<B>Assessment method: </B>Assessed based on the definitions in included RCTs (number of participants without a clinically relevant improvement of hepatic encephalopathy).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
<BR/>(240 to 340)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
<BR/>(168 to 238)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.56 </B>
<BR/>(0.84 to 2.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>245<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trial Sequential Analysis:</B>
</P>
<P>The Trial Sequential Analysis found no evidence to support or refute a difference between the 2 interventions being compared.</P>
<P>
<B>Assessment method: </B>Assessed based on the definitions in included RCTs (number of participants without a clinically relevant improvement of hepatic encephalopathy.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>106 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>165 per 1000</B>
<BR/>(89 to 304)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>120 per 1000</B>
<BR/>(65 to 222)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Quality of life (secondary outcome)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No data were available for this outcome</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None of the included RCTs assessed quality of life.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Non-serious adverse events (secondary outcome)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.55 </B>
<BR/>(0.88 to 2.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>169<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Assessment method: </B>The outcome includes all adverse events that do not fulfil the criteria for 'serious' (<LINK REF="REF-ICH_x002d_GCP-2007" TYPE="REFERENCE">ICH-GCP 2007</LINK>).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>247 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>383 per 1000</B>
<BR/>(217 to 677)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>246 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>381 per 1000</B>
<BR/>(216 to 674)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RCT:</B> randomised clinical trial; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Mortality, hepatic encephalopathy, and serious adverse events are downgraded three levels to '<I>very low quality evidence</I>' because i) the Trial Sequential Analysis found insufficient evidence to support or refute a difference between the intervention and control group, ii) the confidence intervals were wide, and ii) none of the included RCTs had a low risk of bias in the overall assessment of bias control.</P>
<P>
<SUP>2</SUP>Non-serious adverse events is downgraded three levels to '<I>very low quality evidence</I>' because i) none of the included RCTs had a low risk of bias in the overall assessment of bias control, ii) only six RCTs reported the outcome, and iii) the confidence intervals were wide (uncertainty).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2015-05-26 11:50:52 +0200" MODIFIED_BY="[Empty name]">Definitions and assessment of overt hepatic encephalopathy with corresponding recommended definitions in the EASL/AASLD guidelines</TITLE>
<TABLE COLS="4" ROWS="17">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Trial</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Definition in trial publication</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Definition based on classification in EASL/AASLD guidelines</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Assessment of hepatic encephalopathy</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Elkington-1969" TYPE="STUDY">Elkington 1969</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mental status assessed using Parsons-Smith criteria</P>
<P>Arterial blood ammonia concentrations</P>
<P>Electroencephalogram</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Simmons-1970" TYPE="STUDY">Simmons 1970</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute, acute remittent, and chronic remittent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic (81%)</P>
<P>Recurrent (19%)</P>
</TD>
<TD VALIGN="TOP">
<P>Mental status assessed on a scale similar to but more extensive than the West Haven Criteria</P>
<P>Venous blood ammonia concentrations</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Brown-1971" TYPE="STUDY">Brown 1971</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Mental status</P>
<P>Blood ammonia concentrations</P>
<P>Electroencephalogram*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Germain-1973" TYPE="STUDY">Germain 1973</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Mental status assessed using Parson-Smith criteria</P>
<P>Psychometric tests</P>
<P>Venous blood ammonia concentrations</P>
<P>Electroencephalogram</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rodgers-1973" TYPE="STUDY">Rodgers 1973</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Clinical assessment of mental status</P>
<P>Blood ammonia concentrations</P>
<P>Electroencephalogram*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Corazza-1982" TYPE="STUDY">Corazza 1982</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Encephalopathy Intensity Score</P>
<P>Plasma ammonia concentrations</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Heredia-1987" TYPE="STUDY">Heredia 1987</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic/recurrent</P>
</TD>
<TD VALIGN="TOP">
<P>Conn score</P>
<P>Number Connection Test</P>
<P>Blood ammonia concentrations</P>
<P>Electroencephalogram</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Morgan-1987a" TYPE="STUDY">Morgan 1987a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Morgan-1987b" TYPE="STUDY">Morgan 1987b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Uribe-1987a" TYPE="STUDY">Uribe 1987a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Uribe-1987b" TYPE="STUDY">Uribe 1987b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic persistent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Heredia-1988" TYPE="STUDY">Heredia 1988</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic recurrent hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Grandi-1991" TYPE="STUDY">Grandi 1991</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Chronic hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Persistent</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index modified by omitting the electroencephalogram</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pai-1995" TYPE="STUDY">Pai 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic</P>
</TD>
<TD VALIGN="TOP">
<P>Portal Systemic Encephalopathy Sum and Index</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jankovic-1996" TYPE="STUDY">Jankovic 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic</P>
</TD>
<TD VALIGN="TOP">
<P>Mental status using West Haven criteria</P>
<P>Number connection Test A</P>
<P>Electroencephalogram*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Raza-2004" TYPE="STUDY">Raza 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute hepatic encephalopathy</P>
</TD>
<TD VALIGN="TOP">
<P>Episodic</P>
</TD>
<TD VALIGN="TOP">
<P>Clinical scoring</P>
<P>Modified Portal Systemic Encephalopathy Sum and Index with electroencephalogram omitted and Digit Symbol test replacing Number Connection Test A</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*The trial is not included in the analysis of hepatic encephalopathy, because we were unable to extract data on the number of participants with (or without) an overall improvement.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-09-08 22:23:44 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-09-08 14:32:49 +0200" MODIFIED_BY="[Empty name]">Liver-related serious adverse events</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH VALIGN="TOP">
<P>Event</P>
</TH>
<TH VALIGN="TOP">
<P>Non-absorbable disaccharides</P>
</TH>
<TH>
<P>Placebo/no intervention</P>
</TH>
</TR>
<TR>
<TD>
<P>Variceal bleeding</P>
</TD>
<TD>
<P>19/438 (4%)</P>
</TD>
<TD>
<P>17/336 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Hepatorenal syndrome</P>
</TD>
<TD>
<P>10/196 (5%)</P>
</TD>
<TD>
<P>7/153 (5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Spontaneous bacterial peritonitis</P>
</TD>
<TD>
<P>10/140 (7%)</P>
</TD>
<TD>
<P>16/138 (12%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Liver failure</P>
</TD>
<TD>
<P>9/189 (5%)</P>
</TD>
<TD>
<P>7/117 (6%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The overall risk of serious adverse events is analysed as one of the primary outcomes. </P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-03-23 12:27:46 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-11-17 20:33:58 +0100" MODIFIED_BY="[Empty name]">Quero 1996: Sickness Impact Profile selected subscores</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>End of treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Control (n = 21)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Lactulose (n = 19)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Psychological subscore</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10.9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Physical subscore</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<TITLE MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">Prasad 2007: Sickness Impact Profile selected subscores</TITLE>
<TABLE COLS="5" ROWS="19">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Change from baseline</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Control (n = 20)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Lactulose (n = 25)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Psychosocial scales</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Social interactions</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.68</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.35</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Alertness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10.43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.73</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Emotional behaviour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.76</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.83</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.98</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.55</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Communication</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.22</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total psychological subscore</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.47</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.98</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Physical scales</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ambulation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-1.89</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.67</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.80</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mobility</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.35</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Body care and movements</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.72</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.55</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total physical subscore</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.01</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.52</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.99</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.56</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Independent scales</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sleep and rest</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.29</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9.04</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.95</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Work</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.06</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.83</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.45</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Home management</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.94</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12.64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.71</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recreation and pastimes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.97</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Eating</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.31</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.88</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.21</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<TITLE MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">Mittal 2009: Sickness Impact Profile selected subscores</TITLE>
<TABLE COLS="5" ROWS="17">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Change from baseline</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Control (n = 31)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Lactulose (n = 35)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Subscores</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sleep and rest</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.87</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.5</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Emotional behaviour</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9.84</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Body care and movements</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8211;0.38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.4</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Home management</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8211;0.25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.34</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.20</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mobility</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.3</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Social interaction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.88</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Alertness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ambulation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8211;0.18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Communication</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.80</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.07</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Work</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9.46</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.7</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recreation and pastime</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.06</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.74</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.7</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Eating</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Psychosocial</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.9</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Physical</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8211;0.05</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.1</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="6">
<TITLE MODIFIED="2014-11-17 20:36:15 +0100" MODIFIED_BY="[Empty name]">Zeng 2003: WHO-Bref selected subscores</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>End of treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Control (n = 20)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Short term lactulose (n = 20)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Long-term lactulose (n = 20)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standard deviation</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Physical health</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Psychological health</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Social relationships</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Environment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>53</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-04-07 08:05:49 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-03-23 12:45:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Non-absorbable disaccharides versus placebo/no intervention</NAME>
<DICH_OUTCOME CHI2="7.157937789324565" CI_END="0.8655860121778747" CI_START="0.40271877720694316" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5904131946287345" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.06268977035562859" LOG_CI_START="-0.3949981204614935" LOG_EFFECT_SIZE="-0.228843945408561" METHOD="IV" MODIFIED="2015-10-27 16:22:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8938298615294854" P_Q="1.0" P_Z="0.006945293120469536" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="768" TOTAL_2="719" WEIGHT="100.0" Z="2.699456037971608">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.53587531167703" CI_START="0.4086015514312896" EFFECT_SIZE="0.7921875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18635595941380265" LOG_CI_START="-0.3886999887149051" LOG_EFFECT_SIZE="-0.10117201465055117" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.33779071050365506" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.1141025641025641" WEIGHT="33.39352831530222"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.647315309129183" CI_START="0.17653149806038052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2213442053834143" LOG_CI_START="-0.7531777933166784" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.3452380952380953" WEIGHT="2.8324258870569476"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="1.9708382095901178"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.4554823796289753"/>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="1.7146415885529973"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.481778357580718"/>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="2.786272518808029"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="2.6833008487377192"/>
<DICH_DATA CI_END="1.2403763061649287" CI_START="0.16657168410991996" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0935534616929029" LOG_CI_START="-0.7783988233373155" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.5121890884601724" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.2623376623376623" WEIGHT="14.524362118860505"/>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="8.603874334339654"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="14.28857701952835"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="11.036693973704658"/>
<DICH_DATA CI_END="2.035123629230174" CI_START="0.006605276402967772" EFFECT_SIZE="0.11594202898550725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3085907967856193" LOG_CI_START="-2.1801090042762428" LOG_EFFECT_SIZE="-0.9357591037453117" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="1.782943094609698"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.034608436151645" CI_START="0.013829063605784151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9049647164245223" LOG_CI_START="-1.8592072258638475" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.6236882817719773" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="2.6363636363636362" WEIGHT="1.4452813536994198"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.0" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.0" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:02 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.0" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.060125213166017" CI_END="0.9679339719860134" CI_START="0.4103347229189344" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6302197380269079" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.01415426725788957" LOG_CI_START="-0.3868617310612864" LOG_EFFECT_SIZE="-0.200507999159588" METHOD="IV" MODIFIED="2016-02-18 14:39:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.7728267976120281" P_Q="1.0" P_Z="0.03495920411910887" Q="0.0" RANDOM="YES" SCALE="363.85425500572774" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-10" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="350" WEIGHT="100.0" Z="2.1088306252556364">
<NAME>Mortality in trials with a low risk of bias</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="10.823001787418558"/>
<DICH_DATA CI_END="16.647315309129183" CI_START="0.17653149806038052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2213442053834143" LOG_CI_START="-0.7531777933166784" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.3452380952380953" WEIGHT="3.5629704999289404"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="17.973913682677242"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.8308831328938315"/>
<DICH_DATA CI_END="1.2403763061649287" CI_START="0.16657168410991996" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0935534616929029" LOG_CI_START="-0.7783988233373155" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.5121890884601724" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.2623376623376623" WEIGHT="18.27051291836499"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="3.3753828512069948"/>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="2.156885172488468"/>
<DICH_DATA CI_END="1.53587531167703" CI_START="0.4086015514312896" EFFECT_SIZE="0.7921875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18635595941380265" LOG_CI_START="-0.3886999887149051" LOG_EFFECT_SIZE="-0.10117201465055117" MODIFIED="2015-09-08 16:03:58 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.33779071050365506" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.1141025641025641" WEIGHT="42.00644995502098"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.95858460976385" CI_END="0.6883300401096424" CI_START="0.49631125421332317" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5844877633616666" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="320" I2="32.16744155229587" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.16220327654656178" LOG_CI_START="-0.30424587675244774" LOG_EFFECT_SIZE="-0.23322457664950477" METHOD="IV" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07435000486646193" P_Q="1.0" P_Z="1.2245073848561424E-10" Q="0.0" RANDOM="YES" SCALE="229.85" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03990815179574574" TOTALS="YES" TOTAL_1="732" TOTAL_2="683" WEIGHT="100.00000000000001" Z="6.436263063053797">
<NAME>Hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="7.164390324489449"/>
<DICH_DATA CI_END="0.8120437020860286" CI_START="0.25011023904588797" EFFECT_SIZE="0.45066666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.09042059752719295" LOG_CI_START="-0.6018685287008977" LOG_EFFECT_SIZE="-0.34614456311404534" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.30042704647952434" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.09025641025641029" WEIGHT="5.348348153918891"/>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1189" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="1.7359899125818432"/>
<DICH_DATA CI_END="1.5337246758521959" CI_START="0.6520075054829263" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.18574740492596672" LOG_CI_START="-0.18574740492596675" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.21821789023599236" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.047619047619047616" WEIGHT="7.953703532294758"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="0.7153059192344011"/>
<DICH_DATA CI_END="0.8929071513462805" CI_START="0.4333189839852257" EFFECT_SIZE="0.6220238095238095" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="-0.04919369873117468" LOG_CI_START="-0.36319228382640545" LOG_EFFECT_SIZE="-0.20619299127879004" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.18444432320300247" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.03401970836181363" WEIGHT="9.416820582573354"/>
<DICH_DATA CI_END="0.7972004200626888" CI_START="0.42684094139215295" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="-0.09843248113203706" LOG_CI_START="-0.36973393093469886" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.15936381457791912" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.02539682539682539" WEIGHT="10.66021955883177"/>
<DICH_DATA CI_END="0.6219124554473241" CI_START="0.13552904447273176" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.20627074519986469" LOG_CI_START="-0.8679676235900309" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.38868402181875744" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="0.15107526881720432" WEIGHT="3.645161412037797"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.2665934994004632"/>
<DICH_DATA CI_END="1.2997758213259876" CI_START="0.3072481995062734" EFFECT_SIZE="0.6319444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.1138684538786518" LOG_CI_START="-0.512510653426964" LOG_EFFECT_SIZE="-0.19932109977415607" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.36793818825790614" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.13537851037851037" WEIGHT="3.97158224431952"/>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="3.55151521760445"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="5.438648115102343"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="2.7387183093325054"/>
<DICH_DATA CI_END="1.0403925450325875" CI_START="0.17654246972905982" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.017197231583418224" LOG_CI_START="-0.7531508021726071" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.4525062483125562" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.20476190476190476" WEIGHT="2.845323228154301"/>
<DICH_DATA CI_END="1.9890720084146771" CI_START="0.23639369497106014" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2986505057443792" LOG_CI_START="-0.6263641110217183" LOG_EFFECT_SIZE="-0.1638568026386696" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1191" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.29523809523809524" WEIGHT="2.0771988387714666"/>
<DICH_DATA CI_END="1.2902756366963168" CI_START="0.11912155361105008" EFFECT_SIZE="0.39204545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1106824968953578" LOG_CI_START="-0.9240096510491468" LOG_EFFECT_SIZE="-0.40666357707689454" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1192" O_E="0.0" SE="0.6077832895113378" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="0.36940052700922266" WEIGHT="1.7008322354411292"/>
<DICH_DATA CI_END="1.1448362319904497" CI_START="0.024263538313669918" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.058743365601929894" LOG_CI_START="-1.615045866369217" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="0.6916181314974013"/>
<DICH_DATA CI_END="1.7028707260375606" CI_START="0.47395013744735887" EFFECT_SIZE="0.8983739837398373" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2311816796128989" LOG_CI_START="-0.3242673464494357" LOG_EFFECT_SIZE="-0.04654283341826845" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1193" O_E="0.0" SE="0.326273507426038" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.10645440164808886" WEIGHT="4.756444724261094"/>
<DICH_DATA CI_END="0.78831130906832" CI_START="0.041935020923065836" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10330224302897578" LOG_CI_START="-1.377423135959512" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.748424919507535" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.5601398601398602" WEIGHT="1.1601828208907032"/>
<DICH_DATA CI_END="0.7466235429556289" CI_START="0.3213380492427486" EFFECT_SIZE="0.4898148148148148" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.12689831977468602" LOG_CI_START="-0.4930378471288419" LOG_EFFECT_SIZE="-0.30996808345176396" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="2281" O_E="0.0" SE="0.2150721707877219" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.04625603864734301" WEIGHT="8.079521104734631"/>
<DICH_DATA CI_END="1.0346357938459914" CI_START="0.18499867406335974" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.014787499011108932" LOG_CI_START="-0.7328313842944448" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.43915503282683993" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.19285714285714284" WEIGHT="2.9908470512988923"/>
<DICH_DATA CI_END="0.9507834496644479" CI_START="0.6052959282957625" EFFECT_SIZE="0.7586206896551724" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="-0.021918386664053005" LOG_CI_START="-0.21803224748944672" LOG_EFFECT_SIZE="-0.11997531707674987" MODIFIED="2015-10-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="0.11519825262810389" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.013270637408568445" WEIGHT="13.091035083228869"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.425624095012836" CI_END="0.5994808765885788" CI_START="0.3631308035993841" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46657258005381524" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="149" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.2222246663174621" LOG_CI_START="-0.4399369092644337" LOG_EFFECT_SIZE="-0.3310807877909479" METHOD="IV" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8434767184671108" P_Q="1.0" P_Z="2.5048649562412617E-9" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="768" TOTAL_2="719" WEIGHT="100.00000000000003" Z="5.961138530931962">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="28.56103006913696"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8717261857642553" CI_START="0.11370534344937835" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4581430282998273" LOG_CI_START="-0.9442191256724162" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.6785714285714285" WEIGHT="2.4101570261196743"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="0.8459294980838759"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1398561589712335" CI_START="0.029207570676174695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.0954451150103324" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.2000000000000002" WEIGHT="1.3628864135795775"/>
<DICH_DATA CI_END="1.5609628568553289" CI_START="0.02399863519060957" EFFECT_SIZE="0.1935483870967742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1933925691388498" LOG_CI_START="-1.6198134560401078" LOG_EFFECT_SIZE="-0.713210443450629" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.0650861947046997" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="1.1344086021505375" WEIGHT="1.4416883768292026"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.6360136596704695"/>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="1.1959328279160792"/>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="10.476279905095687"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="18.564723039029925"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="7.632163916045633"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="6.132988861108098"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="4.737205189269703"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="1.314258280029941"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.78831130906832" CI_START="0.041935020923065836" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10330224302897578" LOG_CI_START="-1.377423135959512" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.748424919507535" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.5601398601398602" WEIGHT="2.919741680028159"/>
<DICH_DATA CI_END="3.781113877888278" CI_START="0.009715684927116754" EFFECT_SIZE="0.19166666666666668" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5776197574455104" LOG_CI_START="-2.0125265775055743" LOG_EFFECT_SIZE="-0.7174534100300319" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="2.314855072463768" WEIGHT="0.7065080297034844"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0346357938459914" CI_START="0.18499867406335974" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.014787499011108932" LOG_CI_START="-0.7328313842944448" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.43915503282683993" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.19285714285714284" WEIGHT="8.480182128939596"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:42:08 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="2.5823110994139364"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.041539091631287" CI_END="8.16967206510873" CI_START="4.625176196544748" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="6.397424130826739" ESTIMABLE="YES" I2="71.59711855641112" I2_Q="80.87839473516867" ID="CMP-001.05" MODIFIED="2015-09-08 16:04:14 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.029576704894213934" P_Q="0.022204584235086422" P_Z="1.4940817239604927E-12" Q="5.229686452314812" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.250920371277737" TOTALS="SUB" TOTAL_1="79" TOTAL_2="81" UNITS="" WEIGHT="200.0" Z="7.0750376669660575">
<NAME>Quality of life: sickness impact profile</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactulose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.108836628723756" CI_END="9.068701267948377" CI_START="5.281751448554739" DF="1" EFFECT_SIZE="7.1752263582515585" ESTIMABLE="YES" I2="52.58048981228154" ID="CMP-001.05.01" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1464506731410803" P_Z="1.109345761438794E-13" STUDIES="2" TAU2="1.2494175989194283" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.00000000000001" Z="7.4271833078302185">
<NAME>Change from baseline</NAME>
<CONT_DATA CI_END="11.695005059699803" CI_START="5.844994940300196" EFFECT_SIZE="8.77" ESTIMABLE="YES" MEAN_1="11.64" MEAN_2="2.87" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="411" SD_1="5.5" SD_2="6.5" SE="1.4923769430315406" STUDY_ID="STD-Mittal-2011" TOTAL_1="35" TOTAL_2="31" WEIGHT="26.84524579135589"/>
<CONT_DATA CI_END="6.908310835502405" CI_START="6.2716891644975945" EFFECT_SIZE="6.59" ESTIMABLE="YES" MEAN_1="6.81" MEAN_2="0.22" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="412" SD_1="0.8" SD_2="0.15" SE="0.16240647175825698" STUDY_ID="STD-Prasad-2007" TOTAL_1="25" TOTAL_2="29" WEIGHT="73.15475420864412"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.933900020232981" CI_START="-4.13390002023298" DF="0" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7260252575207198" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="100.0" Z="0.3504176839023531">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="5.933900020232981" CI_START="-4.13390002023298" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="7.4" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1381" SD_1="9.0" SD_2="7.0" SE="2.5683635311361543" STUDY_ID="STD-Quero-1997" TOTAL_1="19" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="67.20640367451709" CI_END="3.5883994436167392" CI_START="1.3139950911691776" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1714371402521886" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="82" I2="59.8252569342024" I2_Q="71.79163990131111" ID="CMP-001.06" LOG_CI_END="0.5549007806660765" LOG_CI_START="0.11859374278683585" LOG_EFFECT_SIZE="0.3367472617264562" METHOD="IV" MODIFIED="2016-03-23 12:45:08 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.7821201569633303E-5" P_Q="8.181624188435821E-4" P_Z="0.0024826367099233244" Q="24.815338344767362" RANDOM="YES" SCALE="794.98" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7909418990846507" TOTALS="SUB" TOTAL_1="1216" TOTAL_2="1213" WEIGHT="800.0" Z="3.025449729550378">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.244238455539183" CI_END="4.93341196667142" CI_START="1.2375486762588883" DF="8" EFFECT_SIZE="2.4708981057085246" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="39" I2="64.03563099725777" ID="CMP-001.06.01" LOG_CI_END="0.6931473829224569" LOG_CI_START="0.09256228996106898" LOG_EFFECT_SIZE="0.392854836441763" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.004482960874445663" P_Z="0.01034425331726513" STUDIES="9" TAU2="0.5025676439466056" TOTAL_1="370" TOTAL_2="369" WEIGHT="100.00000000000001" Z="2.5641040365540064">
<NAME>Overall</NAME>
<DICH_DATA CI_END="5.403026998892731" CI_START="1.479680973579885" EFFECT_SIZE="2.8275" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.7326371377114768" LOG_CI_START="0.17016808948350903" LOG_EFFECT_SIZE="0.4514026135974929" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.33039710319580107" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.10916224580017683" WEIGHT="20.34532350397613"/>
<DICH_DATA CI_END="114.70419217554587" CI_START="0.42718578171065713" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0595792906600843" LOG_CI_START="-0.3693832106315704" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="1.4267845968170128" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="2.0357142857142856" WEIGHT="4.903254582761292"/>
<DICH_DATA CI_END="31.981259724640676" CI_START="0.5002929883863344" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5048955663734804" LOG_CI_START="-0.3007755837175557" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.0606601717798212" STUDY_ID="STD-McClain-1984" TOTAL_1="16" TOTAL_2="16" VAR="1.125" WEIGHT="7.646897227429916"/>
<DICH_DATA CI_END="1.4288482068522237" CI_START="0.6034545123996926" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.1549860941317718" LOG_CI_START="-0.21935546087457428" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.21989008243131009" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.048351648351648346" WEIGHT="22.591044964190633"/>
<DICH_DATA CI_END="3.959540732044643" CI_START="1.01021817192785" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5976448149391891" LOG_CI_START="0.004415176388773367" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.3484660262185848" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.12142857142857144" WEIGHT="19.945381393806837"/>
<DICH_DATA CI_END="537.8211059946424" CI_START="2.024836860922391" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7306378414669568" LOG_CI_START="0.30639003828881833" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.4240151598070012" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="2.0278191753601593" WEIGHT="4.91855332512349"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="7.124252582770513"/>
<DICH_DATA CI_END="102.163166686205" CI_START="0.244706588596531" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0092943460117243" LOG_CI_START="-0.6113543373396868" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.539382009020818" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="2.3696969696969696" WEIGHT="4.333111387032659"/>
<DICH_DATA CI_END="86.58582984355299" CI_START="1.6630896794566206" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9374468236075126" LOG_CI_START="0.22091566848773705" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="1.0082988974836113" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.0166666666666664" WEIGHT="8.192181032908547"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.272250982395406" CI_END="22.400893079616676" CI_START="1.8362212966596902" DF="6" EFFECT_SIZE="6.413501145005654" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="6" I2="51.10921371631802" ID="CMP-001.06.02" LOG_CI_END="1.350265333147454" LOG_CI_START="0.2639250200714301" LOG_EFFECT_SIZE="0.8070951766094421" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05616365903783538" P_Z="0.003587714633682239" STUDIES="7" TAU2="1.3539116275109637" TOTAL_1="318" TOTAL_2="316" WEIGHT="99.99999999999997" Z="2.9123055808751865">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="588.6207224837088" CI_START="2.2123408858273543" EFFECT_SIZE="36.08641975308642" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="2.7698355474372365" LOG_CI_START="0.34485204552033694" LOG_EFFECT_SIZE="1.5573437964787866" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.424447312887917" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="2.029050147193607" WEIGHT="12.036768436964811"/>
<DICH_DATA CI_END="114.70419217554587" CI_START="0.42718578171065713" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0595792906600843" LOG_CI_START="-0.3693832106315704" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="1.4267845968170128" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="2.0357142857142856" WEIGHT="12.013103674463354"/>
<DICH_DATA CI_END="31.981259724640676" CI_START="0.5002929883863344" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5048955663734804" LOG_CI_START="-0.3007755837175557" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.0606601717798212" STUDY_ID="STD-McClain-1984" TOTAL_1="16" TOTAL_2="16" VAR="1.125" WEIGHT="16.426534557066354"/>
<DICH_DATA CI_END="2.925649438310225" CI_START="0.3418044509726267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.30000000000000004" WEIGHT="24.62037683023213"/>
<DICH_DATA CI_END="476.86373571280296" CI_START="1.7636065337258162" EFFECT_SIZE="29.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.6783942966870544" LOG_CI_START="0.2464016991108579" LOG_EFFECT_SIZE="1.462397997898956" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="1.428564490373771" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="2.0407965031568724" WEIGHT="11.995118857305613"/>
<DICH_DATA CI_END="412.9014964465082" CI_START="1.5136782147287975" EFFECT_SIZE="25.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.615846456856982" LOG_CI_START="0.18003356048709301" LOG_EFFECT_SIZE="1.3979400086720377" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.4308085527959702" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="2.047213114754099" WEIGHT="11.972488690933462"/>
<DICH_DATA CI_END="102.163166686205" CI_START="0.244706588596531" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0092943460117243" LOG_CI_START="-0.6113543373396868" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.539382009020818" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="2.3696969696969696" WEIGHT="10.935608953034267"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.532052325651732" CI_END="17.271275559842127" CI_START="1.174521689738083" DF="5" EFFECT_SIZE="4.503941357797394" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="10" I2="56.64258313433011" ID="CMP-001.06.03" LOG_CI_END="1.2373244133140573" LOG_CI_START="0.06986104124694635" LOG_EFFECT_SIZE="0.6535927272805019" MODIFIED="2015-09-08 19:56:56 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.041793922557349816" P_Z="0.02819714402855385" STUDIES="6" TAU2="1.4350323693843154" TOTAL_1="282" TOTAL_2="281" WEIGHT="100.00000000000001" Z="2.194532585221791">
<NAME>Bloating</NAME>
<DICH_DATA CI_END="374.2422602025967" CI_START="1.34458106027281" EFFECT_SIZE="22.432098765432098" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.573152827355607" LOG_CI_START="0.12858698950316227" LOG_EFFECT_SIZE="1.3508699084293845" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.4359500739505824" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="2.0619526148786833" WEIGHT="13.448317828582393"/>
<DICH_DATA CI_END="1.8318221259186125" CI_START="0.43133197574731574" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2628833004003573" LOG_CI_START="-0.36518834529511995" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-09-08 19:56:52 +0200" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.3689323936863109" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.13611111111111113" WEIGHT="29.932699396314554"/>
<DICH_DATA CI_END="226.44870787323092" CI_START="0.7463058702662526" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.354969846921706" LOG_CI_START="-0.12708314230803266" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="1.4579702122339973" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="2.1256771397616467" WEIGHT="13.207638924026922"/>
<DICH_DATA CI_END="163.58495412635662" CI_START="0.4951555626407661" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2137433565456317" LOG_CI_START="-0.3052583376669818" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.479674064439977" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="2.189435336976321" WEIGHT="12.975302670683977"/>
<DICH_DATA CI_END="72.98606354122126" CI_START="0.13426702924773704" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8632399408743792" LOG_CI_START="-0.8720306200470282" LOG_EFFECT_SIZE="0.4956046604136756" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="1.6067114672928786" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.5815217391304346" WEIGHT="11.708684668395847"/>
<DICH_DATA CI_END="53.472577975118114" CI_START="0.9163575397991978" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7281311224466887" LOG_CI_START="-0.03793504241817497" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2015-09-08 19:56:56 +0200" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="1.0373960074101287" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.076190476190476" WEIGHT="18.72735651199632"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="190.5337733482898" CI_START="0.63505801556145" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="2.2799719683515804" LOG_CI_START="-0.19718659803513053" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2015-09-08 19:57:03 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09936700350020851" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.6479301602810232">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="190.5337733482898" CI_START="0.63505801556145" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2799719683515804" LOG_CI_START="-0.19718659803513053" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="1.4550952040282188" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="2.1173020527859236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.029420173963111577" CI_END="0.2915806164141629" CI_START="0.005481724138532804" DF="1" EFFECT_SIZE="0.03997955106458538" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="24" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="-0.5352413502586336" LOG_CI_START="-2.261082823617288" LOG_EFFECT_SIZE="-1.3981620869379612" MODIFIED="2015-09-08 19:57:03 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.863812500927539" P_Z="0.0014949338638559275" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="3.175665178117179">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="0.5542209813511711" CI_START="0.002040822275892705" EFFECT_SIZE="0.033631332481907195" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="-0.2563170369937825" LOG_CI_START="-2.6901948139805465" LOG_EFFECT_SIZE="-1.4732559254871644" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.429671854091327" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="2.0439616103809324" WEIGHT="50.281042304308734"/>
<DICH_DATA CI_END="0.7972217750956001" CI_START="0.0028443449075048217" EFFECT_SIZE="0.047619047619047616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.09842084760989597" LOG_CI_START="-2.5460177418579426" LOG_EFFECT_SIZE="-1.3222192947339193" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="1.4377305314813302" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="2.0670690811535883" WEIGHT="49.718957695691266"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.109562615691253" CI_START="0.014918558805304112" DF="0" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.06" LOG_CI_END="0.9089974314350545" LOG_CI_START="-1.8262731294863532" LOG_EFFECT_SIZE="-0.4586378490256493" MODIFIED="2016-03-23 12:45:08 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.511003554487279" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6572758679743783">
<NAME>Hyponatraemia</NAME>
<DICH_DATA CI_END="8.109562615691253" CI_START="0.014918558805304112" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9089974314350545" LOG_CI_START="-1.8262731294863532" LOG_EFFECT_SIZE="-0.4586378490256493" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="1.6067114672928786" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.5815217391304346" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.109562615691253" CI_START="0.014918558805304112" DF="0" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.07" LOG_CI_END="0.9089974314350545" LOG_CI_START="-1.8262731294863532" LOG_EFFECT_SIZE="-0.4586378490256493" MODIFIED="2015-09-08 19:57:03 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.511003554487279" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6572758679743783">
<NAME>Anal fissure</NAME>
<DICH_DATA CI_END="8.109562615691253" CI_START="0.014918558805304112" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9089974314350545" LOG_CI_START="-1.8262731294863532" LOG_EFFECT_SIZE="-0.4586378490256493" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="1.6067114672928786" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.5815217391304346" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.109562615691253" CI_START="0.014918558805304112" DF="0" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.08" LOG_CI_END="0.9089974314350545" LOG_CI_START="-1.8262731294863532" LOG_EFFECT_SIZE="-0.4586378490256493" MODIFIED="2015-09-08 19:57:03 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.511003554487279" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6572758679743783">
<NAME>Hyperglycaemia</NAME>
<DICH_DATA CI_END="8.109562615691253" CI_START="0.014918558805304112" EFFECT_SIZE="0.34782608695652173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9089974314350545" LOG_CI_START="-1.8262731294863532" LOG_EFFECT_SIZE="-0.4586378490256493" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="1.6067114672928786" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.5815217391304346" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.613508666151022" CI_END="0.46790288674495173" CI_START="-11.588324832361225" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.560210972808137" ESTIMABLE="YES" I2="60.35995905391694" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2016-02-18 14:40:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="7" P_CHI2="0.02728277583298222" P_Q="1.0" P_Z="0.07063275196811675" Q="0.0" RANDOM="YES" SCALE="149.66423649852703" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="24.276156080797843" TOTALS="YES" TOTAL_1="128" TOTAL_2="147" UNITS="" WEIGHT="100.00000000000001" Z="1.8078313560514445">
<NAME>Number connection test, end of treatment</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disaccharide</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1478184197359602" CI_START="-3.8078184197359595" EFFECT_SIZE="-1.3299999999999996" ESTIMABLE="YES" MEAN_1="3.81" MEAN_2="5.14" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="534" SD_1="0.94" SD_2="3.21" SE="1.2642163015650671" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" WEIGHT="36.55917960002809"/>
<CONT_DATA CI_END="3.65524568368798" CI_START="-7.055245683687978" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="28.3" MEAN_2="30.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1379" SD_1="11.0" SD_2="4.8" SE="2.7323184129552756" STUDY_ID="STD-Quero-1997" TOTAL_1="19" TOTAL_2="21" WEIGHT="29.801371762333904"/>
<CONT_DATA CI_END="-0.04723401275716199" CI_START="-21.35276598724283" EFFECT_SIZE="-10.699999999999996" ESTIMABLE="YES" MEAN_1="47.7" MEAN_2="58.4" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="523" SD_1="25.2" SD_2="32.1" SE="5.43518456016054" STUDY_ID="STD-Sharma-2012" TOTAL_1="57" TOTAL_2="56" WEIGHT="17.57697364285841"/>
<CONT_DATA CI_END="14.869251751343846" CI_START="-94.86925175134385" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="154.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="651" SD_1="56.0" SD_2="60.0" SE="27.995030614922264" STUDY_ID="STD-Uribe-1987a" TOTAL_1="5" TOTAL_2="23" WEIGHT="1.170729284595047"/>
<CONT_DATA CI_END="7.066408307355154" CI_START="-21.26640830735517" EFFECT_SIZE="-7.1000000000000085" ESTIMABLE="YES" MEAN_1="88.55" MEAN_2="95.65" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="2177" SD_1="21.27" SD_2="24.34" SE="7.227892154701812" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.36231493650022"/>
<CONT_DATA CI_END="-16.348149438306173" CI_START="-89.65185056169383" EFFECT_SIZE="-53.0" ESTIMABLE="YES" MEAN_1="59.0" MEAN_2="112.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="720" SD_1="37.0" SD_2="75.0" SE="18.700267377767624" STUDY_ID="STD-Zeng-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.5294307736843464"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="25.92431814863635" CI_END="-2.1429524269457882" CI_START="-21.138688865872652" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.640820646409221" ESTIMABLE="YES" I2="80.71308965067995" I2_Q="75.6219875510492" ID="CMP-001.08" MODIFIED="2016-02-18 14:41:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="8" P_CHI2="9.230312367680682E-5" P_Q="0.04283117542955528" P_Z="0.016297686107958273" Q="4.102057138965152" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="83.48501419477188" TOTALS="YES" TOTAL_1="187" TOTAL_2="187" UNITS="" WEIGHT="100.00000000000003" Z="2.402180014531859">
<NAME>Ammonia end of treatment</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.547379140834302" CI_END="-3.528292147558533" CI_START="-27.786499030709216" DF="4" EFFECT_SIZE="-15.657395589133873" ESTIMABLE="YES" I2="74.27219106341707" ID="CMP-001.08.01" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00369074204787212" P_Z="0.011402769525389779" STUDIES="5" TAU2="106.89150713152571" TOTAL_1="107" TOTAL_2="109" WEIGHT="73.65608656137826" Z="2.5301071587211164">
<NAME>Venous</NAME>
<CONT_DATA CI_END="-9.863903804881948" CI_START="-20.51609619511806" EFFECT_SIZE="-15.190000000000005" ESTIMABLE="YES" MEAN_1="62.12" MEAN_2="77.31" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1250" SD_1="8.99" SD_2="6.11" SE="2.7174459516244296" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="25.842696731995563"/>
<CONT_DATA CI_END="7.1713865994679775" CI_START="-9.971386599467989" EFFECT_SIZE="-1.4000000000000057" ESTIMABLE="YES" MEAN_1="125.0" MEAN_2="126.4" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="514" SD_1="12.7" SD_2="17.8" SE="4.373236787552213" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" WEIGHT="22.885768624315126"/>
<CONT_DATA CI_END="13.406111964042786" CI_START="-61.406111964042786" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="146.0" MEAN_2="170.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="651" SD_1="54.0" SD_2="73.0" SE="19.085101695284926" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" WEIGHT="5.244977924804395"/>
<CONT_DATA CI_END="-31.874815192055017" CI_START="-142.12518480794498" EFFECT_SIZE="-87.0" ESTIMABLE="YES" MEAN_1="121.0" MEAN_2="208.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="719" SD_1="61.0" SD_2="110.0" SE="28.12561110447202" STUDY_ID="STD-Zeng-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.68521395077037"/>
<CONT_DATA CI_END="-4.407928662709574" CI_START="-33.39207133729044" EFFECT_SIZE="-18.900000000000006" ESTIMABLE="YES" MEAN_1="55.64" MEAN_2="74.54" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="510" SD_1="28.1" SD_2="23.33" SE="7.394049814997643" STUDY_ID="STD-Ziada-2013" TOTAL_1="24" TOTAL_2="25" WEIGHT="16.997429329492785"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4311049969143834" CI_START="-6.891104996914391" DF="0" EFFECT_SIZE="-2.230000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3483984463461032" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="78" WEIGHT="26.34391343862176" Z="0.9377003282306896">
<NAME>Arterial</NAME>
<CONT_DATA CI_END="2.4311049969143834" CI_START="-6.891104996914391" EFFECT_SIZE="-2.230000000000004" ESTIMABLE="YES" MEAN_1="82.97" MEAN_2="85.2" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="455" SD_1="12.9" SD_2="16.7" SE="2.378158493564468" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" WEIGHT="26.34391343862176"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="36.10307221446238" CI_END="29.08956144722644" CI_START="8.858691697243582" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="18.97412657223501" ESTIMABLE="YES" I2="94.46030523906819" I2_Q="96.30899700845006" ID="CMP-001.09" MODIFIED="2015-09-08 20:01:50 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.4465184050571622E-8" P_Q="1.9391529748613578E-7" P_Z="2.3652836881571143E-4" Q="27.09290678683731" RANDOM="YES" SCALE="5.72" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="69.24494016376718" TOTALS="YES" TOTAL_1="78" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="3.6764217435304842">
<NAME>Ammonia change from baseline</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactulose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.529697673835454" CI_END="15.305152679173759" CI_START="5.60402427555875" DF="1" EFFECT_SIZE="10.454588477366254" ESTIMABLE="YES" I2="81.9158286947288" ID="CMP-001.09.01" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.018696437625414508" P_Z="2.3960156314151413E-5" STUDIES="2" TAU2="10.035712962962958" TOTAL_1="67" TOTAL_2="67" WEIGHT="74.54848855071558" Z="4.224378038577393">
<NAME>Arterial</NAME>
<CONT_DATA CI_END="15.719266367784602" CI_START="10.080733632215399" EFFECT_SIZE="12.9" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="13.1" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="880" SD_1="6.95" SD_2="2.75" SE="1.4384276394987945" STUDY_ID="STD-Jain-2013" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.3506402983431"/>
<CONT_DATA CI_END="10.962229362860594" CI_START="4.937770637139409" EFFECT_SIZE="7.950000000000001" ESTIMABLE="YES" MEAN_1="8.47" MEAN_2="0.52" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="1354" SD_1="5.8" SD_2="7.8" SE="1.5368799562750501" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="37.197848252372474"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="55.66300594260544" CI_START="32.33699405739456" DF="0" EFFECT_SIZE="44.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.4227897004177317E-13" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="25.451511449284418" Z="7.394184290409208">
<NAME>Venous</NAME>
<CONT_DATA CI_END="55.66300594260544" CI_START="32.33699405739456" EFFECT_SIZE="44.0" ESTIMABLE="YES" MEAN_1="55.0" MEAN_2="11.0" MODIFIED="2015-06-03 10:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="530" SD_1="6.7" SD_2="17.7" SE="5.950622580109504" STUDY_ID="STD-Simmons-1970" TOTAL_1="11" TOTAL_2="10" WEIGHT="25.451511449284418"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.44026819274781" CI_END="0.8157212033236958" CI_START="0.4833229377730171" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6278986927794556" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="130" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.08845824877926828" LOG_CI_START="-0.31576259341510254" LOG_EFFECT_SIZE="-0.2021104210971854" METHOD="IV" MODIFIED="2015-10-26 15:22:12 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9701767698271179" P_Q="0.8441234826236825" P_Z="4.913070883931487E-4" Q="0.03866018856698705" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1536" TOTAL_2="1438" WEIGHT="200.00000000000003" Z="3.485451603534889">
<NAME>Mortality in worst-case scenario analyses</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.330711974175223" CI_END="0.8825721900058967" CI_START="0.42433988239991344" DF="14" EFFECT_SIZE="0.6119726949109219" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="67" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-0.05424976136340636" LOG_CI_START="-0.37228614831299284" LOG_EFFECT_SIZE="-0.2132679548381996" MODIFIED="2015-10-26 15:22:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9212101441370475" P_Z="0.008573351756972806" STUDIES="24" TAU2="0.0" TOTAL_1="768" TOTAL_2="719" WEIGHT="100.0" Z="2.62861438308092">
<NAME>Worst-case scenario</NAME>
<DICH_DATA CI_END="1.53587531167703" CI_START="0.4086015514312896" EFFECT_SIZE="0.7921875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18635595941380265" LOG_CI_START="-0.3886999887149051" LOG_EFFECT_SIZE="-0.10117201465055117" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.33779071050365506" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.1141025641025641" WEIGHT="30.58675624683773"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.647315309129183" CI_START="0.17653149806038052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2213442053834143" LOG_CI_START="-0.7531777933166784" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.3452380952380953" WEIGHT="2.5943565883975364"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="1.8051865424194682"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.3331470800849365"/>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="1.5705236003986036"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.3572328448561184"/>
<DICH_DATA CI_END="2.484165575427855" CI_START="0.09332083952160651" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.39518053920911933" LOG_CI_START="-1.0300213629134205" LOG_EFFECT_SIZE="-0.3174204118521506" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.8371706521699748" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.7008547008547008" WEIGHT="4.9796731206741915"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="2.4577657150312007"/>
<DICH_DATA CI_END="1.2403763061649287" CI_START="0.16657168410991996" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0935534616929029" LOG_CI_START="-0.7783988233373155" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.5121890884601724" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.2623376623376623" WEIGHT="13.303569469381758"/>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="7.880706841100044"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="13.087602432541141"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="10.109044637549019"/>
<DICH_DATA CI_END="2.035123629230174" CI_START="0.006605276402967772" EFFECT_SIZE="0.11594202898550725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3085907967856193" LOG_CI_START="-2.1801090042762428" LOG_EFFECT_SIZE="-0.9357591037453117" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="1.6330842707573239"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.772821117272873" CI_START="0.20951968980798236" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6787751575514255" LOG_CI_START="-0.6787751575514254" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:45:24 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.7974317750738529" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.6358974358974359" WEIGHT="5.488349407194674"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.0" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.585150750468739" CI_START="0.032959134000672394" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.879964216559285" LOG_CI_START="-1.4820242078872474" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-22 15:45:55 +0200" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="1.3874436925511608" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="1.925" WEIGHT="1.813001202776262"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:27:34 +0200" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.0" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.070896030005596" CI_END="0.9376385393420832" CI_START="0.44365488850774754" DF="14" EFFECT_SIZE="0.6449712564389045" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="63" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="-0.027964550345158268" LOG_CI_START="-0.3529547287506012" LOG_EFFECT_SIZE="-0.19045963954787976" MODIFIED="2015-10-22 15:49:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8264823953314901" P_Z="0.02160374380832501" STUDIES="24" TAU2="0.0" TOTAL_1="768" TOTAL_2="719" WEIGHT="100.00000000000003" Z="2.297263479492727">
<NAME>Extreme worst-case scenario analysis</NAME>
<DICH_DATA CI_END="1.53587531167703" CI_START="0.4086015514312896" EFFECT_SIZE="0.7921875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18635595941380265" LOG_CI_START="-0.3886999887149051" LOG_EFFECT_SIZE="-0.10117201465055117" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.33779071050365506" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.1141025641025641" WEIGHT="31.938923386251208"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.647315309129183" CI_START="0.17653149806038052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2213442053834143" LOG_CI_START="-0.7531777933166784" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.3452380952380953" WEIGHT="2.7090468712912865"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="1.8849895101965235"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.3920823152942028"/>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="1.6399526822860264"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.4172328539625711"/>
<DICH_DATA CI_END="4.482156381929963" CI_START="0.11637365897684451" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6514870049488084" LOG_CI_START="-0.9341453105417471" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-10-22 15:47:22 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.9314082711257011" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.8675213675213675" WEIGHT="4.200833765580823"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="2.566417642990572"/>
<DICH_DATA CI_END="1.2403763061649287" CI_START="0.16657168410991996" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0935534616929029" LOG_CI_START="-0.7783988233373155" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.5121890884601724" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.2623376623376623" WEIGHT="13.891688370524214"/>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="8.229093990750414"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="13.666173948924792"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="10.55594125710053"/>
<DICH_DATA CI_END="2.035123629230174" CI_START="0.006605276402967772" EFFECT_SIZE="0.11594202898550725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3085907967856193" LOG_CI_START="-2.1801090042762428" LOG_EFFECT_SIZE="-0.9357591037453117" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="1.7052790098460553"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="28.092926570009606" CI_START="0.3203653409897097" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.44859698402184" LOG_CI_START="-0.494354474582515" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-10-22 15:48:42 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.1412993045490314" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="1.3025641025641026" WEIGHT="2.797799391118462"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.0" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.11328941979413" CI_START="0.06538021389049867" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.557667048432407" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.18655669273384623" MODIFIED="2015-10-22 15:48:53 +0200" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="1.6107940200861126" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="2.59465737514518" WEIGHT="1.4045450038823333"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:44:07 +0200" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.0" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="57.74593327510998" CI_END="0.6623707981192993" CI_START="0.5354577414236599" CI_STUDY="95" CI_TOTAL="95" DF="43" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5955430895795425" ESTIMABLE="YES" EVENTS_1="384" EVENTS_2="644" I2="25.53588181674754" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.17889882250216968" LOG_CI_START="-0.27127479820411265" LOG_EFFECT_SIZE="-0.22508681035314118" METHOD="IV" MODIFIED="2016-02-18 14:42:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="11" P_CHI2="0.06578890500372758" P_Q="0.89468222293344" P_Z="1.2789929266224484E-21" Q="0.01752497173981052" RANDOM="YES" SCALE="116.01261660848336" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02713050311531932" TOTALS="YES" TOTAL_1="1464" TOTAL_2="1366" WEIGHT="99.99999999999999" Z="9.551445347881172">
<NAME>Hepatic encephalopathy worst-case scenario analysis</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="29.266315199563923" CI_END="0.6883696323856573" CI_START="0.504936691745221" DF="21" EFFECT_SIZE="0.5895617735866936" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="324" I2="28.24515195437755" ID="CMP-001.11.01" LOG_CI_END="-0.16217829694157232" LOG_CI_START="-0.29676306970162314" LOG_EFFECT_SIZE="-0.22947068332159773" MODIFIED="2015-10-26 15:35:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10775320769337704" P_Z="2.3316910062113822E-11" STUDIES="22" TAU2="0.032347453487226535" TOTAL_1="732" TOTAL_2="683" WEIGHT="50.18806446639375" Z="6.68358337417544">
<NAME>Worst-case scenario</NAME>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="3.488904273910523"/>
<DICH_DATA CI_END="0.8120437020860286" CI_START="0.25011023904588797" EFFECT_SIZE="0.45066666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.09042059752719295" LOG_CI_START="-0.6018685287008977" LOG_EFFECT_SIZE="-0.34614456311404534" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.30042704647952434" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.09025641025641029" WEIGHT="2.5082660387008495"/>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1189" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="0.7583875540619045"/>
<DICH_DATA CI_END="1.5337246758521959" CI_START="0.6520075054829263" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.18574740492596672" LOG_CI_START="-0.18574740492596675" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.21821789023599236" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.047619047619047616" WEIGHT="3.9389883324456836"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="0.3065577245333057"/>
<DICH_DATA CI_END="0.8929071513462805" CI_START="0.4333189839852257" EFFECT_SIZE="0.6220238095238095" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="-0.04919369873117468" LOG_CI_START="-0.36319228382640545" LOG_EFFECT_SIZE="-0.20619299127879004" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.18444432320300247" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.03401970836181363" WEIGHT="4.814989205856347"/>
<DICH_DATA CI_END="0.7972004200626888" CI_START="0.42684094139215295" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="-0.09843248113203706" LOG_CI_START="-0.36973393093469886" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.15936381457791912" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.02539682539682539" WEIGHT="5.605417532897221"/>
<DICH_DATA CI_END="0.6219124554473241" CI_START="0.13552904447273176" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.20627074519986469" LOG_CI_START="-0.8679676235900309" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.38868402181875744" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="0.15107526881720432" WEIGHT="1.6522338474520053"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.11330802947010504"/>
<DICH_DATA CI_END="1.2065271949171692" CI_START="0.3415855843466945" EFFECT_SIZE="0.6419753086419753" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.08153711527866864" LOG_CI_START="-0.46650046576636983" LOG_EFFECT_SIZE="-0.19248167524385063" MODIFIED="2015-10-26 15:34:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.3219199879356338" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.10363247863247863" WEIGHT="2.251689310405209"/>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="1.6068271906532845"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="2.5553110364479097"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="1.2196264665563743"/>
<DICH_DATA CI_END="1.0403925450325875" CI_START="0.17654246972905982" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.017197231583418224" LOG_CI_START="-0.7531508021726071" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.4525062483125562" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.20476190476190476" WEIGHT="1.2697164641721204"/>
<DICH_DATA CI_END="1.9890720084146771" CI_START="0.23639369497106014" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2986505057443792" LOG_CI_START="-0.6263641110217183" LOG_EFFECT_SIZE="-0.1638568026386696" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1191" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.29523809523809524" WEIGHT="0.9133569761513632"/>
<DICH_DATA CI_END="1.2902756366963168" CI_START="0.11912155361105008" EFFECT_SIZE="0.39204545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1106824968953578" LOG_CI_START="-0.9240096510491468" LOG_EFFECT_SIZE="-0.40666357707689454" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1192" O_E="0.0" SE="0.6077832895113378" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="0.36940052700922266" WEIGHT="0.7425335871085587"/>
<DICH_DATA CI_END="1.1448362319904497" CI_START="0.024263538313669918" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.058743365601929894" LOG_CI_START="-1.615045866369217" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="0.29627535391635323"/>
<DICH_DATA CI_END="1.7028707260375606" CI_START="0.47395013744735887" EFFECT_SIZE="0.8983739837398373" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2311816796128989" LOG_CI_START="-0.3242673464494357" LOG_EFFECT_SIZE="-0.04654283341826845" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1193" O_E="0.0" SE="0.326273507426038" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.10645440164808886" WEIGHT="2.2041233530068807"/>
<DICH_DATA CI_END="1.0170466695872906" CI_START="0.1454495634333758" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.0073408820074992625" LOG_CI_START="-0.8372875779491352" LOG_EFFECT_SIZE="-0.4149733479708179" MODIFIED="2015-10-26 15:34:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.4961389383568338" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.24615384615384617" WEIGHT="1.0774038432337305"/>
<DICH_DATA CI_END="0.7466235429556289" CI_START="0.3213380492427486" EFFECT_SIZE="0.4898148148148148" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.12689831977468602" LOG_CI_START="-0.4930378471288419" LOG_EFFECT_SIZE="-0.30996808345176396" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="2281" O_E="0.0" SE="0.2150721707877219" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.04625603864734301" WEIGHT="4.012147202009623"/>
<DICH_DATA CI_END="0.9760639620255266" CI_START="0.20237491791789453" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="-0.01052172183684098" LOG_CI_START="-0.693843314385884" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-10-26 15:34:57 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.4013864859597432" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.1611111111111111" WEIGHT="1.5641472764043427"/>
<DICH_DATA CI_END="0.9507834496644479" CI_START="0.6052959282957625" EFFECT_SIZE="0.7586206896551724" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="-0.021918386664053005" LOG_CI_START="-0.21803224748944672" LOG_EFFECT_SIZE="-0.11997531707674987" MODIFIED="2015-10-26 15:23:42 +0100" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="0.11519825262810389" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.013270637408568445" WEIGHT="7.287853867000053"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="28.468384984759" CI_END="0.6971258038231671" CI_START="0.5134731976635302" DF="21" EFFECT_SIZE="0.5982937536552094" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="320" I2="26.23396089647276" ID="CMP-001.11.02" LOG_CI_END="-0.15668884173543418" LOG_CI_START="-0.2894822208313019" LOG_EFFECT_SIZE="-0.22308553128336805" MODIFIED="2015-10-26 15:35:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12736056938473783" P_Z="4.540834671184839E-11" STUDIES="22" TAU2="0.02945251162163173" TOTAL_1="732" TOTAL_2="683" WEIGHT="49.81193553360624" Z="6.585262153344677">
<NAME>Extreme worst-case scenario</NAME>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="3.488904273910523"/>
<DICH_DATA CI_END="0.8120437020860286" CI_START="0.25011023904588797" EFFECT_SIZE="0.45066666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.09042059752719295" LOG_CI_START="-0.6018685287008977" LOG_EFFECT_SIZE="-0.34614456311404534" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.30042704647952434" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.09025641025641029" WEIGHT="2.5082660387008495"/>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1189" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="0.7583875540619045"/>
<DICH_DATA CI_END="1.5337246758521959" CI_START="0.6520075054829263" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.18574740492596672" LOG_CI_START="-0.18574740492596675" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.21821789023599236" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.047619047619047616" WEIGHT="3.9389883324456836"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="0.3065577245333057"/>
<DICH_DATA CI_END="0.8929071513462805" CI_START="0.4333189839852257" EFFECT_SIZE="0.6220238095238095" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="-0.04919369873117468" LOG_CI_START="-0.36319228382640545" LOG_EFFECT_SIZE="-0.20619299127879004" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.18444432320300247" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.03401970836181363" WEIGHT="4.814989205856347"/>
<DICH_DATA CI_END="0.7972004200626888" CI_START="0.42684094139215295" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="-0.09843248113203706" LOG_CI_START="-0.36973393093469886" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.15936381457791912" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.02539682539682539" WEIGHT="5.605417532897221"/>
<DICH_DATA CI_END="0.6219124554473241" CI_START="0.13552904447273176" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.20627074519986469" LOG_CI_START="-0.8679676235900309" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.38868402181875744" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="0.15107526881720432" WEIGHT="1.6522338474520053"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.11330802947010504"/>
<DICH_DATA CI_END="1.4140819045187198" CI_START="0.36886472884265653" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.1504745648006012" LOG_CI_START="-0.4331328703935398" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-10-26 15:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.3428138963364343" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.11752136752136752" WEIGHT="2.0354911893102914"/>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="1.6068271906532845"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="2.5553110364479097"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="1.2196264665563743"/>
<DICH_DATA CI_END="1.0403925450325875" CI_START="0.17654246972905982" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.017197231583418224" LOG_CI_START="-0.7531508021726071" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.4525062483125562" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.20476190476190476" WEIGHT="1.2697164641721204"/>
<DICH_DATA CI_END="1.9890720084146771" CI_START="0.23639369497106014" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2986505057443792" LOG_CI_START="-0.6263641110217183" LOG_EFFECT_SIZE="-0.1638568026386696" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1191" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.29523809523809524" WEIGHT="0.9133569761513632"/>
<DICH_DATA CI_END="1.2902756366963168" CI_START="0.11912155361105008" EFFECT_SIZE="0.39204545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1106824968953578" LOG_CI_START="-0.9240096510491468" LOG_EFFECT_SIZE="-0.40666357707689454" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1192" O_E="0.0" SE="0.6077832895113378" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="0.36940052700922266" WEIGHT="0.7425335871085587"/>
<DICH_DATA CI_END="1.1448362319904497" CI_START="0.024263538313669918" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.058743365601929894" LOG_CI_START="-1.615045866369217" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="0.29627535391635323"/>
<DICH_DATA CI_END="1.7028707260375606" CI_START="0.47395013744735887" EFFECT_SIZE="0.8983739837398373" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2311816796128989" LOG_CI_START="-0.3242673464494357" LOG_EFFECT_SIZE="-0.04654283341826845" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1193" O_E="0.0" SE="0.326273507426038" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.10645440164808886" WEIGHT="2.2041233530068807"/>
<DICH_DATA CI_END="1.2351604262036664" CI_START="0.16727508902059463" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.09172336868086255" LOG_CI_START="-0.776568730325275" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-10-26 15:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.5100390770714144" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.2601398601398601" WEIGHT="1.0249494756849735"/>
<DICH_DATA CI_END="0.7466235429556289" CI_START="0.3213380492427486" EFFECT_SIZE="0.4898148148148148" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.12689831977468602" LOG_CI_START="-0.4930378471288419" LOG_EFFECT_SIZE="-0.30996808345176396" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="2281" O_E="0.0" SE="0.2150721707877219" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.04625603864734301" WEIGHT="4.012147202009623"/>
<DICH_DATA CI_END="1.1351497483419437" CI_START="0.22023526003081312" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.05505315720201257" LOG_CI_START="-0.6571131485299749" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.175" WEIGHT="1.4566708322605113"/>
<DICH_DATA CI_END="0.9507834496644479" CI_START="0.6052959282957625" EFFECT_SIZE="0.7586206896551724" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="-0.021918386664053005" LOG_CI_START="-0.21803224748944672" LOG_EFFECT_SIZE="-0.11997531707674987" MODIFIED="2015-10-26 15:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="0.11519825262810389" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.013270637408568445" WEIGHT="7.287853867000053"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.824786243303897" CI_END="0.572486339134465" CI_START="0.40555246401493866" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4818435902353316" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="302" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.2422348721484325" LOG_CI_START="-0.3919529556122561" LOG_EFFECT_SIZE="-0.3170939138803443" METHOD="IV" MODIFIED="2016-03-23 12:45:28 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.985500960840307" P_Q="0.8692405645388388" P_Z="1.0222494317391497E-16" Q="0.027100810316603628" RANDOM="YES" SCALE="881.18" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1536" TOTAL_2="1438" WEIGHT="100.0" Z="8.302172143053003">
<NAME>Serious adverse events worst-case scenario analysis</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.917531201377386" CI_END="0.6055246367786723" CI_START="0.37256370098597846" DF="16" EFFECT_SIZE="0.4749699987540818" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="153" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="-0.2178681821669068" LOG_CI_START="-0.4287994608445848" LOG_EFFECT_SIZE="-0.3233338215057458" MODIFIED="2015-10-26 15:39:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9167707942218266" P_Z="1.868937383550282E-9" STUDIES="24" TAU2="0.0" TOTAL_1="768" TOTAL_2="719" WEIGHT="50.38097261823424" Z="6.008806746043098">
<NAME>Worst-case scenario analysis</NAME>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="13.506930975038525"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8717261857642553" CI_START="0.11370534344937835" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4581430282998273" LOG_CI_START="-0.9442191256724162" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.6785714285714285" WEIGHT="1.1397986876523831"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="0.4000524950504054"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1398561589712335" CI_START="0.029207570676174695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.0954451150103324" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.2000000000000002" WEIGHT="0.6445290198034308"/>
<DICH_DATA CI_END="1.5609628568553289" CI_START="0.02399863519060957" EFFECT_SIZE="0.1935483870967742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1933925691388498" LOG_CI_START="-1.6198134560401078" LOG_EFFECT_SIZE="-0.713210443450629" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.0650861947046997" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="1.1344086021505375" WEIGHT="0.6817956266356673"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.30078020924160104"/>
<DICH_DATA CI_END="2.484165575427855" CI_START="0.09332083952160651" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.39518053920911933" LOG_CI_START="-1.0300213629134205" LOG_EFFECT_SIZE="-0.3174204118521506" MODIFIED="2015-10-26 15:39:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.8371706521699748" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.7008547008547008" WEIGHT="1.1035594436634355"/>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="4.954386771442744"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="8.779530431917006"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="3.6093625108992127"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="2.9003805891154384"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="2.2402939722822697"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="0.6215320606002804"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0170466695872906" CI_START="0.1454495634333758" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.0073408820074992625" LOG_CI_START="-0.8372875779491352" LOG_EFFECT_SIZE="-0.4149733479708179" MODIFIED="2015-10-26 15:39:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.4961389383568338" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.24615384615384617" WEIGHT="3.142078971541726"/>
<DICH_DATA CI_END="3.781113877888278" CI_START="0.009715684927116754" EFFECT_SIZE="0.19166666666666668" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5776197574455104" LOG_CI_START="-2.0125265775055743" LOG_EFFECT_SIZE="-0.7174534100300319" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="2.314855072463768" WEIGHT="0.33411803311769656"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9760639620255266" CI_START="0.20237491791789453" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="-0.01052172183684098" LOG_CI_START="-0.693843314385884" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2015-10-26 15:39:32 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.4013864859597432" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.1611111111111111" WEIGHT="4.800629940604866"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="1.2212128796275534"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.880154231609913" CI_END="0.6244736644657909" CI_START="0.38279785761693685" DF="16" EFFECT_SIZE="0.4889245145170189" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="149" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="-0.20448587213108227" LOG_CI_START="-0.4170305014796927" LOG_EFFECT_SIZE="-0.31075818680538747" MODIFIED="2015-10-26 15:39:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.918266758565226" P_Z="9.968407306863842E-9" STUDIES="24" TAU2="0.0" TOTAL_1="768" TOTAL_2="719" WEIGHT="49.619027381765754" Z="5.7312655314431895">
<NAME>Extreme worst-case scenario analysis</NAME>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="13.506930975038525"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8717261857642553" CI_START="0.11370534344937835" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4581430282998273" LOG_CI_START="-0.9442191256724162" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.6785714285714285" WEIGHT="1.1397986876523831"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="0.4000524950504054"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1398561589712335" CI_START="0.029207570676174695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.0954451150103324" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.2000000000000002" WEIGHT="0.6445290198034308"/>
<DICH_DATA CI_END="1.5609628568553289" CI_START="0.02399863519060957" EFFECT_SIZE="0.1935483870967742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1933925691388498" LOG_CI_START="-1.6198134560401078" LOG_EFFECT_SIZE="-0.713210443450629" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.0650861947046997" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="1.1344086021505375" WEIGHT="0.6817956266356673"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.30078020924160104"/>
<DICH_DATA CI_END="4.482156381929963" CI_START="0.11637365897684451" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6514870049488084" LOG_CI_START="-0.9341453105417471" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-10-26 15:39:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.9314082711257011" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.8675213675213675" WEIGHT="0.8915455603980462"/>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="4.954386771442744"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="8.779530431917006"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="3.6093625108992127"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="2.9003805891154384"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="2.2402939722822697"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="0.6215320606002804"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2351604262036664" CI_START="0.16727508902059463" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.09172336868086255" LOG_CI_START="-0.776568730325275" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-10-26 15:39:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.5100390770714144" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.2601398601398601" WEIGHT="2.973149994577117"/>
<DICH_DATA CI_END="3.781113877888278" CI_START="0.009715684927116754" EFFECT_SIZE="0.19166666666666668" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5776197574455104" LOG_CI_START="-2.0125265775055743" LOG_EFFECT_SIZE="-0.7174534100300319" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="2.314855072463768" WEIGHT="0.33411803311769656"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1351497483419437" CI_START="0.22023526003081312" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.05505315720201257" LOG_CI_START="-0.6571131485299749" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-26 15:39:43 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.175" WEIGHT="4.419627564366383"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-26 15:33:39 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="1.2212128796275534"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-02-18 14:43:38 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Prevention trials: non-absorbable disaccharides versus placebo/no intervention</NAME>
<DICH_OUTCOME CHI2="2.2802926904614282" CI_END="0.9774716449989405" CI_START="0.4038603362632283" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6283009050105237" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.00989583198744527" LOG_CI_START="-0.39376879745607524" LOG_EFFECT_SIZE="-0.2018323147217602" METHOD="IV" MODIFIED="2016-02-18 14:43:03 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.8091570702482276" P_Q="0.7080831077033727" P_Z="0.039301560457964485" Q="0.14019926891253384" RANDOM="YES" SCALE="175.87883860157345" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-10" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="333" WEIGHT="100.0" Z="2.0610155095870146">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3203604686080586" CI_END="1.1721354508142166" CI_START="0.26896702568873315" DF="3" EFFECT_SIZE="0.5614853389981097" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.06897780122314857" LOG_CI_START="-0.5703009595485751" LOG_EFFECT_SIZE="-0.25066157916271326" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7243041899094742" P_Z="0.12429182324069547" STUDIES="4" TAU2="0.0" TOTAL_1="185" TOTAL_2="185" WEIGHT="36.05740797631706" Z="1.5370060687571778">
<NAME>Primary</NAME>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="11.481182109625772"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="19.066963146342793"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="3.5806503561207137"/>
<DICH_DATA CI_END="8.034608436151645" CI_START="0.013829063605784151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9049647164245223" LOG_CI_START="-1.8592072258638475" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.6236882817719773" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="2.6363636363636362" WEIGHT="1.9286123642277775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8197329529408358" CI_END="1.1634049985796568" CI_START="0.38518943343780154" DF="1" EFFECT_SIZE="0.6694261066477796" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.06573092541636205" LOG_CI_START="-0.4143256350018071" LOG_EFFECT_SIZE="-0.17429735479272251" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36525831747421866" P_Z="0.1546681771178825" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="63.942592023682934" Z="1.4232345359336809">
<NAME>Secondary</NAME>
<DICH_DATA CI_END="1.2403763061649287" CI_START="0.16657168410991996" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0935534616929029" LOG_CI_START="-0.7783988233373155" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.5121890884601724" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.2623376623376623" WEIGHT="19.38159950189301"/>
<DICH_DATA CI_END="1.53587531167703" CI_START="0.4086015514312896" EFFECT_SIZE="0.7921875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18635595941380265" LOG_CI_START="-0.3886999887149051" LOG_EFFECT_SIZE="-0.10117201465055117" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.33779071050365506" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.1141025641025641" WEIGHT="44.56099252178992"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2802926904614287" CI_END="0.9774716449989406" CI_START="0.4038603362632284" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6283009050105237" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.009895831987445222" LOG_CI_START="-0.3937687974560751" LOG_EFFECT_SIZE="-0.2018323147217602" METHOD="IV" MODIFIED="2016-02-18 14:43:38 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.8091570702482276" P_Q="0.6934241759962148" P_Z="0.03930156045796452" Q="0.15540367021705986" RANDOM="YES" SCALE="167.50279658738012" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-04" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="333" WEIGHT="99.99999999999999" Z="2.061015509587014">
<NAME>Mortality and bias control</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1248890202443684" CI_END="0.9940217748216255" CI_START="0.4071615910713978" DF="4" EFFECT_SIZE="0.6361819609168338" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="44" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.0026041019394094423" LOG_CI_START="-0.39023319720494315" LOG_EFFECT_SIZE="-0.19641864957217628" MODIFIED="2015-09-08 21:12:29 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7128014955796831" P_Z="0.04700022700796552" STUDIES="5" TAU2="0.0" TOTAL_1="270" TOTAL_2="268" WEIGHT="98.07138763577221" Z="1.9862981584999173">
<NAME>Low risk of bias</NAME>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="19.066963146342793"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="3.5806503561207137"/>
<DICH_DATA CI_END="1.2403763061649287" CI_START="0.16657168410991996" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0935534616929029" LOG_CI_START="-0.7783988233373155" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.5121890884601724" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.2623376623376623" WEIGHT="19.38159950189301"/>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="11.481182109625772"/>
<DICH_DATA CI_END="1.53587531167703" CI_START="0.4086015514312896" EFFECT_SIZE="0.7921875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18635595941380265" LOG_CI_START="-0.3886999887149051" LOG_EFFECT_SIZE="-0.10117201465055117" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.33779071050365506" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.1141025641025641" WEIGHT="44.56099252178992"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.034608436151645" CI_START="0.013829063605784151" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.9049647164245223" LOG_CI_START="-1.8592072258638475" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 21:12:40 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49865009120161063" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="1.9286123642277775" Z="0.6766152721562805">
<NAME>High risk of bias</NAME>
<DICH_DATA CI_END="8.034608436151645" CI_START="0.013829063605784151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9049647164245223" LOG_CI_START="-1.8592072258638475" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.6236882817719773" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="2.6363636363636362" WEIGHT="1.9286123642277775"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.175002507155552" CI_END="0.6810371388742598" CI_START="0.3275288086739414" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4722915230640879" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="114" I2="30.31361320064273" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.16682920413954738" LOG_CI_START="-0.4847504944573322" LOG_EFFECT_SIZE="-0.3257898492984398" METHOD="IV" MODIFIED="2015-10-19 16:54:45 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2079472286344215" P_Q="0.8579467283995331" P_Z="5.8957158799173855E-5" Q="0.032036904704264416" RANDOM="YES" SCALE="229.85" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06160086217666975" TOTALS="YES" TOTAL_1="335" TOTAL_2="333" WEIGHT="100.0" Z="4.016946273182344">
<NAME>Hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.619745347994048" CI_END="0.9769870827603057" CI_START="0.23319560730348915" DF="3" EFFECT_SIZE="0.477314462479353" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="47" I2="54.68103616842184" ID="CMP-002.03.01" LOG_CI_END="-0.010111178269974194" LOG_CI_START="-0.6322796346241002" LOG_EFFECT_SIZE="-0.3211954064470372" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08505799761831878" P_Z="0.04300424685741893" STUDIES="4" TAU2="0.2855366874034767" TOTAL_1="185" TOTAL_2="185" WEIGHT="47.362256103459416" Z="2.0236687418224895">
<NAME>Primary</NAME>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="16.018878769792643"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="12.64107065863279"/>
<DICH_DATA CI_END="1.0403925450325875" CI_START="0.17654246972905982" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.017197231583418224" LOG_CI_START="-0.7531508021726071" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.4525062483125562" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.20476190476190476" WEIGHT="13.093052557280057"/>
<DICH_DATA CI_END="0.78831130906832" CI_START="0.041935020923065836" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10330224302897578" LOG_CI_START="-1.377423135959512" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.748424919507535" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.5601398601398602" WEIGHT="5.609254117753926"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.19981990632783964" CI_END="0.638982169891307" CI_START="0.30785540574269726" DF="1" EFFECT_SIZE="0.44352465001873054" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="67" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.1945112601919181" LOG_CI_START="-0.5116532160740848" LOG_EFFECT_SIZE="-0.35308223813300144" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6548662617626243" P_Z="1.2761454271817859E-5" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="52.63774389654058" Z="4.364155908646785">
<NAME>Secondary</NAME>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="29.340532409437035"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-09-08 12:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="23.297211487103542"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.12257723434556" CI_END="0.6979079556255934" CI_START="0.33211959331533214" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4814446036605945" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="110" I2="29.800691021086376" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.15620185101553674" LOG_CI_START="-0.4787055025475802" LOG_EFFECT_SIZE="-0.3174536767815585" METHOD="IV" MODIFIED="2015-10-19 16:54:45 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2116826508695543" P_Q="0.7814786522439612" P_Z="1.1406306296211794E-4" Q="0.07694666814239294" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06222922571778698" TOTALS="YES" TOTAL_1="335" TOTAL_2="333" WEIGHT="100.0" Z="3.8585471531620983">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.368597223683908" CI_END="1.0303417898021383" CI_START="0.24040118333956736" DF="3" EFFECT_SIZE="0.4976900496419854" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="43" I2="52.89386509099011" ID="CMP-002.04.01" LOG_CI_END="0.012981314804335184" LOG_CI_START="-0.6190633989131439" LOG_EFFECT_SIZE="-0.3030410420544043" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0949913914301489" P_Z="0.06018250922409017" STUDIES="4" TAU2="0.28579088326904795" TOTAL_1="185" TOTAL_2="185" WEIGHT="46.09291406848936" Z="1.8794541442193375">
<NAME>Primary prevention</NAME>
<DICH_DATA CI_END="2.4404499277174314" CI_START="0.5186031418328453" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3874699013844254" LOG_CI_START="-0.2851648564896628" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Riggio-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="16.436543771944464"/>
<DICH_DATA CI_END="0.8848542017578296" CI_START="0.1441491944715565" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.05312828250935531" LOG_CI_START="-0.8411877801750831" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Sharma-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.2142857142857143" WEIGHT="12.978541063364752"/>
<DICH_DATA CI_END="1.3757153755427283" CI_START="0.1817236358947965" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13852859115431085" LOG_CI_START="-0.7405885824822732" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="0.2666666666666667" WEIGHT="10.911539446270432"/>
<DICH_DATA CI_END="0.78831130906832" CI_START="0.041935020923065836" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10330224302897578" LOG_CI_START="-1.377423135959512" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.748424919507535" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="0.5601398601398602" WEIGHT="5.7662897869097085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.19981990632783964" CI_END="0.638982169891307" CI_START="0.30785540574269726" DF="1" EFFECT_SIZE="0.44352465001873054" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="67" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.1945112601919181" LOG_CI_START="-0.5116532160740848" LOG_EFFECT_SIZE="-0.35308223813300144" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6548662617626243" P_Z="1.2761454271817859E-5" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="53.907085931510636" Z="4.364155908646785">
<NAME>Secondary prevention</NAME>
<DICH_DATA CI_END="0.7581648075978646" CI_START="0.2967475704372966" EFFECT_SIZE="0.4743243243243243" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.12023637847034539" LOG_CI_START="-0.5276128280599589" LOG_EFFECT_SIZE="-0.3239246032651521" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.2392949430348869" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.05726206976206977" WEIGHT="30.03365633502783"/>
<DICH_DATA CI_END="0.7156551095420906" CI_START="0.22357137937906357" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14529622365456987" LOG_CI_START="-0.6505837936895053" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-10-19 16:53:35 +0200" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.08809523809523809" WEIGHT="23.87342959648281"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.141293915489846" CI_START="1.6569107289904679" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.619495050668749" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.6171360542999255" LOG_CI_START="0.21929911013856596" LOG_EFFECT_SIZE="0.41821758221924576" METHOD="IV" MODIFIED="2015-10-22 15:20:48 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="3.7765665207223664E-5" Q="0.0" RANDOM="YES" SCALE="794.98" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="275" TOTAL_2="273" WEIGHT="0.0" Z="4.1207404736081035">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.403026998892731" CI_START="1.479680973579885" EFFECT_SIZE="2.8275" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.7326371377114768" LOG_CI_START="0.17016808948350903" LOG_EFFECT_SIZE="0.4514026135974929" MODIFIED="2015-10-22 15:20:48 +0200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.33039710319580107" STUDY_ID="STD-Agrawal-2012" TOTAL_1="80" TOTAL_2="78" VAR="0.10916224580017683" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.959540732044643" CI_START="1.01021817192785" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5976448149391891" LOG_CI_START="0.004415176388773367" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-10-22 15:20:48 +0200" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.3484660262185848" STUDY_ID="STD-Sharma-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.12142857142857144" WEIGHT="0.0"/>
<DICH_DATA CI_END="537.8211059946424" CI_START="2.024836860922391" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7306378414669568" LOG_CI_START="0.30639003828881833" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2015-10-22 15:20:48 +0200" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.4240151598070012" STUDY_ID="STD-Sharma-2012" TOTAL_1="60" TOTAL_2="60" VAR="2.0278191753601593" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.163166686205" CI_START="0.244706588596531" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0092943460117243" LOG_CI_START="-0.6113543373396868" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-10-22 15:20:48 +0200" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="1.539382009020818" STUDY_ID="STD-Wen-2013" TOTAL_1="65" TOTAL_2="65" VAR="2.3696969696969696" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-10-22 17:25:08 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Treatment trials: non-absorbable disaccharides versus placebo/no intervention</NAME>
<DICH_OUTCOME CHI2="4.574058210547606" CI_END="1.0526588650244644" CI_START="0.22828706798379164" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49021261293808105" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" I2_Q="6.764471651960716" ID="CMP-003.01" LOG_CI_END="0.022287652248324984" LOG_CI_START="-0.6415186897465255" LOG_EFFECT_SIZE="-0.3096155187491002" METHOD="IV" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7117821002893019" P_Q="0.3003700204712836" P_Z="0.0674969936738058" Q="1.0725525105269913" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="433" TOTAL_2="386" WEIGHT="100.0" Z="1.828350310662232">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6886211519811342" CI_END="0.9429150844387224" CI_START="0.13591817314641796" DF="2" EFFECT_SIZE="0.3579934297010374" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.025527416509975275" LOG_CI_START="-0.8667224713797541" LOG_EFFECT_SIZE="-0.4461249439448646" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7087088702078101" P_Z="0.037624658006040035" STUDIES="6" TAU2="0.0" TOTAL_1="89" TOTAL_2="83" WEIGHT="62.27150654340051" Z="2.078920501671863">
<NAME>Overt</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="11.117928526884688"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="44.03918638412325"/>
<DICH_DATA CI_END="2.035123629230174" CI_START="0.006605276402967772" EFFECT_SIZE="0.11594202898550725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3085907967856193" LOG_CI_START="-2.1801090042762428" LOG_EFFECT_SIZE="-0.9357591037453117" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="7.114391632392575"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.812884548039481" CI_END="2.8579027338284133" CI_START="0.23732510207190854" DF="4" EFFECT_SIZE="0.8235605976595862" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.4560474438809749" LOG_CI_START="-0.6246563236673915" LOG_EFFECT_SIZE="-0.08430443989320827" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5896106979469317" P_Z="0.7597652994533722" STUDIES="12" TAU2="0.0" TOTAL_1="344" TOTAL_2="303" WEIGHT="37.72849345659948" Z="0.3057890069215753">
<NAME>Minimal</NAME>
<DICH_DATA CI_END="16.647315309129183" CI_START="0.17653149806038052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2213442053834143" LOG_CI_START="-0.7531777933166784" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.3452380952380953" WEIGHT="11.302092080881188"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="7.864140425736296"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="5.807740972795314"/>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="6.841851434873835"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="5.912668542312844"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.0" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.0" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.0" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.574058210547606" CI_END="1.0526588650244644" CI_START="0.22828706798379164" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49021261293808105" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.022287652248324984" LOG_CI_START="-0.6415186897465255" LOG_EFFECT_SIZE="-0.3096155187491002" METHOD="IV" MODIFIED="2015-10-22 15:01:21 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7117821002893019" P_Q="0.8448785248906182" P_Z="0.0674969936738058" Q="0.03828176169974296" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="433" TOTAL_2="386" WEIGHT="100.0" Z="1.828350310662232">
<NAME>Mortality in trials with a low risk of bias</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9125875352059953" CI_END="2.6767053647292096" CI_START="0.117827208691158" DF="2" EFFECT_SIZE="0.5615948019833256" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.42760056935112356" LOG_CI_START="-0.9287544105677605" LOG_EFFECT_SIZE="-0.2505769206083186" MODIFIED="2015-10-22 15:00:37 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3843146831182114" P_Z="0.46895599659088283" STUDIES="3" TAU2="0.0" TOTAL_1="85" TOTAL_2="82" WEIGHT="23.951684488550338" Z="0.7241787688627473">
<NAME>Low risk of bias</NAME>
<DICH_DATA CI_END="16.647315309129183" CI_START="0.17653149806038052" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2213442053834143" LOG_CI_START="-0.7531777933166784" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.3452380952380953" WEIGHT="11.302092080881188"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-10-22 15:00:37 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="5.807740972795314"/>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2015-10-22 15:00:35 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="6.841851434873835"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6231889136418687" CI_END="1.1282053508288332" CI_START="0.19552035586136418" DF="4" EFFECT_SIZE="0.46966702213243444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.05238815515708019" LOG_CI_START="-0.7088080209890633" LOG_EFFECT_SIZE="-0.32820993291599154" MODIFIED="2015-10-22 15:00:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6227210027321368" P_Z="0.09099333680714389" STUDIES="15" TAU2="0.0" TOTAL_1="348" TOTAL_2="304" WEIGHT="76.04831551144966" Z="1.6901809757913084">
<NAME>High risk of bias</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:00:13 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:00:11 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="7.864140425736296"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-22 15:00:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="5.912668542312844"/>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="11.117928526884688"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="44.03918638412325"/>
<DICH_DATA CI_END="2.035123629230174" CI_START="0.006605276402967772" EFFECT_SIZE="0.11594202898550725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3085907967856193" LOG_CI_START="-2.1801090042762428" LOG_EFFECT_SIZE="-0.9357591037453117" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="7.114391632392575"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.0" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.0" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.0" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6886211519811343" CI_END="0.9429150844387224" CI_START="0.13591817314641796" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3579934297010374" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.025527416509975275" LOG_CI_START="-0.8667224713797541" LOG_EFFECT_SIZE="-0.4461249439448646" METHOD="IV" MODIFIED="2015-10-19 16:58:54 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7087088702078101" P_Q="1.0" P_Z="0.037624658006040035" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="83" WEIGHT="99.99999999999999" Z="2.078920501671863">
<NAME>Mortality in acute or chronic hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6886211519811343" CI_END="0.9429150844387224" CI_START="0.13591817314641796" DF="2" EFFECT_SIZE="0.3579934297010374" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-0.025527416509975275" LOG_CI_START="-0.8667224713797541" LOG_EFFECT_SIZE="-0.4461249439448646" MODIFIED="2015-10-19 16:58:00 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7087088702078101" P_Z="0.037624658006040035" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="48" WEIGHT="99.99999999999999" Z="2.078920501671863">
<NAME>Acute</NAME>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-10-19 16:54:57 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="17.85395784368245"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-19 16:54:57 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="70.72124769204011"/>
<DICH_DATA CI_END="2.035123629230174" CI_START="0.006605276402967772" EFFECT_SIZE="0.11594202898550725" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3085907967856193" LOG_CI_START="-2.1801090042762428" LOG_EFFECT_SIZE="-0.9357591037453117" MODIFIED="2015-10-19 16:54:57 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="11.424794464277422"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-10-19 16:58:00 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Chronic</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-19 16:56:53 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-19 16:58:00 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-19 16:55:41 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.95308780136385" CI_END="0.7437956376126218" CI_START="0.5303088996131147" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6280457356907891" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="206" I2="24.823665643496504" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.12854637312187292" LOG_CI_START="-0.2754710845155406" LOG_EFFECT_SIZE="-0.20200872881870668" METHOD="IV" MODIFIED="2015-10-19 16:58:29 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1737398301969162" P_Q="0.9712719319339947" P_Z="7.063007937573074E-8" Q="0.00129694199207265" RANDOM="YES" SCALE="229.85" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02496857714139884" TOTALS="YES" TOTAL_1="397" TOTAL_2="350" WEIGHT="100.00000000000001" Z="5.389560806916079">
<NAME>Hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.01481045675814" CI_END="0.994667951791835" CI_START="0.38641331241065324" DF="4" EFFECT_SIZE="0.6199620456129575" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" I2="0.3688955410886193" ID="CMP-003.04.01" LOG_CI_END="-0.002321874804009193" LOG_CI_START="-0.4129479200233755" LOG_EFFECT_SIZE="-0.2076348974136924" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4040053991279148" P_Z="0.04746479111577367" STUDIES="5" TAU2="0.0011815718543956195" TOTAL_1="73" TOTAL_2="67" WEIGHT="11.540396025145109" Z="1.982129120168691">
<NAME>Overt</NAME>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1189" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="1.9292474848638352"/>
<DICH_DATA CI_END="1.2997758213259876" CI_START="0.3072481995062734" EFFECT_SIZE="0.6319444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.1138684538786518" LOG_CI_START="-0.512510653426964" LOG_EFFECT_SIZE="-0.19932109977415607" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.36793818825790614" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.13537851037851037" WEIGHT="4.645193617412516"/>
<DICH_DATA CI_END="1.9890720084146771" CI_START="0.23639369497106014" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2986505057443792" LOG_CI_START="-0.6263641110217183" LOG_EFFECT_SIZE="-0.1638568026386696" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1191" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.29523809523809524" WEIGHT="2.3261328753181463"/>
<DICH_DATA CI_END="1.2902756366963168" CI_START="0.11912155361105008" EFFECT_SIZE="0.39204545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1106824968953578" LOG_CI_START="-0.9240096510491468" LOG_EFFECT_SIZE="-0.40666357707689454" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1192" O_E="0.0" SE="0.6077832895113378" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="0.36940052700922266" WEIGHT="1.8886957920357017"/>
<DICH_DATA CI_END="1.1448362319904497" CI_START="0.024263538313669918" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.058743365601929894" LOG_CI_START="-1.615045866369217" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="0.7511262555149111"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.896929854788915" CI_END="0.7576036848418325" CI_START="0.5169236850767177" DF="10" EFFECT_SIZE="0.6257981212788516" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="176" I2="37.09477181225957" ID="CMP-003.04.02" LOG_CI_END="-0.1205579216729684" LOG_CI_START="-0.28657356831119685" LOG_EFFECT_SIZE="-0.20356574499208266" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10262125154641166" P_Z="1.5355454442299386E-6" STUDIES="11" TAU2="0.03305964401920614" TOTAL_1="324" TOTAL_2="283" WEIGHT="88.4596039748549" Z="4.806553318916787">
<NAME>Minimal</NAME>
<DICH_DATA CI_END="0.8120437020860286" CI_START="0.25011023904588797" EFFECT_SIZE="0.45066666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.09042059752719295" LOG_CI_START="-0.6018685287008977" LOG_EFFECT_SIZE="-0.34614456311404534" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.30042704647952434" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.09025641025641029" WEIGHT="6.4642512387233335"/>
<DICH_DATA CI_END="1.5337246758521959" CI_START="0.6520075054829263" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.18574740492596672" LOG_CI_START="-0.18574740492596675" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.21821789023599236" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.047619047619047616" WEIGHT="10.26129825815762"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="0.7772532428211283"/>
<DICH_DATA CI_END="0.8929071513462805" CI_START="0.4333189839852257" EFFECT_SIZE="0.6220238095238095" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="-0.04919369873117468" LOG_CI_START="-0.36319228382640545" LOG_EFFECT_SIZE="-0.20619299127879004" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.18444432320300247" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.03401970836181363" WEIGHT="12.62696925608398"/>
<DICH_DATA CI_END="0.7972004200626888" CI_START="0.42684094139215295" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="-0.09843248113203706" LOG_CI_START="-0.36973393093469886" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.15936381457791912" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.02539682539682539" WEIGHT="14.788788135920845"/>
<DICH_DATA CI_END="0.6219124554473241" CI_START="0.13552904447273176" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.20627074519986469" LOG_CI_START="-0.8679676235900309" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.38868402181875744" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="0.15107526881720432" WEIGHT="4.231009970625833"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.28687570694968945"/>
<DICH_DATA CI_END="1.7028707260375606" CI_START="0.47395013744735887" EFFECT_SIZE="0.8983739837398373" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2311816796128989" LOG_CI_START="-0.3242673464494357" LOG_EFFECT_SIZE="-0.04654283341826845" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1193" O_E="0.0" SE="0.326273507426038" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.10645440164808886" WEIGHT="5.667526899624246"/>
<DICH_DATA CI_END="0.7466235429556289" CI_START="0.3213380492427486" EFFECT_SIZE="0.4898148148148148" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.12689831977468602" LOG_CI_START="-0.4930378471288419" LOG_EFFECT_SIZE="-0.30996808345176396" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="2281" O_E="0.0" SE="0.2150721707877219" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.04625603864734301" WEIGHT="10.457666345683569"/>
<DICH_DATA CI_END="1.0346357938459914" CI_START="0.18499867406335974" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.014787499011108932" LOG_CI_START="-0.7328313842944448" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.43915503282683993" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.19285714285714284" WEIGHT="3.4194459108095905"/>
<DICH_DATA CI_END="0.9507834496644479" CI_START="0.6052959282957625" EFFECT_SIZE="0.7586206896551724" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="-0.021918386664053005" LOG_CI_START="-0.21803224748944672" LOG_EFFECT_SIZE="-0.11997531707674987" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="0.11519825262810389" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.013270637408568445" WEIGHT="19.478519009455056"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.0148104567581395" CI_END="0.9946679517918349" CI_START="0.38641331241065335" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6199620456129576" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" I2="0.3688955410885973" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.0023218748040092414" LOG_CI_START="-0.4129479200233754" LOG_EFFECT_SIZE="-0.20763489741369232" METHOD="IV" MODIFIED="2015-10-19 17:00:43 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4040053991279148" P_Q="0.9460003598041864" P_Z="0.04746479111577364" Q="0.004587388266419952" RANDOM="YES" SCALE="229.85" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0011815718543955486" TOTALS="YES" TOTAL_1="73" TOTAL_2="67" WEIGHT="100.0" Z="1.9821291201686912">
<NAME>Acute or chronic hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5630743761795544" CI_END="0.9995049893921951" CI_START="0.3436537698608211" DF="2" EFFECT_SIZE="0.5860747884010434" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-2.1503360180219006E-4" LOG_CI_START="-0.46387888754490536" LOG_EFFECT_SIZE="-0.23204696057335378" MODIFIED="2015-10-19 17:00:43 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7546228739254263" P_Z="0.04978787819208162" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="48" WEIGHT="77.9301685445213" Z="1.9617819313625815">
<NAME>Acute</NAME>
<DICH_DATA CI_END="1.2997758213259876" CI_START="0.3072481995062734" EFFECT_SIZE="0.6319444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.1138684538786518" LOG_CI_START="-0.512510653426964" LOG_EFFECT_SIZE="-0.19932109977415607" MODIFIED="2015-10-19 16:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.36793818825790614" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="0.13537851037851037" WEIGHT="42.60341563922982"/>
<DICH_DATA CI_END="1.9890720084146771" CI_START="0.23639369497106014" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2986505057443792" LOG_CI_START="-0.6263641110217183" LOG_EFFECT_SIZE="-0.1638568026386696" MODIFIED="2015-10-19 16:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="1191" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.29523809523809524" WEIGHT="19.62732770116953"/>
<DICH_DATA CI_END="1.2902756366963168" CI_START="0.11912155361105008" EFFECT_SIZE="0.39204545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1106824968953578" LOG_CI_START="-0.9240096510491468" LOG_EFFECT_SIZE="-0.40666357707689454" MODIFIED="2015-10-19 16:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="1192" O_E="0.0" SE="0.6077832895113378" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="0.36940052700922266" WEIGHT="15.699425204121937"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2566271236296496" CI_END="4.101284304864856" CI_START="0.07250013167881755" DF="1" EFFECT_SIZE="0.5452922630617179" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="69.29338355183084" ID="CMP-003.05.02" LOG_CI_END="0.6129198760307882" LOG_CI_START="-1.1396612046382213" LOG_EFFECT_SIZE="-0.2633706643037166" MODIFIED="2015-10-19 17:00:43 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07113536160792" P_Z="0.5558139005468472" STUDIES="2" TAU2="1.4981496737430169" TOTAL_1="19" TOTAL_2="19" WEIGHT="22.069831455478706" Z="0.5890706253916954">
<NAME>Chronic</NAME>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-10-19 17:00:43 +0200" MODIFIED_BY="[Empty name]" ORDER="1189" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="16.05863495633946"/>
<DICH_DATA CI_END="1.1448362319904497" CI_START="0.024263538313669918" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.058743365601929894" LOG_CI_START="-1.615045866369217" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2015-10-19 17:00:32 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="6.011196499139245"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1083999906188287" CI_END="0.6949317346822854" CI_START="0.2585816386856658" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4239063419304053" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.15805785541983175" LOG_CI_START="-0.5874023166582735" LOG_EFFECT_SIZE="-0.37273008603905267" METHOD="IV" MODIFIED="2015-10-19 17:02:19 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9787566333243144" P_Q="0.8916606404430633" P_Z="6.66412542157481E-4" Q="0.018551315697062233" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="433" TOTAL_2="386" WEIGHT="100.0" Z="3.4030370042917393">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03666622763513727" CI_END="1.0181491866221493" CI_START="0.15816238954804035" DF="2" EFFECT_SIZE="0.40128905825172057" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.007811418648797399" LOG_CI_START="-0.8008967822395995" LOG_EFFECT_SIZE="-0.3965426817954011" MODIFIED="2015-10-19 17:02:19 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9818339200723306" P_Z="0.05459306464617401" STUDIES="6" TAU2="0.0" TOTAL_1="89" TOTAL_2="83" WEIGHT="28.185648715785728" Z="1.9221008858278399">
<NAME>Overt</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="4.651069321028946"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="18.423333826887426"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="5.111245567869358"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0531824472866287" CI_END="0.7761332943491221" CI_START="0.24171044463104385" DF="7" EFFECT_SIZE="0.4331276066820068" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="-0.11006368592089122" LOG_CI_START="-0.6167045827424441" LOG_EFFECT_SIZE="-0.36338413433166766" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8800392278630497" P_Z="0.004930541820496923" STUDIES="12" TAU2="0.0" TOTAL_1="344" TOTAL_2="303" WEIGHT="71.81435128421427" Z="2.8115370089998444">
<NAME>Minimal</NAME>
<DICH_DATA CI_END="2.8717261857642553" CI_START="0.11370534344937835" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4581430282998273" LOG_CI_START="-0.9442191256724162" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1194" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Dhiman-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.6785714285714285" WEIGHT="9.37327510490764"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Jain-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="3.289881040515612"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="0.0" STUDY_ID="STD-Li-1999" TOTAL_1="48" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1398561589712335" CI_START="0.029207570676174695" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33038458107600793" LOG_CI_START="-1.5345045637319326" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="1.0954451150103324" STUDY_ID="STD-Mittal-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.2000000000000002" WEIGHT="5.300363898608485"/>
<DICH_DATA CI_END="1.5609628568553289" CI_START="0.02399863519060957" EFFECT_SIZE="0.1935483870967742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1933925691388498" LOG_CI_START="-1.6198134560401078" LOG_EFFECT_SIZE="-0.713210443450629" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.0650861947046997" STUDY_ID="STD-Prasad-2007" TOTAL_1="31" TOTAL_2="30" VAR="1.1344086021505375" WEIGHT="5.606830436821868"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="2.4735031526839597"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.0" SE="0.0" STUDY_ID="STD-Watanabe-1997" TOTAL_1="41" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.781113877888278" CI_START="0.009715684927116754" EFFECT_SIZE="0.19166666666666668" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5776197574455104" LOG_CI_START="-2.0125265775055743" LOG_EFFECT_SIZE="-0.7174534100300319" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Xing-2003" TOTAL_1="23" TOTAL_2="22" VAR="2.314855072463768" WEIGHT="2.747660859632385"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Yao-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0346357938459914" CI_START="0.18499867406335974" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.014787499011108932" LOG_CI_START="-0.7328313842944448" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.43915503282683993" STUDY_ID="STD-Zeng-2003" TOTAL_1="40" TOTAL_2="20" VAR="0.19285714285714284" WEIGHT="32.98004203578614"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-09-08 12:18:52 +0200" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="10.042794755258184"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03666622763513727" CI_END="1.0181491866221493" CI_START="0.15816238954804035" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40128905825172057" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.007811418648797399" LOG_CI_START="-0.8008967822395995" LOG_EFFECT_SIZE="-0.3965426817954011" METHOD="IV" MODIFIED="2015-10-19 17:02:09 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9818339200723306" P_Q="1.0" P_Z="0.05459306464617401" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="83" WEIGHT="100.0" Z="1.9221008858278399">
<NAME>Serious adverse events in acute or chronic hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03666622763513727" CI_END="1.0181491866221493" CI_START="0.15816238954804035" DF="2" EFFECT_SIZE="0.40128905825172057" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.007811418648797399" LOG_CI_START="-0.8008967822395995" LOG_EFFECT_SIZE="-0.3965426817954011" MODIFIED="2015-10-19 17:02:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9818339200723306" P_Z="0.05459306464617401" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="48" WEIGHT="100.0" Z="1.9221008858278399">
<NAME>Acute</NAME>
<DICH_DATA CI_END="3.5730989028040665" CI_START="0.036495277101220476" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5530450375703605" LOG_CI_START="-1.4377633344912615" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2015-10-19 17:00:58 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="1.1694106924093723" STUDY_ID="STD-Raza-2004" TOTAL_1="18" TOTAL_2="13" VAR="1.3675213675213675" WEIGHT="16.501551438211376"/>
<DICH_DATA CI_END="1.355699415217075" CI_START="0.13548244347243096" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1321634087173448" LOG_CI_START="-0.8681169793065336" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2015-10-19 17:00:58 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Simmons-1970" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="65.36423558195133"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-10-19 17:00:58 +0200" MODIFIED_BY="[Empty name]" ORDER="1197" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="18.134212979837294"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-10-19 17:02:09 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Chronic</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-19 17:02:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.0" STUDY_ID="STD-Corazza-1982" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-19 17:02:07 +0200" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Germain-1973" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-10-19 17:02:04 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.0" STUDY_ID="STD-Uribe-1987b" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.435723594796679" CI_END="7.275191029099119" CI_START="0.6172970717439562" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.119187136295609" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="19" I2="61.670123171962636" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.8618444013410264" LOG_CI_START="-0.20950578317942817" LOG_EFFECT_SIZE="0.32616930908079905" METHOD="IV" MODIFIED="2015-10-22 17:25:02 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.033694030682015264" P_Q="1.0" P_Z="0.2327087985780899" Q="0.0" RANDOM="YES" SCALE="794.98" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.1090122795949051" TOTALS="YES" TOTAL_1="95" TOTAL_2="96" WEIGHT="100.0" Z="1.1934101620504722">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Disaccharide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disaccharides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="114.70419217554587" CI_START="0.42718578171065713" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0595792906600843" LOG_CI_START="-0.3693832106315704" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2015-10-22 15:21:00 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="1.4267845968170128" STUDY_ID="STD-Horsmans-1997" TOTAL_1="7" TOTAL_2="7" VAR="2.0357142857142856" WEIGHT="12.593754183987132"/>
<DICH_DATA CI_END="31.981259724640676" CI_START="0.5002929883863344" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5048955663734804" LOG_CI_START="-0.3007755837175557" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-10-22 15:21:00 +0200" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.0606601717798212" STUDY_ID="STD-McClain-1984" TOTAL_1="16" TOTAL_2="16" VAR="1.125" WEIGHT="17.727706199779487"/>
<DICH_DATA CI_END="1.4288482068522237" CI_START="0.6034545123996926" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.1549860941317718" LOG_CI_START="-0.21935546087457428" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2015-10-22 15:21:00 +0200" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.21989008243131009" STUDY_ID="STD-Quero-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.048351648351648346" WEIGHT="34.2190666073593"/>
<DICH_DATA CI_END="3.1025745046258315" CI_START="0.03914223153785429" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4917222193599262" LOG_CI_START="-1.4073544184084776" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2015-10-22 15:21:00 +0200" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Uribe-1987a" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="16.828290059534783"/>
<DICH_DATA CI_END="86.58582984355299" CI_START="1.6630896794566206" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9374468236075126" LOG_CI_START="0.22091566848773705" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2015-10-22 15:21:00 +0200" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="1.0082988974836113" STUDY_ID="STD-Ziada-2013" TOTAL_1="30" TOTAL_2="30" VAR="1.0166666666666664" WEIGHT="18.631182949339294"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-04-07 08:05:49 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Lactulose versus lactitol</NAME>
<DICH_OUTCOME CHI2="0.41870841141903264" CI_END="2.854969664852841" CI_START="0.5940413671959742" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3022941614751307" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.4556014980610227" LOG_CI_START="-0.22618331104675846" LOG_EFFECT_SIZE="0.11470909350713208" METHOD="IV" MODIFIED="2015-10-22 15:35:35 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9363512464896521" P_Q="1.0" P_Z="0.5095612838616123" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="113" WEIGHT="100.00000000000003" Z="0.6595209777919071">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactulose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactitol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.41870841141903264" CI_END="2.854969664852841" CI_START="0.5940413671959742" DF="3" EFFECT_SIZE="1.3022941614751307" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.4556014980610227" LOG_CI_START="-0.22618331104675846" LOG_EFFECT_SIZE="0.11470909350713208" MODIFIED="2015-09-08 22:10:31 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9363512464896521" P_Z="0.5095612838616123" STUDIES="6" TAU2="0.0" TOTAL_1="87" TOTAL_2="87" WEIGHT="100.00000000000003" Z="0.6595209777919071">
<NAME>Overt hepatic encephalopathy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 22:10:29 +0200" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.0" STUDY_ID="STD-Grandi-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-09-08 21:57:23 +0200" MODIFIED_BY="[Empty name]" ORDER="1276" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Heredia-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="33.18356926395128"/>
<DICH_DATA CI_END="13.869026920848867" CI_START="0.1744717275573397" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1420459911575829" LOG_CI_START="-0.7582749386797566" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2015-09-08 21:57:23 +0200" MODIFIED_BY="[Empty name]" ORDER="852" O_E="0.0" SE="1.116257920926766" STUDY_ID="STD-Jankovic-1996" TOTAL_1="9" TOTAL_2="7" VAR="1.246031746031746" WEIGHT="12.871843109392563"/>
<DICH_DATA CI_END="3.3955211694053795" CI_START="0.3456350446834742" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5309064424238162" LOG_CI_START="-0.4613822299053924" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2015-09-08 21:57:23 +0200" MODIFIED_BY="[Empty name]" ORDER="1277" O_E="0.0" SE="0.5828752780343234" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" VAR="0.33974358974358976" WEIGHT="47.208323066074065"/>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.14577691612966426" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-09-08 22:10:31 +0200" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Morgan-1987b" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="6.736264560582107"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:57:23 +0200" MODIFIED_BY="[Empty name]" ORDER="1274" O_E="0.0" SE="0.0" STUDY_ID="STD-Pai-1995" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-09-08 22:11:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Minimal hepatic encephalopathy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 22:10:06 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-09-08 22:11:36 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Prevention of hepatic encephalopathy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 22:11:36 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.614057417969391" CI_END="1.1909413242918148" CI_START="0.8408090066723024" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0006768668670207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.07589036503943787" LOG_CI_START="-0.0753026448305146" LOG_EFFECT_SIZE="2.938601044616291E-4" METHOD="IV" MODIFIED="2016-04-07 08:05:24 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8995442344891539" P_Q="0.5242836654732567" P_Z="0.9939211299066604" Q="1.2914449045701868" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="98" WEIGHT="100.0" Z="0.007618807532615209">
<NAME>Hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactulose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactitol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3226125133992039" CI_END="1.9629956153297072" CI_START="0.5958504822961349" DF="3" EFFECT_SIZE="1.081504454054353" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.29291932953365885" LOG_CI_START="-0.22486270479019863" LOG_EFFECT_SIZE="0.034028312371730124" MODIFIED="2016-04-07 08:05:12 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9557210647204573" P_Z="0.7967038814191167" STUDIES="5" TAU2="0.0" TOTAL_1="80" TOTAL_2="82" WEIGHT="8.526473972381975" Z="0.25761522139470167">
<NAME>Overt hepatic encephalopathy</NAME>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.4066676111076039" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Grandi-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="2.2535675753383226"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="1272" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Heredia-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.6318937614518896"/>
<DICH_DATA CI_END="2.4890605496092" CI_START="0.30176490131147704" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.39603546151068564" LOG_CI_START="-0.5203312750083746" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="1273" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" VAR="0.28974358974358977" WEIGHT="2.722229858705142"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="1260" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1987b" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.673237050689143" CI_START="0.2975509588760451" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.565048956247348" LOG_CI_START="-0.5264386458565746" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="1274" O_E="0.0" SE="0.6411452204266123" STUDY_ID="STD-Pai-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.4110671936758893" WEIGHT="1.9187827768866206"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2000599982148181" CI_START="0.8332916699894815" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.07920295958282342" LOG_CI_START="-0.07920295958282345" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-07 08:05:18 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="91.10046923305188" Z="0.0">
<NAME>Minimal hepatic encephalopathy</NAME>
<DICH_DATA CI_END="1.2000599982148181" CI_START="0.8332916699894815" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.07920295958282342" LOG_CI_START="-0.07920295958282345" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.093048421039847" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.008658008658008642" WEIGHT="91.10046923305188"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3319367975283288E-32" CI_END="3.457217603031377" CI_START="0.011569997782299557" DF="0" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="100.0" ID="CMP-004.02.03" LOG_CI_END="0.5387267156203925" LOG_CI_START="-1.93666672429243" LOG_EFFECT_SIZE="-0.6989700043360186" MODIFIED="2016-04-07 08:05:24 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.26835481412344053" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.3730567945661413" Z="1.1068592270492958">
<NAME>Prevention hepatic encephalopathy</NAME>
<DICH_DATA CI_END="3.4572176030313764" CI_START="0.011569997782299557" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5387267156203925" LOG_CI_START="-1.93666672429243" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2015-09-08 21:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="1275" O_E="0.0" SE="1.4540583599999397" STUDY_ID="STD-Riggio-1989" TOTAL_1="6" TOTAL_2="6" VAR="2.1142857142857143" WEIGHT="0.3730567945661413"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.580153858971706" CI_END="2.8810061136085885" CI_START="0.8429162844130538" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5583475121596735" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.4595441798714082" LOG_CI_START="-0.0742155558887073" LOG_EFFECT_SIZE="0.19266431199135045" METHOD="IV" MODIFIED="2015-10-26 16:36:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9036388983955632" P_Q="1.0" P_Z="0.1570903601676472" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="123" WEIGHT="100.00000000000001" Z="1.4149254329627619">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactulose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactitol</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.0" STUDY_ID="STD-Grandi-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="1276" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Heredia-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="20.338554135508836"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="746" O_E="0.0" SE="0.0" STUDY_ID="STD-Heredia-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.869026920848867" CI_START="0.1744717275573397" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1420459911575829" LOG_CI_START="-0.7582749386797566" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="852" O_E="0.0" SE="1.116257920926766" STUDY_ID="STD-Jankovic-1996" TOTAL_1="9" TOTAL_2="7" VAR="1.246031746031746" WEIGHT="7.889286285684636"/>
<DICH_DATA CI_END="33.527260326363646" CI_START="0.5600749239570927" EFFECT_SIZE="4.333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5253980665885478" LOG_CI_START="-0.25175387141419936" LOG_EFFECT_SIZE="0.6368220975871743" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="1277" O_E="0.0" SE="1.0439078454267838" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" VAR="1.0897435897435899" WEIGHT="9.020746951866856"/>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.14577691612966426" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Morgan-1987b" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="4.128726489508293"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.640292411447435" CI_START="0.30286028576523877" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5611362703461713" LOG_CI_START="-0.5187576722062951" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2015-09-08 22:02:26 +0200" MODIFIED_BY="[Empty name]" ORDER="1274" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Pai-1995" TOTAL_1="20" TOTAL_2="21" VAR="0.4023809523809524" WEIGHT="24.43033425744552"/>
<DICH_DATA CI_END="4.576420933182969" CI_START="0.5593891028331353" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6605259634578462" LOG_CI_START="-0.25228599814599656" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2015-06-03 13:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="1275" O_E="0.0" SE="0.5361902647381804" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="0.2875" WEIGHT="34.192351879985864"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.673084285118964" CI_END="1.8623607796087023" CI_START="0.9781790469350006" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3497119294304118" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="55" I2="3.1056229757806695" I2_Q="18.639410630451156" ID="CMP-004.04" LOG_CI_END="0.2700638170404169" LOG_CI_START="-0.009581644211494355" LOG_EFFECT_SIZE="0.13024108641446128" METHOD="IV" MODIFIED="2016-04-07 08:05:49 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4185538611300921" P_Q="0.287590602923227" P_Z="0.06790249196106071" Q="7.3745778472023265" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013351163261826364" TOTALS="SUB" TOTAL_1="302" TOTAL_2="307" WEIGHT="700.0" Z="1.8256533650639997">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactulose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactitol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.57537680788148" CI_END="2.7397073827265874" CI_START="0.8779190144285893" DF="5" EFFECT_SIZE="1.550884007676285" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="21" I2="33.99668258352559" ID="CMP-004.04.01" LOG_CI_END="0.4377041800271483" LOG_CI_START="-0.05654554469636642" LOG_EFFECT_SIZE="0.19057931766539093" MODIFIED="2016-04-07 08:05:49 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18124245705860964" P_Z="0.13066175828590856" STUDIES="6" TAU2="0.1598689224013728" TOTAL_1="84" TOTAL_2="85" WEIGHT="100.0" Z="1.511497448102122">
<NAME>Overall</NAME>
<DICH_DATA CI_END="2.32713583140198" CI_START="0.42971277675594527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3668217331392064" LOG_CI_START="-0.3668217331392064" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 13:54:17 +0200" MODIFIED_BY="[Empty name]" ORDER="1336" O_E="0.0" SE="0.4309458036856673" STUDY_ID="STD-Grandi-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.18571428571428572" WEIGHT="24.39020464613566"/>
<DICH_DATA CI_END="13.869026920848867" CI_START="0.1744717275573397" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1420459911575829" LOG_CI_START="-0.7582749386797566" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2015-06-03 13:53:37 +0200" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="1.116257920926766" STUDY_ID="STD-Jankovic-1996" TOTAL_1="9" TOTAL_2="7" VAR="1.246031746031746" WEIGHT="5.995334775395604"/>
<DICH_DATA CI_END="1.9484690120305326" CI_START="0.267699889015957" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2896935032715574" LOG_CI_START="-0.572351808864496" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-06-03 13:53:37 +0200" MODIFIED_BY="[Empty name]" ORDER="1277" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" VAR="0.2564102564102564" WEIGHT="20.248058507925386"/>
<DICH_DATA CI_END="3.495530603915682" CI_START="1.0426537519342138" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.5435131087976035" LOG_CI_START="0.01814011035378498" LOG_EFFECT_SIZE="0.2808266095756942" MODIFIED="2015-06-03 13:54:46 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.3086066999241838" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.09523809523809523" WEIGHT="33.04042846881277"/>
<DICH_DATA CI_END="226.62920087324275" CI_START="0.8262731237060139" EFFECT_SIZE="13.68421052631579" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3553158674032204" LOG_CI_START="-0.0828763733672422" LOG_EFFECT_SIZE="1.136219747017989" MODIFIED="2015-06-03 13:55:12 +0200" MODIFIED_BY="[Empty name]" ORDER="1337" O_E="0.0" SE="1.4322061914748119" STUDY_ID="STD-Pai-1995" TOTAL_1="18" TOTAL_2="19" VAR="2.0512145748987853" WEIGHT="3.812088136201566"/>
<DICH_DATA CI_END="15.211487000674808" CI_START="0.9162666199010965" EFFECT_SIZE="3.7333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1821716706356207" LOG_CI_START="-0.037978134734582544" LOG_EFFECT_SIZE="0.5720967679505192" MODIFIED="2015-06-03 13:55:49 +0200" MODIFIED_BY="[Empty name]" ORDER="1338" O_E="0.0" SE="0.7167220355134033" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="0.5136904761904761" WEIGHT="12.513885465529013"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4063907719814151" CI_END="1.6439824400103018" CI_START="0.3857395705284625" DF="2" EFFECT_SIZE="0.7963347790759284" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.2158971743674396" LOG_CI_START="-0.4137058073857998" LOG_EFFECT_SIZE="-0.09890431650918009" MODIFIED="2015-06-03 13:53:56 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8161188498305862" P_Z="0.5380388177911943" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="0.615781385703534">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="13.869026920848867" CI_START="0.1744717275573397" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1420459911575829" LOG_CI_START="-0.7582749386797566" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="1.116257920926766" STUDY_ID="STD-Jankovic-1996" TOTAL_1="9" TOTAL_2="7" VAR="1.246031746031746" WEIGHT="10.976898514823358"/>
<DICH_DATA CI_END="1.9484690120305326" CI_START="0.267699889015957" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2896935032715574" LOG_CI_START="-0.572351808864496" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1277" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" VAR="0.2564102564102564" WEIGHT="53.34249968751065"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="35.680601797665986"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.186493311976205" CI_END="4.5350058623491325" CI_START="1.0635524535641914" DF="3" EFFECT_SIZE="2.196182281102689" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" I2="28.340981904402696" ID="CMP-004.04.03" LOG_CI_END="0.6565778528038834" LOG_CI_START="0.02675891382663892" LOG_EFFECT_SIZE="0.34166838331526106" MODIFIED="2015-06-03 13:53:53 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24201777797350033" P_Z="0.03346092579332315" STUDIES="4" TAU2="0.1601042747572204" TOTAL_1="63" TOTAL_2="65" WEIGHT="100.0" Z="2.1265086980121213">
<NAME>Bloating and flatulence</NAME>
<DICH_DATA CI_END="3.6779408112447576" CI_START="0.5329068901836568" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5656047358980815" LOG_CI_START="-0.2733486645416055" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1258" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Grandi-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.24285714285714288" WEIGHT="33.96590340923852"/>
<DICH_DATA CI_END="3.495530603915682" CI_START="1.0426537519342138" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.5435131087976035" LOG_CI_START="0.01814011035378498" LOG_EFFECT_SIZE="0.2808266095756942" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.3086066999241838" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.09523809523809523" WEIGHT="53.60234021713819"/>
<DICH_DATA CI_END="226.62920087324275" CI_START="0.8262731237060139" EFFECT_SIZE="13.68421052631579" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3553158674032204" LOG_CI_START="-0.0828763733672422" LOG_EFFECT_SIZE="1.136219747017989" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1376" O_E="0.0" SE="1.4322061914748119" STUDY_ID="STD-Pai-1995" TOTAL_1="18" TOTAL_2="19" VAR="2.0512145748987853" WEIGHT="6.189495734850014"/>
<DICH_DATA CI_END="225.8401304283226" CI_START="0.8447796938841731" EFFECT_SIZE="13.8125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3538011159548584" LOG_CI_START="-0.07325653389648644" LOG_EFFECT_SIZE="1.1402722910291858" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="1.4256656776518082" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="2.0325226244343892" WEIGHT="6.242260638773277"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.225486135307677" CI_END="13.433676809344298" CI_START="0.7634513467951397" DF="3" EFFECT_SIZE="3.2024925686884176" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="1.1281948957263506" LOG_CI_START="-0.11721863443161194" LOG_EFFECT_SIZE="0.5054881306473693" MODIFIED="2015-06-03 13:53:51 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7468984724343466" P_Z="0.11160521458113923" STUDIES="4" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="1.5910193790100557">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="72.01150960625446" CI_START="0.22218670442384858" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8574019153063224" LOG_CI_START="-0.6532819326503977" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="852" O_E="0.0" SE="1.4747881203752624" STUDY_ID="STD-Jankovic-1996" TOTAL_1="9" TOTAL_2="7" VAR="2.175" WEIGHT="24.606117974108702"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="21.537855092581125"/>
<DICH_DATA CI_END="164.34912504657598" CI_START="0.546097781143286" EFFECT_SIZE="9.473684210526315" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2157673963491584" LOG_CI_START="-0.26272958804820445" LOG_EFFECT_SIZE="0.976518904150477" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1376" O_E="0.0" SE="1.4558813973929519" STUDY_ID="STD-Pai-1995" TOTAL_1="18" TOTAL_2="19" VAR="2.119590643274854" WEIGHT="25.249359711740595"/>
<DICH_DATA CI_END="15.570001590060363" CI_START="0.07307499432139536" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19228865691972" LOG_CI_START="-1.1362312097192329" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="1.3677840960229555" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="1.8708333333333333" WEIGHT="28.606667221569577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.45938986445702" CI_START="0.14405130711161593" DF="0" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" MODIFIED="2016-03-23 12:47:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.4599122083836973" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.7389914278442653">
<NAME>Hyponatraemia</NAME>
<DICH_DATA CI_END="72.45938986445702" CI_START="0.14405130711161593" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1277" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4022935101097895" CI_END="1.9058729470452145" CI_START="0.47335241346235574" DF="2" EFFECT_SIZE="0.949815539584642" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-004.04.06" LOG_CI_END="0.2800939454962551" LOG_CI_START="-0.3248154042216621" LOG_EFFECT_SIZE="-0.022360729362703505" MODIFIED="2015-06-03 13:53:46 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8177924850242819" P_Z="0.8847884120331642" STUDIES="3" TAU2="0.0" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0" Z="0.14490179144820056">
<NAME>Abdominal pain</NAME>
<DICH_DATA CI_END="2.32713583140198" CI_START="0.42971277675594527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3668217331392064" LOG_CI_START="-0.3668217331392064" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1258" O_E="0.0" SE="0.4309458036856673" STUDY_ID="STD-Grandi-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.18571428571428572" WEIGHT="67.98459052465563"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="27.055092147567038"/>
<DICH_DATA CI_END="8.076548849507702" CI_START="0.015530646828864726" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973133" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="4.960317327777337"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.076548849507702" CI_START="0.015530646828864726" DF="0" EFFECT_SIZE="0.35416666666666674" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.04.07" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973132" MODIFIED="2015-06-03 13:53:43 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5152999312716893" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.6506074386868684">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="8.076548849507702" CI_START="0.015530646828864726" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973133" MODIFIED="2015-06-03 13:08:04 +0200" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Riggio-1989" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.2402945487798898" CI_END="7.6803949008405406" CI_START="-16.12158765321058" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.220596376185019" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2016-03-23 12:48:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7433571955129277" P_Q="1.0" P_Z="0.4870011774401526" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="0.695086375415813">
<NAME>Number Connection Test: end of treatment</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactulose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactitol</GRAPH_LABEL_2>
<CONT_DATA CI_END="123.21890365313348" CI_START="-63.21890365313348" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="226.0" MEAN_2="196.0" MODIFIED="2015-06-03 13:08:08 +0200" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="161.0" SD_2="139.0" SE="47.561539083591484" STUDY_ID="STD-Heredia-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.6298899878486226"/>
<CONT_DATA CI_END="30.364708906314974" CI_START="-90.36470890631497" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="180.0" MODIFIED="2015-06-03 13:08:08 +0200" MODIFIED_BY="[Empty name]" ORDER="435" SD_1="60.0" SD_2="40.0" SE="30.798886807341407" STUDY_ID="STD-Jankovic-1996" TOTAL_1="5" TOTAL_2="7" WEIGHT="3.886870329907618"/>
<CONT_DATA CI_END="13.27798027587253" CI_START="-22.47798027587252" EFFECT_SIZE="-4.599999999999994" ESTIMABLE="YES" MEAN_1="32.7" MEAN_2="37.3" MODIFIED="2015-06-03 13:08:08 +0200" MODIFIED_BY="[Empty name]" ORDER="1844" SD_1="13.1" SD_2="18.1" SE="9.121586119383698" STUDY_ID="STD-Morgan-1987b" TOTAL_1="6" TOTAL_2="6" WEIGHT="44.312817693750674"/>
<CONT_DATA CI_END="13.801933438565655" CI_START="-19.801933438565655" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="33.9" MEAN_2="36.9" MODIFIED="2015-06-03 13:08:08 +0200" MODIFIED_BY="[Empty name]" ORDER="1374" SD_1="18.3" SD_2="20.0" SE="8.572572542708519" STUDY_ID="STD-Morgan-1989" TOTAL_1="10" TOTAL_2="10" WEIGHT="50.17042198849309"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9448458248241313" CI_START="-0.5448458248241309" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2016-03-23 12:47:43 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5986980288957624" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.526273738596261">
<NAME>Number Connection Test: change from baseline</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactulose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactitol</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9448458248241313" CI_START="-0.5448458248241309" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.4" MODIFIED="2015-06-03 13:08:42 +0200" MODIFIED_BY="[Empty name]" ORDER="1368" SD_1="0.9" SD_2="1.0" SE="0.38003036315941513" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03750965234886939" CI_END="21.29082364291738" CI_START="-8.357155300541804" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="6.466834171187788" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2016-03-23 12:48:10 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9814199563108688" P_Q="1.0" P_Z="0.3925417802075989" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="99.99999999999997" Z="0.8550169368166831">
<NAME>Venous blood ammonia: end of treatment</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactitol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactulose</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.474589670565575" CI_START="-11.07458967056554" EFFECT_SIZE="5.700000000000017" ESTIMABLE="YES" MEAN_1="155.4" MEAN_2="149.7" MODIFIED="2015-06-03 13:08:46 +0200" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="21.0" SD_2="32.0" SE="8.558621384311845" STUDY_ID="STD-Heredia-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="78.09556741168143"/>
<CONT_DATA CI_END="163.69828896155076" CI_START="-140.83828896155075" EFFECT_SIZE="11.430000000000007" ESTIMABLE="YES" MEAN_1="152.09" MEAN_2="140.66" MODIFIED="2015-06-03 13:08:46 +0200" MODIFIED_BY="[Empty name]" ORDER="747" SD_1="141.76" SD_2="200.65" SE="77.68933009107492" STUDY_ID="STD-Heredia-1988" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.9477881195254754"/>
<CONT_DATA CI_END="41.48204150225103" CI_START="-23.282041502251026" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="64.7" MEAN_2="55.6" MODIFIED="2015-06-03 13:08:46 +0200" MODIFIED_BY="[Empty name]" ORDER="1845" SD_1="26.6" SD_2="30.5" SE="16.52175333714111" STUDY_ID="STD-Morgan-1987b" TOTAL_1="6" TOTAL_2="6" WEIGHT="20.956644468793076"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.345696425678021E-33" CI_END="0.3954798055629628" CI_START="-0.7954798055629629" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2016-03-23 12:48:17 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="0.510357853002996" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.6582805886043833">
<NAME>Venous blood ammonia: change from baseline</NAME>
<GROUP_LABEL_1>Lactulose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lactitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactitol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lactulose</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3954798055629628" CI_START="-0.7954798055629629" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.9" MODIFIED="2015-06-03 13:08:49 +0200" MODIFIED_BY="[Empty name]" ORDER="1369" SD_1="0.6" SD_2="0.9" SE="0.3038218101251" STUDY_ID="STD-Morgan-1987a" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-04-07 11:47:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-03-23 12:49:27 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAASECAYAAABONYnbAABxS0lEQVR42uydD6RV2d//v4wxRkYi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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-04-07 11:47:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdsAAAZSCAIAAADwANz9AAB8QElEQVR42uzdv24bSdugfQEGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-04-07 10:42:05 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of mortality in 24 RCTs evaluating non-absorbable disaccharides versus placebo/no intervention. The primary meta-analysis found a RR of 0.59 (95% CI 0.40 to 0.87). When we set the RRR to 30% and CGR to 15%, (power 80%, alpha 5%, and diversity 0%), the cumulative Z-curve (the green line) crossed the monitoring boundary (inward sloping line) after 1037 participants before reaching the heterogeneity adjusted information size. The cumulative Z-curve did not cross the monitoring boundary when we increased the diversity to 20% and reduced the RRR to 20%.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJUCAIAAACwht8EAABWHElEQVR42uzdDUxc6Z3vee9UWFxT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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-04-07 10:42:05 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of mortality in 8 RCTs with a low risk of bias. The RCTs compare non-absorbable disaccharides versus placebo/no intervention and the primary meta-analysis found an effect of non-absorbable disaccharides with a RR of 0.63 (95% CI 0.41 to 0.97). When we set the RRR to 30% and CGR to 45% (power 80%, alpha 5%, and diversity 0%), the cumulative Z-curve (the green line) did not cross the monitoring boundary (inward sloping line). The heterogeneity adjusted information size was 1725 participants.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJUCAYAAAA/5EhTAABxd0lEQVR42uzdB3gUVdvG8QCKUhR9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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-04-07 10:42:05 +0200" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of hepatic encephalopathy in 22 RCTs evaluating non-absorbable disaccharides versus placebo/no intervention. A meta-analysis including all trials found a RR of 0.58 (95% CI 0.48 to 0.69). The analysis includes a RRR of 30% and CGR of 45% (power 80%, alpha 5%, and diversity 30%). The analysis found that the Z-curve (green line) crossed the monitoring boundary (inward sloping black line) before reaching the information size of 581 participants. None of the RCTs were low risk of bias in the overall assessment. The Z-curve crossed the monitoring boundary before reaching the information size when we decreased the RRR to 20% (information size 1337 participants) and when we increased diversity to 50% (814 participants).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJUCAYAAAA/5EhTAAB9mUlEQVR42uzdBZwU9f/H8QUs1J+K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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-04-07 10:42:05 +0200" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis of serious adverse events including 24 RCTs evaluating non-absorbable disaccharides versus placebo/no intervention. The primary meta-analysis found a beneficial intervention effect with a RR of 0.47 (95% CI 0.36 to 0.60). None of the included RCTs had a low risk of bias in the overall assessment. When conducting the Trial Sequential Analysis with RRR 30%, CGR 30%, power 80%, alpha 5%, and diversity 0%, the Z-curve crossed the monitoring boundary before reaching the required information size of 737 participants. The Z-curve also crossed the monitoring boundary before reaching the required information size when we reduced the RRR to 20% (information size 1719 participants) and when we increased diversity to 20% (information size 921 participants).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJUCAYAAAA/5EhTAACAAElEQVR42uzdB3gU1RrG8QUrwhUr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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2014-10-12 23:02:07 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-30 11:53:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P/>
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Search terms</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>October 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(disaccharid* or lactulos* or lactitol*) AND (encephalopath* OR liver disease* OR cirrho*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 10 of 12, 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Disaccharides] explode all trees</P>
<P>#2 MeSH descriptor: [Lactulose] explode all trees</P>
<P>#3 disaccharid* or lactulos* or lactitol*</P>
<P>#4 #1 or #2 or #3</P>
<P>#5 MeSH descriptor: [Hepatic Encephalopathy] explode all trees</P>
<P>#6 MeSH descriptor: [Liver Diseases] explode all trees</P>
<P>#7 MeSH descriptor: [Fibrosis] explode all trees</P>
<P>#8 encephalopath* or liver disease* or cirrho*</P>
<P>#9 #5 or #6 or #7 or #8</P>
<P>#10 #4 and #9</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to October 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Disaccharides/</P>
<P>2. exp Lactulose/</P>
<P>3. (disaccharid* or lactulos* or lactitol*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>4. 1 or 2 or 3</P>
<P>5. exp Hepatic Encephalopathy/</P>
<P>6. exp Liver Diseases/</P>
<P>7. exp Fibrosis/</P>
<P>8. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>9. 5 or 6 or 7 or 8</P>
<P>10. 4 and 9</P>
<P>11. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>12. 10 and 11</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Embase (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to October 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp disaccharide/</P>
<P>2. exp lactulose/</P>
<P>3. exp lactitol/</P>
<P>4. (disaccharid* or lactulos* or lactitol*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>5. 1 or 2 or 3 or 4</P>
<P>6. exp hepatic encephalopathy/</P>
<P>7. exp liver disease/</P>
<P>8. exp fibrosis/</P>
<P>9. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>10. 6 or 7 or 8 or 9</P>
<P>11. 5 and 10</P>
<P>12. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>13. 11 and 12</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (Web of Science)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to October 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 #4 AND #3</P>
<P>4 TS=(random* or blind* or placebo* or meta-analysis)</P>
<P>3 #2 AND #1</P>
<P>2 TS=(encephalopath* or liver disease* or cirrho*)</P>
<P>1 TS=(disaccharid* or lactulos* or lactitol*)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 randomised clinical trials described in 52 references included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;38 randomised clinical trials described in 56 references included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;82 records assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;884 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;884 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1378 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;10 additional records identified through other sources (8 records through manual searches of reference lists and 2 records through trial registries)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;802 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26 records referring to 2 ongoing randomised controlled trials, 4 randomised controlled trials on lactulose without a placebo/no intervention or lactitol comparison group, and 18 observational studies&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>